B7h3 single domain antibody and therapeutic composition of the same

B7H3-binding polypeptides with chimeric antigen receptors enhance immune cell activation and cytotoxicity against cancer cells, addressing the need for improved therapeutic agents by specifically targeting B7H3 on tumors.

JP2024167342AInactive Publication Date: 2024-12-03INHIBRX INC
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024148159
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-07-23
Filing Date
2024-08-30
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapeutic molecules targeting B7H3 for cancer treatment are inadequate, necessitating the development of improved agents that can effectively bind and modulate B7H3 expression on tumor cells to enhance immune response against cancer.

Method used

Development of B7H3-binding polypeptides, including multivalent and multispecific constructs with chimeric antigen receptors, such as those comprising heavy chain-only variable domains (VHH) and immunoglobulin Fc regions, designed to specifically target B7H3 on tumor cells and activate immune cells like T cells and NK cells.

Benefits of technology

These constructs enhance immune cell activation and cytotoxicity against B7H3-expressing tumors, inducing apoptosis and inhibiting tumor growth through mechanisms like ADCC, thereby providing a targeted therapeutic approach for cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167342000001_ABST
    Figure 2024167342000001_ABST
Patent Text Reader

Abstract

To provide an improved therapeutic molecule and a therapeutic agent targeting B7H3.SOLUTION: Provided is binding polypeptide that specifically binds to B7H3. More specifically, provided is fusion protein that binds to B7H3, and includes a multivalent and / or multi-specific construct and a chimeric antigen receptor. Further, also provided are a pharmaceutical composition containing the polypeptide, nucleic acid molecules encoding the polypeptide, and a vector and a cell thereof, and a method for using provided B7H3 binding polypeptide for treating diseases and conditions such as cancer, and use thereof.SELECTED DRAWING: Figure 3A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 744,640, filed October 11, 2018, entitled "B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF"; U.S. Provisional Patent Application No. 62 / 832,274, filed April 10, 2019, entitled "B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF"; and U.S. Provisional Patent Application No. 62 / 877,812, filed July 23, 2019, entitled "B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF", the contents of which are incorporated by reference in their entireties for all purposes.

[0002] INCORPORATION BY REFERENCE TO SEQUENCE LISTING This application has been submitted with an electronic sequence listing. The sequence listing is provided in a file named 744952000440SeqList.TXT, created on October 8, 2019, and is 471 kilobytes in size. The information in the electronic format of the sequence listing is incorporated by reference in its entirety.

[0003] Field The present disclosure generally provides binding polypeptides that specifically bind to B7H3. More specifically, the present disclosure relates to fusion proteins that include multivalent and / or multispecific constructs and chimeric antigen receptors that bind at least B7H3. The present disclosure also provides nucleic acid molecules that encode these polypeptides, as well as vectors and cells thereof, and methods of using the provided B7H3 binding polypeptides and their use for treating diseases and conditions, such as cancer. [Background technology]

[0004] background B7H3 is a member of the B7 family of immune cell regulatory molecules. It is expressed on the surface of a wide variety of tumor cells and tumor vasculature, and its expression is associated with poor prognosis in a wide variety of cancers. The expression of B7H3 on a wide variety of cancers in humans, including solid tumors, makes it a desirable therapeutic target. There is a need for improved therapeutic molecules and therapeutic agents that target B7H3. An embodiment that meets such a need is provided herein. Summary of the Invention

[0005] overview Provided herein is a B7H3 binding polypeptide construct that comprises at least one heavy chain-only variable domain (B7H3 VHH domain) that specifically binds to B7H3. In some embodiments, the B7H3 binding polypeptide construct further comprises one or more additional binding domains that bind to targets other than B7H3.

[0006] Complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, and 145; and a complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, and 167; and a complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, and 483-488. Provided herein are B7H3 binding constructs comprising a VHH domain. In some embodiments, the B7H3 binding polypeptide construct further comprises one or more additional binding domains that bind to targets other than B7H3.

[0007] In some embodiments, the B7H3 binding polypeptide construct is a dimer.

[0008] In some embodiments, B7H3 has the sequence shown in SEQ ID NO:190, or a mature form thereof lacking the signal sequence. In some embodiments, B7H3 is human B7H3.

[0009] In some embodiments, at least one B7H3 VHH domain is humanized. In some embodiments, the B7H3 VHH is a Camelidae VHH. In some embodiments, the B7H3 VHH is a humanized version of a Camelidae VHH.

[0010] In some embodiments, the one or more additional binding domains bind to an activating receptor on an immune cell. In some embodiments, the immune cell is a T cell. In some embodiments, the activating receptor is CD3 (CD3ε). In some embodiments, the binding polypeptide construct is bispecific for B7H3 and CD3. In some embodiments, the immune cell is a natural killer (NK) cell. In some embodiments, the activating receptor is CD16 (CD16a). In some embodiments, the B7H3 binding polypeptide construct is bispecific for B7H3 and CD16a.

[0011] In some embodiments, the one or more additional binding domains bind to a cytokine receptor. In some embodiments, the one or more additional binding domains are a cytokine or a truncated fragment or variant thereof that can bind to a cytokine receptor. In some embodiments, the cytokine is an interferon or a truncated fragment or variant of an interferon. In some embodiments, the interferon is a type I interferon, a type II interferon, a truncated fragment or variant of a type I interferon, or a truncated fragment or variant of a type II interferon. In some embodiments, the interferon is selected from a type I interferon that is IFN-α or IFN-β or a truncated fragment or variant thereof, or a type II interferon that is IFN-γ or a truncated fragment or variant thereof.

[0012] In some embodiments, the one or more additional binding domains comprise an antibody or antigen-binding fragment thereof. In some embodiments, the one or more additional binding domains are monovalent. In some embodiments, the antibody or antigen-binding fragment thereof is an Fv, a disulfide-stabilized Fv (dsFv), an scFv, a Fab, a single domain antibody (sdAb), a VNAR, or a VHH.

[0013] In some of the embodiments provided, the polypeptide comprises an immunoglobulin Fc region. In some embodiments, the polypeptide comprises an immunoglobulin Fc region that links at least one VHH domain and one or more additional binding domains. In some embodiments, the B7H3 binding polypeptide construct is a dimer. In some embodiments, the Fc region is a homodimeric Fc region.

[0014] In some of any of the embodiments provided, the Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs: 198, 200, 201, 202, or 203, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 198, 200, 201, 202, or 203. In some embodiments, the Fc region is a human IgG1.

[0015] In some of any of the embodiments provided, the B7H3 binding polypeptide construct is a dimer. In some embodiments, the Fc region is a homodimeric Fc region.

[0016] In some of any of the embodiments provided, the Fc region is human IgG1.

[0017] In some of any of the embodiments provided, the Fc region comprises a sequence of amino acids set forth in SEQ ID NO:198, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:198.

[0018] In some embodiments, the Fc region is a heterodimeric Fc region. In some embodiments, the Fc region exhibits effector function. In some embodiments, the Fc region comprises a polypeptide comprising one or more amino acid modifications that reduce effector function and / or reduce binding to an effector molecule selected from Fcγ receptor or C1q. In some embodiments, the one or more amino acid modifications are deletion of one or more of Glu233, Leu234, or Leu235.

[0019] In some of any of the embodiments provided, the Fc region comprises a sequence of amino acids set forth in SEQ ID NO:199, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:199.

[0020] In some embodiments, at least one B7H3 VHH domain comprises a VHH domain sequence set forth in any of SEQ ID NOs: 1-114, 466, 467, 489, 490, or 492-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 1-114, 466, 467, 489, 490, or 492-518, and binds to B7H3.

[0021] In some embodiments, at least one B7H3 VHH domain comprises a VHH domain sequence set forth in any of SEQ ID NOs:1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs:1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, and binds to B7H3.

[0022] In some of any of the provided embodiments, at least one B7H3 domain comprises (i) a sequence as set forth in SEQ ID NO:1, (ii) a humanized variant of SEQ ID NO:1, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, and 121; a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, and 151; and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168 and 169. In some embodiments, at least one B7H3 VHH domain comprises a CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 115, 146, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises a CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 115, 147, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 115, 148, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 115, 149, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 115, 150, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 116, 146, and 168, respectively.In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 117, 146, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 118, 146, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 115, 146, and 169, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 119, 146, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:120, 146, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:115, 151, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:116, 147, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:118, 147, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:119, 147, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:116, 151, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:115, 146, and 168, respectively.In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:121, 147, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:115, 146, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:119, 149, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:122, 151, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:2-34 and 467, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:2-34 and 467, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:2-34 and 467. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497.

[0023] In some of any of the provided embodiments, at least one B7H3 VHH domain comprises (i) a sequence set forth in SEQ ID NO:35, (ii) a humanized variant of SEQ ID NO:35, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:35, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:123; a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:152 and 153; and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:170 and 171. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 123, 152, and 170, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 123, 152, and 171, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 123, 153, and 170, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 123, 153, and 171, respectively. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:36-43, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:36-43, and binds to B7H3.In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 36-43. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 40, 41, or 498-503, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 40, 41, or 498-503, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 40, 41, or 498-503.

[0024] In some of any of the provided embodiments, at least one B7H3 VHH domain comprises (i) a sequence as set forth in SEQ ID NO:44, (ii) a humanized variant of SEQ ID NO:44, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:44, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133; a CDR2 comprising an amino acid sequence set forth in SEQ ID NO: 154; and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, and 183. In some embodiments, at least one B7H3 VHH domain comprises a CDR1, CDR2, and CDR3 set forth in SEQ ID NO: 124, 154, and 172, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 174, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 175, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 125, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:126, 154, and 173, respectively.In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 127, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 128, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 129, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 130, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 131, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 176, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 177, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 178, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 179, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 180, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 181, respectively.In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 182, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 183, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 126, 154, and 176, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 179, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 124, 154, and 182, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 132, 154, and 176, respectively; or SEQ ID NOs: 133, 154, and 173, respectively. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 45-91 and 466, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 45-91 and 466, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 45-91 and 466.In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:56-91, 466, and 504-514, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:56-91, 466, and 504-514, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:56-91, 466, and 504-514.

[0025] In some of any of the provided embodiments, at least one B7H3 VHH domain comprises (i) a sequence set forth in SEQ ID NO:105, (ii) a humanized variant of SEQ ID NO:105, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:105, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:145; a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:167; and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:488. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 106-109, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 106-109, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 106-109.

[0026] In some of any of the provided embodiments, at least one B7H3 VHH domain comprises (i) a sequence set forth in SEQ ID NO:110, (ii) a humanized variant of SEQ ID NO:110, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:110, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:139; a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:161; and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:189. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 111-114, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 111-114, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 111-114. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:515-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:515-518, and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs:515-518.

[0027] In some of any of the provided embodiments, at least one B7H3 VHH domain is selected from the group consisting of (i) a sequence as set forth in SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104, (ii) a humanized variant of SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104, or (iii) a sequence as set forth in SEQ ID and binds to B7H3. In some embodiments, at least one B7H3 VHH domain comprises a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs:92, 93, 94, 95, ...134, 155, and 184, respectively. In some embodiments, at least one B7H3 VHH domain comprises a CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:135, 156, and 168, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 136, 157, and 185, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 137, 158, and 186, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 138, 159, and 187, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 138, 160, and 188, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:139, 161, and 189, respectively.In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:140, 162, and 483, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:141, 163, and 484, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:139, 161, and 189, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs:142, 164, and 485, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 143, 165, and 486, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 144, 166, and 487, respectively. In some embodiments, at least one B7H3 VHH domain comprises CDR1, CDR2, and CDR3 as set forth in SEQ ID NOs: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104.

[0028] In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:1. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:8. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:43. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:503. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:67. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:85. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:455. In some embodiments, the B7H3 VHH domain comprises a VHH domain sequence depicted in SEQ ID NO:456. In some embodiments, the B7H3 VHH domain comprises the VHH domain sequence shown in SEQ ID NO: 466. In some embodiments, the B7H3 VHH domain comprises the VHH domain sequence shown in SEQ ID NO: 467.

[0029] In some of any of the embodiments provided, the B7H3 VHH domain may include additional amino acids at its N-terminus and / or C-terminus, for example, for linking to another amino acid sequence, such as another polypeptide. In some of any of the embodiments provided, the B7H3 VHH domain may include a flexible linker, such as a glycine linker, or a linker composed primarily of the amino acids glycine and serine, referred to herein as a GS linker. Such linkers of the present disclosure can be of various lengths, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids in length. In some embodiments, the linker is GGSGGS, i.e., TIFF2024167342000002.tif23166. In some embodiments, the linker is (GGGGS)n, where n is 1 to 5 (SEQ ID NO:123); (GGGGGS)n, where n is 1 to 4 (SEQ ID NO:124); TIFF2024167342000003.tif16148. In some embodiments, the linker is a GG linker. In some embodiments, the B7H3 binding polypeptide comprises a combination of a GS linker and a glycine linker. In some embodiments, the B7H3 VHH domain may comprise an additional linker at its C-terminus, for example, for linking to another amino acid sequence, such as another polypeptide. In some of any of the provided embodiments, the B7H3 VHH domain may comprise a linker at its N-terminus, for example, for linking to another amino acid sequence, such as another polypeptide.

[0030] Provided herein is a multispecific polypeptide construct comprising a first component comprising a heterodimeric Fc region comprising a first Fc polypeptide and a second Fc polypeptide, and a second component comprising an anti-CD3 antibody or antigen-binding fragment comprising a variable heavy chain region (VH) and a variable light chain region (VL), wherein the VH and VL constituting the anti-CD3 antibody or antigen-binding fragment are linked to opposing polypeptides of the heterodimeric Fc; the first and second components are coupled by a linker, and the heterodimeric Fc region is positioned at the N-terminus of the anti-CD3 antibody; and one or both of the first and second components comprises at least one antigen-binding domain (B7H3 VHH domain) comprising a single domain antibody that specifically binds to B7H3. In certain embodiments, the B7H3 VHH domain can comprise any of the provided B7H3 VHH domain sequences, including any as described above or elsewhere herein.

[0031] In some embodiments, the multispecific polypeptide construct comprises at least (i) a first polypeptide comprising a first Fc polypeptide of a heterodimeric Fc region, a linker, and a VH or VL domain of an anti-CD3 antibody or antigen-binding fragment; and (ii) a second polypeptide comprising a second Fc polypeptide of a heterodimeric Fc region, a linker, optionally the same linker as present in the first polypeptide, and the other of the VH or VL domain of the anti-CD3 antibody or antigen-binding fragment, wherein one or both of the first and second polypeptides comprises at least one B7H3 VHH domain.

[0032] In some embodiments, one or both of the first and second Fc polypeptides of the heterodimeric Fc region comprise at least one modification that induces heterodimerization, compared to the polypeptide of the homodimeric Fc region, and optionally compared to the Fc polypeptide set forth in SEQ ID NO:198 or an immunologically active fragment thereof. In some embodiments, each of the first and second Fc polypeptides of the heterodimeric Fc region independently comprises at least one amino acid modification. In some embodiments, each of the first and second Fc polypeptides of the heterodimeric Fc region comprises a knob-into-hole modification or a charge mutation that increases electrostatic complementarity of the polypeptides.

[0033] In some embodiments, the amino acid modification is a knob-into-hole modification. In one embodiment, the first Fc polypeptide of the heterodimeric Fc region comprises a modification selected from Thr366Ser, Leu368Ala, Tyr407Val, and combinations thereof, and the second Fc polypeptide of the heterodimeric Fc region comprises a modification Thr366Trp. In such an embodiment, the first and second Fc polypeptides can further comprise a modification of a non-cysteine ​​residue to a cysteine ​​residue, the modification of the first Fc polypeptide being at one of positions Ser354 and Tyr349, and the modification of the second Fc polypeptide being at the other of positions Ser354 and Tyr349.

[0034] In some embodiments, the amino acid modification is a charge mutation that increases the electrostatic complementarity of the polypeptide. In some embodiments, the first and / or second Fc polypeptide, or each of the first and second Fc polypeptides, contains a modification at a complementary position, which is a substitution of an amino acid having an opposite charge to the complementary amino acid of the other polypeptide.

[0035] In some of any of the embodiments provided, one of the first or second Fc polypeptides of the heterodimeric Fc region further comprises a modification at residue Ile253. In some embodiments, the modification is Ile253Arg. In some embodiments, one of the first or second Fc polypeptides of the heterodimeric Fc region further comprises a modification at residue His435. In some embodiments, the modification is His435Arg.

[0036] In some embodiments, the Fc region of any of the provided polypeptides or constructs comprises a polypeptide that lacks Lys447.

[0037] In some embodiments, the Fc region of any of the provided polypeptides or constructs comprises at least one modification that enhances FcRn binding. In some embodiments, the modification is at a position selected from the group consisting of Met252, Ser254, Thr256, Met428, Asn434, and combinations thereof. In some embodiments, the modification is at Met252Y, Ser254T, Thr256E, Met428L, Met428V, Asn434S, and combinations thereof. In some embodiments, the modification is at position Met252 and position Met428. In some embodiments, the modification is at Met252Y and Met428L. In some embodiments, the modification is at Met252Y and Met428V.

[0038] In some of any of the provided embodiments, the first Fc polypeptide of the heterodimeric Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs: 293, 297, 305, or 307, and the second Fc polypeptide of the heterodimeric Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs: 294, 298, 301, 303, 309, or 311.

[0039] In some of any of the embodiments provided, the Fc region of the provided polypeptide or construct comprises a polypeptide comprising at least one amino acid modification that reduces effector function and / or reduces binding to an effector molecule selected from an Fcγ receptor or C1q. In some embodiments, the one or more amino acid modifications are deletions of one or more of Glu233, Leu234, or Leu235.

[0040] In some of any of the embodiments provided, the first Fc polypeptide of the heterodimeric Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs:295, 299, 306, or 308, and the second Fc polypeptide of the heterodimeric Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs:296, 300, 302, 304, 310, or 312.

[0041] In some of any of the provided embodiments, the anti-CD3 antibody or antigen-binding fragment is monovalent. In some embodiments, the anti-CD3 antibody or antigen-binding fragment is an Fv antibody fragment. In some embodiments, the Fv antibody fragment comprises a disulfide-stabilized anti-CD3 binding Fv fragment (dsFv).

[0042] In some embodiments, the anti-CD3 antibody or antigen-binding fragment is not a single chain antibody, e.g., is not a single chain variable fragment (scFv).

[0043] In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises: VH CDR1 comprising the amino acid sequence TYAMN (SEQ ID NO:219); Amino acid sequence VH CDR2 containing TIFF2024167342000004.tif4128; Amino acid sequence VH CDR3 containing TIFF2024167342000005.tif4128, Amino acid sequence VL CDR1 containing TIFF2024167342000006.tif4128; VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 containing the amino acid sequence ALWYSNLWV (SEQ ID NO:224) In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises a VH having an amino acid sequence of any of SEQ ID NOs: 225-255, 480, 460, or 462, or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 225-255, 480, 460, or 462; and a VL having an amino acid sequence of any of SEQ ID NOs: 256-274, 417, 459, or 461, or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 6256-274, 417, 459, or 461. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:237 and the amino acid sequence of SEQ ID NO:265. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:237 and the amino acid sequence of SEQ ID NO:417. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:460 and the amino acid sequence of SEQ ID NO:461. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:480 and the amino acid sequence of SEQ ID NO:459.

[0044] In some embodiments, the VL of the anti-CD3 antibody or antigen-binding fragment is linked to a first Fc polypeptide of the heterodimeric Fc, and the VH of the anti-CD3 antibody or antigen-binding fragment is linked to a second Fc polypeptide of the heterodimeric Fc.

[0045] In some embodiments, the CD3 binding region comprises a variable heavy region (VH) and a variable light region (VL), wherein the VL is C-terminal to a first Fc polypeptide of the heterodimeric Fc region and the VH is C-terminal to a second Fc polypeptide of the heterodimeric Fc region, wherein the first Fc polypeptide comprises a hole mutation and the second Fc polypeptide comprises a knob mutation. In some embodiments, at least one B7H3 single domain antibody is positioned amino-terminal to the Fc region of the multispecific polypeptide construct and / or carboxy-terminal to the CD3 binding region of the multispecific polypeptide construct.

[0046] In some embodiments, the multispecific polypeptide construct comprises a first B7H3 VHH domain that specifically binds B7H3 and a second B7H3 VHH domain that specifically binds B7H3, in some embodiments, the first or second B7H3 VHH domain is positioned amino-terminal to the Fc region of the multispecific construct, and the other of the first or second B7H3 VHH domain is positioned carboxy-terminal to the CD3 binding region of the multispecific construct.

[0047] In some embodiments of any of the multispecific polypeptide constructs provided, the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, a first Fc polypeptide of a heterodimeric Fc region, a linker, a VH or VL domain of an anti-CD3 antibody or antigen-binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second polypeptide comprises, in order from N-terminus to C-terminus, a second Fc polypeptide of the heterodimeric Fc region, a linker, optionally the same linker as present in the first component, and the other of the VH or VL domain of the anti-CD3 antibody or antigen-binding fragment.

[0048] In some embodiments, the multispecific polypeptide construct comprises at least a first polypeptide comprising a first Fc polypeptide of a heterodimeric Fc region, a linker, and a VH or VL domain of an anti-CD3 antibody or antigen-binding fragment; and a second polypeptide comprising a second Fc polypeptide of a heterodimeric Fc region, a linker, optionally the same linker as present in the first polypeptide, and the other of the VH or VL domain of an anti-CD3 antibody or antigen-binding fragment, wherein one or both of said first and second polypeptides comprise at least one B7H3 VHH domain.

[0049] In some embodiments, the polypeptide construct comprises an immunoglobulin Fc region. In some embodiments, the immunoglobulin Fc region links at least one B7H3 VHH domain and one or more additional binding domains. In some embodiments, the Fc region is a homodimeric Fc region. In some embodiments, the Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs: 198, 200, 201, 202, or 203, or a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 198, 200, 201, 202, or 203. In some embodiments, the Fc region is a human IgG1. In some embodiments, the Fc region comprises a sequence of amino acids set forth in SEQ ID NO:198, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:198.

[0050] In some embodiments, the Fc region is a heterodimeric Fc region. In some embodiments, the Fc region exhibits effector function. In some embodiments, the Fc region comprises a polypeptide comprising one or more amino acid modifications that reduce effector function and / or reduce binding to an effector molecule selected from an Fcγ receptor or C1q. In some embodiments, the one or more amino acid modifications are deletions of one or more of Glu233, Leu234, or Leu235. In some embodiments, the Fc region comprises a sequence of amino acids set forth in SEQ ID NO:199, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:199.

[0051] In some embodiments, one or both of the first and second Fc polypeptides of the heterodimeric Fc region comprises at least one modification that induces heterodimerization, compared to the polypeptide of the homodimeric Fc region, optionally compared to the Fc polypeptide set forth in SEQ ID NO:198 or an immunologically active fragment thereof. In some embodiments, each of the first and second Fc polypeptides of the heterodimeric Fc region independently comprises at least one amino acid modification. In some embodiments, each of the first and second Fc polypeptides of the heterodimeric Fc region comprises a knob-into-hole modification or a charge mutation that increases electrostatic complementarity of the polypeptide. In some embodiments, the amino acid modification is a knob-into-hole modification. In some embodiments, the amino acid modification is a charge mutation that increases electrostatic complementarity of the polypeptide. In some embodiments, the first and / or second Fc polypeptide, or each of the first and second Fc polypeptides, comprises a modification at a complementary position, which is a substitution with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide. In some embodiments, the Fc region comprises a polypeptide comprising at least one modification that enhances FcRn binding, In some embodiments, the Fc region comprises a polypeptide comprising at least one amino acid modification that reduces effector function and / or reduces binding to an effector molecule selected from an Fcγ receptor or C1q.

[0052] In some embodiments, one or both of the first and second components comprises at least one costimulatory receptor binding region (CRBR) that binds 41BB (CD137). In some embodiments, the multispecific polypeptide construct comprises only one costimulatory receptor binding region (CRBR). In some embodiments, the at least one costimulatory receptor binding region (CRBR) is positioned amino-terminal to the Fc region of the multispecific polypeptide construct and / or carboxy-terminal to the CD3 binding region of the multispecific polypeptide construct.

[0053] In some embodiments of any of the multispecific polypeptide constructs provided, the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, a first Fc polypeptide of a heterodimeric Fc region, a linker, a VH or VL domain of an anti-CD3 antibody or antigen binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises a CRBR and comprises, in order from N-terminus to C-terminus, a second Fc polypeptide of the heterodimeric Fc region, a linker, optionally the same linker as present in the first component, the other of the VH or VL domain of the anti-CD3 antibody or antigen binding fragment, where the CRBR is positioned amino-terminal to the Fc region of the second component or carboxy-terminal to the anti-CD3 antibody or antigen binding fragment of the second component.

[0054] In some embodiments, at least one costimulatory receptor binding region (CRBR) is or comprises the extracellular domain of the natural cognate binding partner of the costimulatory receptor or a binding fragment thereof, or a variant thereof that exhibits binding activity to the costimulatory receptor. In some embodiments, at least one costimulatory receptor binding region (CRBR) is an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, a Fv fragment, a scFv, a scAb, a dAb, a single-domain heavy chain antibody, and a single-domain light chain antibody. In some embodiments, the antibody or an antigen-binding fragment thereof is an Fv, a scFv, a Fab, a single-domain antibody (VHH domain), a VNAR, or a VHH. In some embodiments, the antibody or antigen-binding fragment is a VHH domain. In some embodiments, the VHH domain is a human VHH domain or a humanized VHH domain.

[0055] In some of any of the provided embodiments, at least one costimulatory receptor binding region (CRBR) binds to a costimulatory receptor selected from among 41BB (CD137), OX40 (CD134), CD27, glucocorticoid-induced TNFR-related protein (GITR), CD28, ICOS, CD40, B-cell activating factor receptor (BAFF-R), B-cell maturation antigen (BCMA), transmembrane activator and CAML interactor (TACI), and NKG2D. In some embodiments, at least one costimulatory receptor binding region (CRBR) binds to a costimulatory receptor selected from among 41BB (CD137), OX40 (CD134), and glucocorticoid-induced TNFR-related protein (GITR).

[0056] In some embodiments, at least one costimulatory receptor binding region (CRBR) binds to 41BB (CD137).

[0057] In some embodiments, at least one costimulatory receptor binding region (CRBR) comprises a sequence of amino acids set forth in SEQ ID NO:400 or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:400, and binds 4-1BB. In some embodiments, at least one costimulatory receptor binding region (CRBR) comprises a sequence of amino acids set forth in SEQ ID NO:481 or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO:481, and binds 4-1BB.

[0058] In some embodiments, at least one costimulatory receptor binding region (CRBR) comprises a sequence of amino acids set forth in SEQ ID NO: 400. In some embodiments, at least one costimulatory receptor binding region (CRBR) comprises a sequence of amino acids set forth in SEQ ID NO: 481.

[0059] In some embodiments, one or both of the first and second components comprises at least one inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor. In some embodiments, the at least one inhibitory receptor binding region (IRBR) is located amino-terminal to the Fc region of the multispecific polypeptide construct and / or carboxy-terminal to the CD3 binding region of the multispecific polypeptide construct. In some embodiments, the multispecific polypeptide construct comprises only one inhibitory receptor binding region (IRBR).

[0060] In some embodiments of any of the multispecific polypeptide constructs provided, the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, a first Fc polypeptide of a heterodimeric Fc region, a linker, a VH or VL domain of an anti-CD3 antibody or antigen binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises an IRBR and comprises, in order from N-terminus to C-terminus, a second Fc polypeptide of the heterodimeric Fc region, a linker, optionally the same linker as present in the first component, the other of the VH or VL domain of the anti-CD3 antibody or antigen binding fragment, wherein the IRBR is positioned amino-terminal to the Fc region of the second component or carboxy-terminal to the anti-CD3 antibody or antigen binding fragment of the second component.

[0061] In some embodiments, at least one IRBR is or comprises the extracellular domain of the natural cognate binding partner of an inhibitory receptor or a binding fragment thereof, or a variant thereof that exhibits binding activity to an inhibitory receptor. In some embodiments, at least one IRBR is an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, a Fv fragment, a scFv, a scAb, a dAb, a single-domain heavy chain antibody, and a single-domain light chain antibody. In some embodiments, the antibody or antigen-binding fragment thereof is an Fv, a scFv, a Fab, a single-domain antibody (VHH domain), a VNAR, or a VHH. In some embodiments, the antibody or antigen-binding fragment is a VHH domain. In some embodiments, the VHH domain is a human VHH domain or a humanized VHH domain. In some embodiments, at least one IRBR binds to an inhibitory receptor selected from among PD-1, CTLA-4, TIGIT, VISTA, and TIM3. In some embodiments, at least one IRBR binds to PD-1.

[0062] In some of any of the provided embodiments of the multispecific polypeptide construct, the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, a first Fc polypeptide of a heterodimeric Fc region, a linker, a VH or VL domain of an anti-CD3 antibody or antigen-binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises, in order from N-terminus to C-terminus, one of an IRBR or a CRBR, a second Fc polypeptide of the heterodimeric Fc region, a linker, optionally the same linker as present in the first component, the other of the VH or VL domain of the anti-CD3 antibody or antigen-binding fragment, and the other of the CRBR or IRBR.

[0063] In some of the embodiments provided, the linker is a peptide or polypeptide linker. In some embodiments, the linker is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length.

[0064] In some embodiments, the linker is a non-cleavable linker, e.g., TIFF2024167342000007.tif4128 and combinations thereof. In some embodiments, the linker is Is or contains TIFF2024167342000008.tif3128.

[0065] In some embodiments, the linker is a cleavable linker, e.g., a polypeptide that functions as a substrate for a protease. In some embodiments, the protease is produced by an immune effector cell, by a tumor, or by a cell present in the tumor microenvironment. In some embodiments, the protease is produced by an immune effector cell, the immune effector cell being an activated T cell, a natural killer (NK) cell, or a NK T cell. In some embodiments, the protease is matriptase, a matrix metalloprotease (MMP), granzyme B, or a combination thereof. In some embodiments, the cleavable linker is the amino acid sequence Includes TIFF2024167342000009.tif4128.

[0066] Provided herein are isolated single domain antibodies that bind to B7H3 and contain any of the B7H3 VHH domain sequences provided herein, including any as described above or elsewhere herein.

[0067] Complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, and 145; Provided herein is an isolated single domain antibody that binds to B7H3, comprising a complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, and 167; and a complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, and 483-488.

[0068] In some embodiments, the heterodimeric Fc region comprises an Fc hole polypeptide and an Fc knob polypeptide, wherein the VL of an anti-CD3 antibody or antigen-binding fragment is positioned at the C-terminus of the Fc hole and the VH of the anti-CD3 antibody or antigen-binding fragment is positioned at the C-terminus of the Fc knob.

[0069] In some embodiments, the anti-CD3 antibody or antigen-binding fragment is monovalent. In some embodiments, the anti-CD3 antibody or antigen-binding fragment is not a single chain antibody, and optionally is not a single chain variable fragment (scFv). In some embodiments, the anti-CD3 antibody or antigen-binding fragment is an Fv antibody fragment. In some embodiments, the Fv antibody fragment comprises a disulfide-stabilized anti-CD3 binding Fv fragment (dsFv). In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:237 and the amino acid sequence of SEQ ID NO:265. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:237 and the amino acid sequence of SEQ ID NO:417. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:460 and the amino acid sequence of SEQ ID NO:461. In some embodiments, the anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:480 and the amino acid sequence of SEQ ID NO:459.

[0070] Provided herein is a polynucleotide encoding any of the provided B7H3 binding polypeptides. Provided herein is a polynucleotide encoding any of the provided multispecific polypeptide constructs. Provided herein is a polynucleotide comprising a first nucleic acid sequence encoding a first polypeptide of any of the provided multispecific constructs and a second nucleic acid sequence encoding a second polypeptide of any of the provided multispecific constructs, wherein the first and second nucleic acid sequences are separated by an internal ribosome entry site (IRES) or a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping.

[0071] Provided herein are polynucleotides encoding any of the provided single domain antibodies. Provided herein are vectors comprising any of the provided polynucleotides.

[0072] Provided herein is a cell comprising any one or more of the provided polynucleotides, or any one or more of the provided vectors.

[0073] Provided herein are methods for producing a polypeptide comprising introducing any of the provided polynucleotide(s) or vector(s) into a cell and culturing the cell under conditions to produce a multispecific polypeptide construct. Provided herein are polypeptides produced by any of the provided methods.

[0074] Provided herein are engineered immune cells that comprise a chimeric antigen receptor that comprises an extracellular domain comprising any of the provided single domain antibodies; a transmembrane domain; and an intracellular signaling domain.

[0075] Provided herein are pharmaceutical compositions comprising any of the provided B7H3 binding polypeptides, multispecific polypeptide constructs, single domain antibodies, or engineered immune cells.

[0076] Provided herein is a method of stimulating or inducing an immune response in a subject, comprising administering to a subject in need thereof any of the provided B7H3 binding polypeptides, multispecific polypeptide constructs, single domain antibodies, or engineered immune cells, or pharmaceutical compositions. Provided herein is a method of treating a disease or condition in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of any of the provided B7H3 binding polypeptides, multispecific polypeptide constructs, single domain antibodies, or engineered immune cells, or pharmaceutical compositions. [Brief description of the drawings]

[0077] [Figure 1-1]1A-1F show a series of graphs illustrating the ability of various anti-B7H3 single domain antibodies (sdAbs) to bind cell surface B7H3. Binding was assessed by flow cytometry on B7H3 positive cell lines NCI-H460 (FIGS. 1A-1B) or A375 (FIG. 1C), or B7H3 transfected 293 cells (FIGS. 1D, 1E, 1F). [Figure 1-2] See description of Figure 1-1. [Figure 1-3] See description of Figure 1-1. [Figure 2-1] Figures 2A-2V show a series of graphs illustrating the ability of humanized sdAbs to bind cell surface B7H3. Figures 2A-2C show the binding of 57B04 and its humanized variants to NCI-H460. Figure 2D shows the binding of 57B06 and its humanized (hz) variants to NCI-H460. Figure 2E shows the binding of 1H5 and its humanized (hz) variants to 293FS cells expressing B7H3. Figures 2F-2I and 2X-Y show the binding of humanized (hz) 1A5 variants to NCI-H460 (Figure 2F) or 293FS cells expressing B7H3 (Figures 2G, 2H, 2I, 2X, 2Y). Figures 2J-2W show the binding of 58E05 and its humanized (hz) variants to HCT-116 (Figures 2J, 2K, 2L), NCI-H460 (Figures 2M, 2N, 2O, 2P, 2R, 2S, 2T, 2U), A549 (Figure 2Q), or 293FS cells expressing B7H3 (Figures 2V and 2W). [Figure 2-2] See description of Figure 2-1. [Figure 2-3] See description of Figure 2-1. [Figure 2-4] See description of Figure 2-1. [Figure 2-5] See description of Figure 2-1. [Figure 2-6] See description of Figure 2-1. [Figure 2-7] See description of Figure 2-1. [Figure 2-8] See description of Figure 2-1. [Figure 2-9]See description of Figure 2-1. [Figure 2-10] See description of Figure 2-1. [Figure 2-11] See description of Figure 2-1. [Figure 2-12] See description of Figure 2-1. [Figure 3A] 3A-3E illustrate a series of schematic diagrams depicting various B7H3-targeted constrained CD3-engaging constructs. The basic components of the B7H3-targeted constrained CD3-engaging constructs of the present disclosure have constrained CD3 binding. An antigen-binding domain is positioned at the amino-terminus and / or carboxy-terminus. An Fc region, such as a heterodimeric Fc region, is positioned N-terminal to the CD3-binding region. This positioning of the Fc adjacent to the CD3-binding region prevents CD3 binding. [Figure 3B] See legend to Figure 3A. [Figure 3C] See legend to Figure 3A. [Figure 3D] See legend to Figure 3A. [Figure 3E] See legend to Figure 3A. [Figure 4] Figures 4A-4C illustrate the presence or absence of binding of cx3855 or B7H3xCD3 DART-Fc to B7H3 target cells or T cells. Figure 4A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 4B illustrates the presence or absence of binding to primary human T cells. Figure 4C illustrates a titration comparing binding to A375 and primary human T cells. [Diagram 5] Figures 5A-5C illustrate the presence or absence of cx4137 binding to B7H3 target cells or T cells. Figure 5A illustrates the presence or absence of binding to B7H3 positive A375 cells. Figure 5B illustrates the presence or absence of binding to primary human T cells. Figure 5C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 6]Figures 6A-6C illustrate the presence or absence of cx3090 binding to B7H3 target cells or T cells. Figure 6A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 6B illustrates the presence or absence of binding to primary human T cells. Figure 6C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 7] Figures 7A-7C illustrate the presence or absence of cx3243 binding to B7H3 target cells or T cells. Figure 7A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 7B illustrates the presence or absence of binding to primary human T cells. Figure 7C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 8] Figures 8A-8C illustrate the presence or absence of cx4736 binding to B7H3 target cells or T cells. Figure 8A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 8B illustrates the presence or absence of binding to primary human T cells. Figure 8C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 9] Figures 9A-9C show the binding or non-binding of cx4136 to B7H3 target cells or T cells. Figure 9A shows the binding or non-binding to the A375 cell line, which is a B7H3 positive cell. Figure 9B shows the binding or non-binding to primary human T cells. Figure 9C shows a titration comparing the binding to A375 and primary human T cells. [Figure 10] Figures 10A-10C illustrate the presence or absence of cx3072 binding to B7H3 target cells or T cells. Figure 10A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 10B illustrates the presence or absence of binding to primary human T cells. Figure 10C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 11]Figures 11A-11C show the binding or non-binding of cx4641 to B7H3 target cells or T cells. Figure 11A shows the binding or non-binding of cx4641 to the A375 cell line, which is a B7H3 positive cell. Figure 11B shows the binding or non-binding of cx4641 to primary human T cells. Figure 11C shows a titration comparing the binding to A375 and primary human T cells. [Figure 12] Figures 12A-12C show the binding or non-binding of cx4645 to B7H3 target cells or T cells. Figure 12A shows the binding or non-binding of cx4645 to B7H3 positive cells, the A375 cell line. Figure 12B shows the binding or non-binding of cx4645 to primary human T cells. Figure 12C shows a titration comparing the binding to A375 and primary human T cells. [Figure 13] Figures 13A-13C illustrate the presence or absence of cx4736 (50 nM) binding to B7H3 target cells or T cells. Figure 13A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 13B illustrates the presence or absence of binding to primary human T cells. Figure 13C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 14] Figures 14A-14C illustrate the presence or absence of cx4736 (12.5 nM) binding to B7H3 target cells or T cells. Figure 14A illustrates the presence or absence of binding to the A375 cell line, which is a B7H3 positive cell. Figure 14B illustrates the presence or absence of binding to primary human T cells. Figure 14C illustrates a titration comparing binding to A375 and primary human T cells. [Figure 15] Figures 15A-15C show the binding or non-binding of cx2846 to B7H3 target cells or T cells. Figure 15A shows the binding or non-binding to the A375 cell line, which is a B7H3 positive cell. Figure 15B shows the binding or non-binding to primary human T cells. Figure 15C shows a titration comparing the binding to A375 and primary human T cells. [Figure 16]Figures 16A-16C show the binding or non-binding of cx3834 to B7H3 target cells or T cells. Figure 16A shows the binding or non-binding of cx3834 to the A375 cell line, which is a B7H3 positive cell. Figure 16B shows the binding or non-binding of cx3834 to primary human T cells. Figure 16C shows a titration comparing the binding to A375 and primary human T cells. [Figure 17] Figures 17A-17C show the binding or non-binding of cx3960 to B7H3 target cells or T cells. Figure 17A shows the binding or non-binding to the A375 cell line, which is a B7H3 positive cell. Figure 17B shows the binding or non-binding to primary human T cells. Figure 17C shows a titration comparing the binding to A375 and primary human T cells. [Figure 18] Figures 18A-18C show the binding or non-binding of cx4904 to B7H3 target cells or T cells. Figure 18A shows the binding or non-binding to the A375 cell line, which is a B7H3 positive cell. Figure 18B shows the binding or non-binding to primary human T cells. Figure 18C shows a titration comparing the binding to A375 and primary human T cells. [Figure 19] Figures 19A-19C show the binding or non-binding of cx4908 to B7H3 target cells or T cells. Figure 19A shows the binding or non-binding of cx4908 to B7H3 positive cells, the A375 cell line. Figure 19B shows the binding or non-binding of cx4908 to primary human T cells. Figure 19C shows a titration comparing the binding to A375 and primary human T cells. [Figure 20] Figures 20A-20B illustrate graphs demonstrating the ability of B7H3-targeted constrained CD3-engaging constructs to elicit B7H3-dependent T cell activation. T cell activation was monitored using Jurkat CD3 NFAT-GFP reporter cell lines. A375 cells (Figure 20A) and A375 cells with CRISPR-disrupted B7H3 gene (A375 B7H3- / -, Figure 20B) were used as antigen-positive and antigen-negative cell lines, respectively. Bispecific B7H3xCD3 in the DART-Fc format was used as a comparison. [Figure 21]Figures 21A-21B illustrate graphs demonstrating the ability of B7H3-targeting constrained CD3-engaging constructs to mediate antigen-specific T cell cytotoxicity against the B7H3-positive cell line A375 (Figure 21A) or an A375 cell line in which the B7H3 gene has been disrupted by CRISPR (A375 B7H3- / -, Figure 21B), used as antigen-positive and antigen-negative cell lines, respectively. Bispecific B7H3xCD3 in the DART-Fc format was used as a comparison. [Figure 22] Figures 22A-22B illustrate CD25 expression in CD4+ T cells in the presence of restricted CD3-engaging constructs targeting B7H3 during co-culture of T cells with either B7H3-positive cells (A375; Figure 22A) or B7H3-negative cells (A375 B7H3- / -; Figure 22B). [Diagram 23] Figures 23A-23B illustrate CD69 expression on CD4+ T cells in the presence of restricted CD3-engaging constructs targeting B7H3 during co-culture of T cells with either B7H3-positive cells (A375; Figure 23A) or B7H3-negative cells (A375 B7H3- / -; Figure 23B). [Figure 24] Figures 24A-24B illustrate CD71 expression in CD4+ T cells in the presence of restricted CD3-engaging constructs targeting B7H3 during co-culture of T cells with either B7H3-positive cells (A375; Figure 24A) or B7H3-negative cells (A375 B7H3- / -; Figure 24B). [Diagram 25] Figures 25A-25B illustrate CD25 expression in CD8+ T cells in the presence of restricted CD3-engaging constructs targeting B7H3 during co-culture of T cells with either B7H3-positive cells (A375; Figure 25A) or B7H3-negative cells (A375 B7H3- / -; Figure 25B). [Figure 26]Figures 26A-26B illustrate CD69 expression on CD8+ T cells in the presence of restricted CD3-engaging constructs targeting B7H3 during co-culture of T cells with either B7H3-positive cells (A375; Figure 26A) or B7H3-negative cells (A375 B7H3- / -; Figure 26B). [Figure 27] Figures 27A-27B illustrate CD71 expression in CD8+ T cells in the presence of restricted CD3-engaging constructs targeting B7H3 during co-culture of T cells with either B7H3-positive cells (A375; Figure 27A) or B7H3-negative cells (A375 B7H3- / -; Figure 27B). [Figure 28A] Figures 28A-28D depict a series of graphs demonstrating the ability of B7H3-targeted restricted CD3-engaging constructs to elicit the production of IFNγ (Figures 28A-28C) or TNFα (Figure 28D) from T cells or PBMCs in an antigen-dependent manner. Cytokine production was monitored using FluoroSpot assays in the presence or absence of the B7H3-positive cell line A375. [Figure 28B] See legend to Figure 28A. [Figure 28C] See legend to Figure 28A. [Figure 28D] See legend to Figure 28A. [Figure 29] Figure 29A illustrates the ability of 58E05-Fc to induce ADCC of A375 target cells, as assessed using a Jurkat reporter engineered to stably express CD16a with an NFAT-driven luciferase reporter gene. Figure 29B illustrates the ability of humanized variants of 58E05-Fc and 1A5-Fc to induce ADCC of SHP-77 target cells, as assessed using a Jurkat reporter engineered to stably express CD16a with an NFAT-driven luciferase reporter gene. A conventional anti-B7H3 IgG1 antibody was used as a comparison, which did not show the ability to mediate CD16a expression in the presence of SHP-77, a cell line that expresses low to intermediate levels of B7H3. [Figure 30A]Figure 30A is a schematic diagram of various B7H3-targeting constrained CD3 constructs composed of two polypeptides, chain 1 and chain 2. Chain 1 contains either a heterodimeric Fc "hole" linked via a non-cleavable linker to a G100C modified anti-CD3 VL domain (top); a B7H3-targeting sdAb linked to a heterodimeric Fc "hole" linked via a non-cleavable linker to an anti-CD3 VL domain (middle); or a B7H3-targeting sdAb linked to a heterodimeric Fc "hole" linked via a non-cleavable linker to a G100C modified anti-CD3 VL domain (bottom). Chain 2 contains either a B7H3-targeting sdAb linked to a complementary heterodimeric Fc "knob" linked via a linker as described above to a G44C-modified anti-CD3 VH domain linked to a second B7H3 sdAb (top); a B7H3-targeting sdAb linked to a complementary heterodimeric Fc "knob" linked via a linker as described above to an anti-CD3 VH domain (middle); or a B7H3-targeting sdAb linked to a complementary heterodimeric Fc "knob" linked via a linker as described above to a G44C-modified anti-CD3 VH domain (bottom). When co-expressed, the CD3-binding domains assemble properly via VL:VH association on the hole and knob, respectively. Where depicted, the VH:VL interaction is stabilized by an engineered disulfide bond between altered residues G44C in the VH domain and G100C in the VL domain. [Figure 30B]Figure 30B is a schematic diagram of various B7H3-targeting constrained CD3 constructs composed of two polypeptides, chain 1 and chain 2. Chain 1 contains a heterodimeric Fc "hole" linked via a non-cleavable linker to a G100C modified anti-CD3 VL domain linked to a costimulatory receptor-targeting sdAb. Chain 2 contains either a B7H3-targeting sdAb linked to a complementary heterodimeric Fc "knob" linked via a linker as described above to a G44C-modified anti-CD3 VH domain linked to a second B7H3-targeting sdAb (top); a heterodimeric Fc "knob" linked via a linker as described above to a G44C-modified anti-CD3 VH domain linked to a B7H3-targeting sdAb (middle); or a B7H3-targeting sdAb linked to a complementary heterodimeric Fc "knob" linked via a linker as described above to a G44C-modified anti-CD3 VH domain (bottom). When co-expressed, the CD3 binding domains assemble properly via VL:VH association on the hole and knob, respectively. The VH:VL interaction is stabilized by an engineered disulfide bond between modified residues G44C in the VH domain and G100C in the VL domain. The resulting constructs engage B7H3 in either a bivalent (top) or monovalent (middle and bottom) manner. All constructs herein contain sdAbs that target costimulatory receptors. [Figure 30C]Figure 30C is a schematic diagram of various B7H3-targeting constrained CD3 constructs composed of three polypeptides, chain 1, chain 2, and chain 3, where the B7H3 targeting domain is FAB. Chain 1 contains an IgG constant heavy chain 1 (CH1) linked via a hinge to a first member of a heterodimeric Fc (Fc-Het-1) linked via a linker as described above to a VH that targets BH73, an anti-CD3 VL domain that either lacks (top) or contains (middle) the G100C modification. Chain 2 contains an IgG constant heavy chain 1 (CH1) linked via a hinge to a second member of a heterodimeric Fc (Fc-Het-2) linked via a linker as described above to a VH that targets BH73, an anti-CD3 VH domain that either lacks (top) or contains (middle) the G44C modification. Chain 3 contains a complementary B7H3-targeting VL domain linked to a human Ig constant light (CL) region. When co-expressed, the CD3-binding domain assembles properly via VL:VH association on the complementary heterodimeric Fc region. When depicted, the VH:VL interaction is stabilized by an engineered disulfide bond between modified residues G44C in the VH domain and G100C in the VL domain. [Figure 31-1] Figures 31A-F illustrate cell binding by a representative B7H3-targeting restricted CD3-engaging construct. Figures 31A, C, and E show binding to A375 cells (a B7H3-positive human melanoma cell line). Figures 31B, D, and F show lack of binding to isolated T cells. [Figure 31-2] See description of Figure 31-1. [Diagram 32]Figures 32A-D illustrate the ability of representative B7H3-targeted constrained CD3-engaging constructs to agonize CD3 in a target-dependent manner. Figures 32A and 32C illustrate the ability to mediate CD3 signaling in the presence of B7H3-positive A375 cells, while Figures 32B and 32D show the inability to mediate CD3 signaling in the presence of B7H3-negative CCRF-CEM cells. CD3 agonism was assessed using the Jurkat CD3 NFAT-GFP reporter cell line. [Diagram 33] Figure 33A illustrates the ability of a representative B7H3-targeting constrained CD3-engaging construct (cx3072) to induce T cell-mediated cytotoxic activity in a target-dependent manner. Target cells were labeled with cytoID red label, and dead cells were visualized by addition of caspase 3 / 7 green reagent. Cytotoxic activity was assessed by measuring the overlap area of ​​red target cells and green dead cells. Antigen-specific T cell-mediated cytotoxic activity was tested using B7H3-negative A375 cell lines generated by CRISPR technology. cx3072 was unable to trigger T cell-mediated cytotoxic activity of these B7H3-deficient A375 cells. Figure 33B shows the ability of cx5952 to induce T cell-mediated cytotoxic activity in the presence of B7H3-positive A375 cells, but not in the presence of B7H3-negative CCRF-CEM cells. [Diagram 34]Figures 34A and 34B illustrate the ability of representative B7H3-targeted restricted CD3-engaging constructs to induce T cell-mediated cytotoxic activity in a target-dependent manner. Figure 34A illustrates the ability of these constructs to induce T cell-mediated cytotoxic activity in the presence of B7H3-positive A375 cells, while Figure 34B illustrates the ability of these constructs to induce T cell-mediated cytotoxic activity in the presence of B7H3-negative CCRF-CEM cells. Cytotoxic activity was assessed by measuring the overlap area between red target cells and green dead cells. Figures 34C and 34D illustrate the ability of representative B7H3-targeted restricted CD3-engaging constructs to induce T cell-mediated cytotoxic activity in a target-dependent manner. Figure 34C illustrates the ability of these constructs to induce T cell-mediated cytotoxicity in the presence of B7H3-positive A375 cells, while Figure 34C illustrates the ability of these constructs to induce T cell-mediated cytotoxicity in the presence of B7H3-negative CCRF-CEM cells. Cytotoxicity was assessed by measuring the overlap area between red target cells and green dead cells. [Figure 35-1]Figures 35A-C illustrate the ability of a representative B7H3-targeted restricted CD3-engaging construct (cx5952) to induce T cell-mediated cytotoxic activity and T cell activation in a target-dependent manner. Cytotoxic activity was assessed by measuring the overlap area of ​​red target cells and green dead cells. Figures 35A-C show the ability of cx5952 to activate CD4+ and CD8+ T cells in a target-dependent manner. T cell activation was assessed by expression of T cell activation markers CD25 (Figure 35A), CD69 (Figure 35B), and CD71 (Figure 35C). Figures 35D-35K illustrate the ability of a representative B7H3-targeted restricted CD3-engaging construct to induce T cell activation in a target-dependent manner. B7H3-targeted dependent CD4+ T cell activation is indicated by expression of T cell activation markers CD25 (Figure 35D) and CD71 (Figure 35F). B7H3 target-dependent CD8+ T cell activation is shown by expression of T cell activation markers CD25 (FIG. 35H) and CD71 (FIG. 35J). No non-target CD8+ T cell activation was observed based on the T cell activation marker CD25 as shown in CD4+ T cells (FIG. 35E) or CD8+ T cells (FIG. 31), or based on the T cell activation marker CD71 as shown in CD4+ T cells (FIG. 35G) or CD8+ T cells (FIG. 35K). [Figure 35-2] See description of Figure 35-1. [Figure 35-3] See description of Figure 35-1. [Figure 36A] Figure 36A illustrates the ability of a representative B7H3-targeted restricted CD3-engaging construct to induce IFNγ production in a target-dependent manner. Figure 36A shows the production of IFNγ from T cells cultured with B7H3-positive A375 cells or B7H3-negative CCRF-CEM cells in the presence of a B7H3-targeted CD3-engaging construct. [Figure 36B]Figure 36B illustrates the ability of a representative B7H3-targeted restricted CD3-engaging construct to induce IFNγ production in a target-dependent manner. Figure 36B shows the production of IFNγ from T cells cultured with B7H3-positive A375 cells or B7H3-negative CCRF-CEM cells in the presence of a B7H3-targeted CD3-engaging construct. [Figure 37] Figures 37A and 37B illustrate the cell binding of representative B7H3-targeting constrained CD3-engaging constructs. cx5187 and cx5823 each contain two B7H3-binding domains, while constructs cx5873 and cx5965 each contain one B7H3-binding domain. Figure 37A shows binding to B7H3-positive A375 cells. Figure 37B shows lack of binding to B7H3-negative CCRF-CEM cells and isolated T cells. Figures 37C and 37D illustrate the ability of representative B7H3-targeting constrained CD3-engaging constructs to agonize CD3 in a target-dependent manner. Figure 37C shows that engagement of B7H3-positive A375 cells with a molecule that is bivalent and bi-epitopic to B7H3 (cx5187) induced stronger CD3 signaling than constructs that are monovalent to B7H3 (cx5873 and cx5965). Figure 37D shows the lack of T cell activation in the presence of B7H3-negative CCRF-CEM cells. CD3 agonism was assessed using the Jurkat CD3 NFAT-GFP reporter cell line. [Figure 38] Figure 38A and Figure 38B illustrate the ability of representative B7H3-targeting constrained CD3-engaging constructs to induce T cell-mediated cytotoxic activity in a target-dependent manner. Figure 38A shows that targeting B7H3-positive A375 cells with a construct that is bivalent and bi-epitopic to B7H3 (cx5187) induced stronger T cell-mediated cytotoxic activity than constructs that are monovalent to B7H3 (cx5873 and cx5965). Figure 38B illustrates the lack of T cell-mediated cytotoxic activity against B7H3-negative CCRF-CEM cells. [Figure 39]Figures 39A-D illustrate the ability of representative B7H3-targeting constrained CD3-engaging constructs to activate T cells in the presence of B7H3-positive A375 cells, but not in the presence of B7H3-negative CCRF-CEM cells. Figures 39A and 39B show that targeting B7H3-positive A375 cells with a construct that is bivalent and bi-epitopic to B7H3 (cx5187) induced stronger CD25 expression on CD4+ and CD8+ T cells, respectively, than constructs that are monovalent to B7H3 (cx5873 and cx5965). Figures 39C and 39D show the lack of CD25 expression on CD4+ and CD8+ T cells, respectively, in the presence of B7H3-negative CCRF-CEM cells. [Figure 40-1] Figures 40A and 40B demonstrate the ability of a representative B7H3-targeting restricted CD3-engaging construct to elicit T cell-mediated cytotoxicity in the presence of B7H3-positive A375 cells (Figure 40A), but not in the presence of CCRF-CEM B7H3-negative cells (Figure 40B). Figures 40C-40J demonstrate the ability of a representative B7H3-targeting restricted CD3 engaging construct to elicit T cell activation in the presence of B7H3 positive A375 cells, but not in the presence of CCRF-CEM B7H3 negative cells, as assessed by expression of CD25 on CD4+ T cells (Figures 40C and 40D, respectively), CD25 expression on CD8+ T cells (Figures 40E and 40F, respectively), CD71 expression on CD4+ T cells (Figures 40G and 40H, respectively), and CD71 expression on CD8+ T cells (Figures 40I and 40J, respectively). Figures 40K and 40L demonstrate the ability of a representative B7H3-targeting restricted CD3-engaging construct to elicit T cell cytokine production in the presence of B7H3-positive A375 cells (Figure 40K), but not in the presence of CCRF-CEM B7H3-negative cells (Figure 40L). [Figure 40-2] See description of Figure 40-1. [Figure 40-3] See description of Figure 40-1. [Figure 40-4] See description of Figure 40-1. [Diagram 41] Figures 41A-41B illustrate various representative B7H3-targeting constrained CD3 engagers with 4-1BB binding domains as CRBRs. cx5841 and cx5187 have a B7H3-targeting sdAb positioned at the N-terminus and C-terminus of the Fc knob, one chain of the heterodimer, and a 41BB-targeting sdAb positioned at the C-terminus of the Fc hole, the opposite chain of the heterodimer, but with the VH and VL of the CD3-binding Fv positioned opposite each other. [Figure 42-1] Figures 42A-D illustrate the results of a T cell reporter assay for the exemplary constructs described in Figures 41A-B. Figures 42A and 42B illustrate the mean fluorescence intensity (MFI) of the GFP reporter when the B7H3 positive cell line A375 or the B7H3 negative cell line CCRF-CEM, respectively, are co-cultured with Jurkat CD3 NFAT-GFP reporter cells. Figures 42C and 42D illustrate the relative light units (RLU) of the luciferase reporter when the B7H3 positive cell line A375 or the B7H3 negative cell line CCRF-CEM, respectively, are co-cultured with Jurkat CD3 NFAT-luciferase reporter cells. [Figure 42-2] See description of Figure 42-1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0078] Detailed Description Polypeptides that specifically bind to B7H3, hereinafter also referred to as B7H3 binding polypeptides, are provided herein. In some embodiments, the binding polypeptides provided comprise at least one VHH domain that binds to B7H3. In some embodiments, the B7H3 binding polypeptides provided herein comprise one, two, three, four, five, six, seven, or eight VHH domains, each of which individually binds to B7H3. In some embodiments, the B7H3 binding polypeptides provided herein comprise one, two, three, or four VHH domains that bind to B7H3. In some embodiments, the B7H3 binding polypeptides are monospecific. In some embodiments, the B7H3 binding polypeptides are multispecific. For example, the B7H3 binding polypeptides provided include polypeptides that may comprise at least one VHH domain that binds to B7H3 and one or more additional binding domains, such as one or more additional VHH domains that bind to one or more target proteins other than B7H3.

[0079] In some embodiments, the B7H3 binding polypeptide comprises at least one VHH domain that binds to B7H3 and an Fc domain. In some embodiments, the B7H3 binding polypeptide provided herein comprises one, two, three, or four VHH domains that bind to B7H3 and an Fc domain. In some embodiments, the Fc domain mediates the dimerization of the B7H3 binding polypeptide under physiological conditions, such that a dimer is formed that doubles the number of B7H3 binding sites. For example, a B7H3 binding polypeptide comprising three VHH domains that bind to B7H3 and an Fc region is trivalent as a monomer, but under physiological conditions, the Fc region can mediate dimerization such that the B7H3 binding polypeptide exists as a hexavalent dimer under such conditions.

[0080] B7H3 (also called CD276) is a member of the B7 family of immune cell regulatory molecules. It is expressed on the surface of a wide variety of tumor cells and tumor vasculature, including but not limited to neuroblastoma, melanoma, renal cell carcinoma, prostate cancer, colon cancer, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, and small cell lung cancer. In humans, B7H3 protein is expressed in two forms, 2Ig and 4Ig. The 2Ig form, like other B7 family members, has an extracellular region that contains only one V-like and one C-like Ig domain (Chapoval et al, 2001, Nat. Immunol. 2:269-274). Type 4Ig contains tandem double V-like and C-like Ig domains (Steinberger et al, 2004, J. Immunol. 172:2352-2359; Sun et al, 2002, J. Immunol. 168:6294-6297) and has been shown to be the predominant isoform induced on immune and tumor cells in humans (Zhou et al. (2007) Tissue Antigens, 70:96-104). In some cases, the level of B7H3 expression on tumor tissue has been shown to strongly correlate with the extent to which the tumor has metastasized, which is accompanied by an increased risk of clinical cancer recurrence and cancer-specific death (Roth et al, 2007, Cancer Res. 67:7893-7900; Zang et al, 2007, Proc. Natl. Acad. Sci. USA 104: 19458-19463).Similarly, high levels of B7H3 expression on tumor tissues have been shown to be associated with clear cell renal cell carcinoma, urothelial cell carcinoma (Crispen et al, 2008, Clin. Cancer Res. 14:5150-5157;Boorjian et al., 2008, Clin. Cancer Res. 14:4800-4808), ovarian cancer (Zang et al, 2010, Mod. Pathol. 23: 1 104-1 112), glioblastoma (Lemke et al, 2012, Clin. Cancer Res. 18: 105-117), osteosarcoma (Wang et al, 2013, PLoS One 8:e70689), and pancreatic cancer (Yamato et al, 2009, Br. J. Cancer 101 : 1709-1716), and has been correlated with poor patient survival in neuroblastoma (Gregorio et al, 2008, Histopathology 53:73-80).

[0081] An exemplary sequence for human B7H3(4ig) is shown below. TIFF2024167342000010.tif36143 (SEQ ID NO:190, signal sequence underlined)

[0082] In some cases, the B7H3 binding polypeptides provided directly block or inhibit the activity of B7H3, which in some aspects can be used as therapeutic agents to inhibit or reduce the growth or survival of tumor cells.

[0083] A variety of B7H3 polypeptide binding formats are provided. In some examples, the B7H3 binding polypeptide comprises a B7H3 VHH-Fc polypeptide. In some embodiments, the Fc is an Fc that exhibits one or more effector functions, such as immune effector activity, for example, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and / or complement-dependent cytotoxicity (CDC).

[0084] In some embodiments, the B7H3 binding polypeptides provided herein can be used to stimulate an immune response in a subject, which in some aspects treats a disease or disorder, such as cancer, in a subject. In some aspects, the B7H3 binding polypeptides provided herein, such as B7H3-Fc, can bind to B7H3-expressing tumor cells and induce an active immune response against tumor cells expressing B7H3. In some cases, the active immune response can cause the death of cancerous cells (e.g., antibody binding to cancer cells induces apoptotic cell death) or inhibit the growth of cancerous cells (e.g., block cell cycle progression). In other cases, the B7H3 binding polypeptides provided herein, such as B7H3 VHH-Fc, can bind to cancerous cells and antibody-dependent cellular cytotoxicity (ADCC) can eliminate the cancerous cells to which the B7H3 binding polypeptide binds. In some cases, the provided B7H3 VHH binding polypeptides can also activate both cellular and humoral immune responses, recruiting more natural killer cells or increased production of cytokines (e.g., IL-2, IFN-γ, IL-12, TNF-α, TNF-β, etc.) that further activate an individual's immune system to destroy cancerous cells. In yet another embodiment, a B7H3 binding polypeptide, such as a B7H3 VHH-Fc, can bind to cancerous cells and allow macrophages or other phagocytic cells to opsonize the cancerous cells, for example, via the CDC or ADCP process.

[0085] In other aspects, also provided herein are VHH binding polypeptides that exhibit multispecific binding. In some cases, the binding polypeptides include a polypeptide that exhibits dual affinity for B7H3 and a T cell antigen, such as CD3. In some aspects, such dual affinity molecules can engage or activate T cells at the site of tumors upon binding of tumor-expressed B7H3. In particular, among such molecules provided herein are molecules that exhibit restricted CD3 binding. Also provided herein are engineered cells, such as engineered T cells, that express chimeric antigen receptors that contain B7H3 binding polypeptides.

[0086] All publications, including patent documents, scientific papers, and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. In the event that the definitions set forth herein conflict or are otherwise inconsistent with the definitions set forth in the patents, applications, published applications, and other publications incorporated herein by reference, the definitions set forth herein take precedence over the definitions incorporated herein by reference.

[0087] The techniques and procedures described or referenced herein are generally well understood and may be found in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FM Ausubel, et al. eds., (2003)); METHODS IN ENZYMOLOGY (Academic Press, Inc.) series: PCR 2: A PRACTICAL APPROACH (MJ MacPherson, BD Hames and GR Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (RI Freshney, ed. (1987)); Oligonucleotide Synthesis (MJ Gait, ed., 1984);Methods in Molecular Biology, Humana Press;Cell Biology: A Laboratory Notebook (JE Cellis, ed., 1998) Academic Press;Animal Cell Culture (RI Freshney), ed., 1987);Introduction to Cell and Tissue Culture (JP Mather and PE Roberts, 1998) Plenum Press;Cell and Tissue Culture Laboratory Procedures (A. Doyle, JB Griffiths, and DG Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (DMWeir and CC Blackwell, eds.);Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987);PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994);Current Protocols in Immunology (JE Coligan et al., eds., 1991);Short Protocols in Molecular Biology (Wiley and Sons, 1999);Immunobiology (CA Janeway and P. Travers, 1997);Antibodies (P. Finch, 1997);Antibodies: A Practical Approach (D. Catty., ed., IRL Press, 1988-1989);Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000);Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT DeVita et al., eds., JB Lippincott Company, 1993); and commonly used by those skilled in the art.

[0088] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0089] I. Definition Unless otherwise defined, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by those skilled in the art. Further, unless otherwise required by context or expressly indicated, singular terms shall include the plural and plural terms shall include the singular. In the event of any discrepancy in definitions among various sources or references, the definitions provided herein shall control.

[0090] It is understood that the embodiments of the invention described herein include "consisting of" and / or "consisting essentially of" embodiments. As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. Use of the term "or" herein is not intended to imply that alternatives are mutually exclusive.

[0091] In this application, unless expressly stated or understood by a person skilled in the art, the use of "or" means "and / or." In the context of multiple dependent claims, the use of "or" refers back to more than one such independent or dependent claim.

[0092] The term "about" as used herein refers to the normal error range for each value, which is easily understood by those skilled in the art. Reference herein to a value or parameter with "about" includes (and describes) the embodiment directed to the value or parameter itself. For example, a description that refers to "about X" includes the description of "X".

[0093] The terms "nucleic acid molecule," "nucleic acid," and "polynucleotide" may be used interchangeably and refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and / or non-natural nucleotides, including, but not limited to, DNA, RNA, and PNA. A "nucleic acid sequence" refers to the linear sequence of nucleotides contained in a nucleic acid molecule or polynucleotide.

[0094] As used herein, the term "isolated polynucleotide" is intended to mean a polynucleotide of genomic, cDNA, or synthetic origin, or some combination thereof, that, by reason of its origin, (1) is not associated with all or a portion of polynucleotides found in nature, (2) is operatively linked to polynucleotides with which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.

[0095] The terms "polypeptide" and "protein" are used interchangeably to refer to polymers of amino acid residues and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, including, but not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by definition. The term also includes post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for the purposes of this disclosure, "polypeptide" refers to proteins that contain modifications, such as deletions, additions, and substitutions (generally conservative in nature), relative to the native sequence, so long as the protein maintains the desired activity. These modifications may be deliberate, such as through site-directed mutagenesis, or may be accidental, such as through mutations of the host that produces the protein or through errors due to PCR amplification.

[0096] The term "isolated protein" as referred to herein means that the subject protein is (1) free from at least some other proteins with which it is typically found in nature, (2) essentially free from other proteins from the same source, e.g., from the same species, (3) expressed by cells from a different species, (4) separated from at least about 50% of the polynucleotides, lipids, carbohydrates, or other materials with which it is naturally associated, (5) the "isolated protein" is not associated (by covalent or non-covalent interactions) with portions of proteins with which it is naturally associated, (6) functionally associated (by covalent or non-covalent interactions) with polypeptides with which it is not naturally associated, or (7) non-naturally occurring. Such isolated proteins can be encoded by genomic DNA, cDNA, mRNA, or other RNA, can be of synthetic origin, or any combination thereof. In certain embodiments, an isolated protein is substantially pure or substantially free from proteins, or polypeptides, or other contaminants found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research, or otherwise).

[0097] As used herein, "substantially pure" means that the species of interest is the predominant species present (i.e., on a molar basis, it is more abundant than any other individual species in the composition), and a substantially purified fraction is a composition in which the species of interest constitutes at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition constitutes greater than about 80% of all macromolecular species present in the composition, e.g., in some embodiments, greater than about 85%, 90%, 95%, and 99%. In some embodiments, the species of interest is purified to essential homogeneity (no contaminant species can be detected in the composition by conventional detection methods), in which the composition consists essentially of a single macromolecular species.

[0098] As used herein, the term "operably linked" refers to the position of the components so described being in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

[0099] The term "specifically binds" to an antigen or epitope is a term well understood in the art, and methods for determining such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" or "preferential binding" when it reacts or associates with a particular cell or substance more frequently, more rapidly, for a longer duration, and / or with a higher affinity than with alternative cells or substances. A single domain antibody (sdAb) or VHH-containing polypeptide "specifically binds" or "preferentially binds" to a target when it binds with higher affinity, avidity, more readily, and / or for a longer duration than it binds to other substances. For example, an sdAb or VHH-containing polypeptide that specifically or preferentially binds to the B7H3 epitope is an sdAb or VHH-containing polypeptide that binds to this epitope with higher affinity, avidity, more readily, and / or for a longer duration than it binds to other B7H3 epitopes or non-B7H3 epitopes. For example, it is understood by reading this definition that an sdAb or VHH-containing polypeptide that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. Thus, "specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding refers to preferential binding. "Specificity" refers to the ability of a binding protein to selectively bind to an antigen.

[0100] As used herein, the term "epitope" refers to a site on a target molecule (e.g., an antigen such as a protein, nucleic acid, carbohydrate, or lipid) to which an antigen-binding molecule (e.g., an sdAb or VHH-containing polypeptide) binds. Epitopes often comprise a chemically active surface arrangement of molecules such as amino acids, polypeptides, or sugar side chains, and have specific three-dimensional structural characteristics and specific charge characteristics. Epitopes can be formed from both contiguous and / or juxtaposed non-contiguous residues (e.g., amino acids, nucleotides, sugars, lipid moieties) of a target molecule. Epitopes formed from contiguous residues (e.g., amino acids, nucleotides, sugars, lipid moieties) are typically retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents. Epitopes can comprise, but are not limited to, at least 3, at least 5, or 8-10 residues (e.g., amino acids or nucleotides). In some embodiments, an epitope is less than 20 residues (e.g., amino acids or nucleotides), less than 15 residues, or less than 12 residues in length. Two antibodies may bind to the same epitope in an antigen if they exhibit competitive binding to the antigen. In some embodiments, an epitope can be specified by a certain minimum distance to the CDR residues on the antigen-binding molecule. In some embodiments, an epitope can be specified by the above distances and further limited to those residues involved in binding (e.g., hydrogen bonds) between the antigen-binding molecule residues and the antigen residues. Epitopes can also be specified by various scans, for example, alanine scans or arginine scans can indicate one or more residues with which the antigen-binding molecule may interact. Unless expressly indicated, a set of residues as an epitope does not exclude other residues from being part of the epitope for a particular antigen-binding molecule. Rather, the existence of such a set indicates a minimum series (or species set) of epitopes. Thus, in some embodiments, the set of residues identified as an epitope represents the minimal epitope associated with the antigen, rather than an exclusive list of residues for the epitope on the antigen.

[0101] A "non-linear epitope" or "conformational epitope" comprises non-contiguous polypeptides, amino acids, and / or sugars in an antigen protein to which an epitope-specific antigen-binding molecule binds. In some embodiments, at least one of the residues will be non-contiguous with other referenced residues of the epitope; however, one or more of the residues may also be contiguous with other residues.

[0102] A "linear" epitope comprises adjacent polypeptides, amino acids, and / or sugars in an antigen protein to which an antigen-binding molecule specific for the epitope binds. In some embodiments, it is noted that not all of the residues in a linear epitope need to be directly bound (or involved in binding) to an antigen-binding molecule. In some embodiments, a linear epitope can be derived from immunization with a peptide that effectively consists of the sequence of a linear epitope, or from a structural segment of a protein that has just that sequence segment and is relatively isolated from the rest of the protein (so that the antigen-binding molecule can at least primarily interact with it).

[0103] The terms "antibody" and "antigen-binding molecule" are used interchangeably in the broadest sense and encompass a variety of polypeptides that contain antibody-like antigen-binding domains, including but not limited to conventional antibodies (typically comprising at least one heavy chain and at least one light chain), single domain antibodies (sdAbs, typically comprising only one chain, similar to a heavy chain), VHH-containing polypeptides (polypeptides comprising at least one heavy chain-only antibody variable domain, i.e., VHH), and fragments of any of the foregoing, so long as they exhibit the desired antigen-binding activity. In some embodiments, the antibody comprises a dimerization domain. Such dimerization domains include, but are not limited to, heavy chain constant domains (comprising CH1, hinge, CH2, and CH3, where CH1 typically pairs with CL, the light chain constant domain, while the hinge mediates dimerization), and Fc domains (comprising hinge, CH2, and CH3, where the hinge mediates dimerization).

[0104] The term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as camelid (including llama), shark, mouse, human, cynomolgus monkey, etc.

[0105] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable regions of the heavy and light chains of a natural antibody (V H and V L ) generally have a similar structure, with each domain containing four conserved framework regions (FRs) and three CDRs. (See, e.g., Kindt et al. Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007).) A single V H or V L A single domain may be sufficient to confer antigen-binding specificity to a single domain antibody, such as a VHH. Furthermore, antibodies that bind to a particular antigen can be identified by dividing the VHHs by the VHHs derived from the antibody that binds the antigen. H or V LUsing the domains, each complementary V L or V H Libraries of domains may be screened and isolated. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).

[0106] "Antibody fragment" or "antigen-binding fragment" refers to a molecule other than a conventional or intact antibody that contains a portion of a conventional or intact antibody that contains at least the variable region that binds to an antigen. Examples of antibody fragments include Fv, single chain Fv (sdFv), Fab, Fab', Fab'-SH, F(ab') 2 ;Diabody;Linear antibody;V H This includes, but is not limited to, single domain antibodies (VHH) which comprise only the domain.

[0107] As used herein, "monovalent" in reference to a binding molecule refers to a binding molecule that has a single antigen recognition site that is specific to a target antigen. Examples of monovalent binding molecules include, for example, monovalent antibody fragments, proteinaceous binding molecules with antibody-like binding properties, or MHC molecules. Examples of monovalent antibody fragments include, but are not limited to, Fab fragments, Fv fragments, and single-chain Fv fragments (scFv).

[0108] The terms "single domain antibody", "sdAb", "VHH" are used interchangeably herein to refer to an antibody having an antigen binding / recognition domain that is a single monomer domain. Such antibodies include camelid antibodies or shark antibodies. In some embodiments, the VHH comprises three CDRs and four framework regions, designated FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In some embodiments, the VHH may be truncated at the N-terminus or C-terminus to comprise only partial FR1 and / or FR4, or to lack one or both of these framework regions, so long as the VHH substantially maintains antigen binding and specificity.

[0109] The term "VHH-containing polypeptide" refers to a polypeptide comprising at least one VHH domain. In some embodiments, a VHH polypeptide comprises two, three, or four or more VHH domains, each of which may be the same or different. In some embodiments, a VHH-containing polypeptide comprises an Fc domain. In some such embodiments, a VHH polypeptide may form a dimer. Non-limiting structures of a VHH-containing polypeptide include a VHH 1 -Fc, VHH 1 -VHH 2 -Fc, and VHH 1 -VHH 2 -VHH 3 -Fc included, VHH 1 , V.H.H. 2 , and V.H.H. 3 may be the same or different. In some embodiments of such structures, one VHH may be connected to another VHH by a linker, or one VHH may be connected to an Fc by a linker. In some such embodiments, the linker comprises 1-20 amino acids, preferably 1-20 amino acids composed primarily of glycines, and optionally serine. In some embodiments, when the VHH-containing polypeptide comprises an Fc, it forms a dimer. Thus, the structure VHH1 -VHH 2 -Fc is considered tetravalent if it forms a dimer (i.e., the dimer has four VHH domains). Similarly, the structure VHH 1 -VHH 2 -VHH 3 -Fc is considered hexavalent if it forms a dimer (i.e., the dimer has six VHH domains).

[0110] As used herein, a B7H3 binding polypeptide is a polypeptide or protein that specifically binds to B7H3. Typically, a B7H3 binding polypeptide herein is a VHH-containing polypeptide that contains at least one VHH domain that binds to B7H3. A B7H3 binding polypeptide includes a conjugate, including a fusion protein. A B7H3 binding polypeptide includes a fusion protein, including a fusion protein that contains an Fc domain. In some embodiments, a B7H3 binding polypeptide contains two, three, or four or more VHH domains, each of which specifically binds to B7H3, and each VHH domain may be the same or different. In some embodiments, a B7H3 binding polypeptide is multivalent. In some embodiments, a B7H3 binding polypeptide is multispecific. In some cases, a B7H3 binding polypeptide may contain one or more additional domains that bind to one or more additional or additional antigens other than B7H3.

[0111] The term "monoclonal antibody" refers to an antibody (including sdAb or VHH-containing polypeptides) of a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible natural mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, directed against a single antigenic site. Moreover, in contrast to polyclonal antibody preparations that typically include a variety of antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Thus, a sample of monoclonal antibodies may bind to the same epitope on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies may be made by the hybridoma method first described by Kohler and Milstein, 1975, Nature 256:495, or may be made by recombinant DNA methods, e.g., as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described in McCafferty et al., 1990, Nature 348:552-554, for example.

[0112] The term "CDR" refers to complementarity determining region as defined in at least one particular manner by those skilled in the art. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described in: Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (the "Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273,927-948 (the "Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography," J. Mol. Biol. 262, 732-745. (the "Contact" numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol, 2003 Jan;27(1):55-77 ("IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol, 2001 Jun 8;309(3):657-70 ("Aho" numbering scheme); and Martin et al., "Modeling antibody hypervariable loops: a combined algorithm," PNAS, 1989, 86(23):9268-9272 ("AbM" numbering scheme).

[0113] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignment, while the Chothia scheme is based on structural information. The numbering of both the Kabat and Chothia schemes is based on the length of the most common antibody region sequences, and insertions and deletions, which are coordinated by the insertion letter, e.g., "30a", appear in some antibodies. The two schemes place certain insertions and deletions ("indels") in different positions, resulting in different numbering. The Contact scheme is based on the analysis of complex crystal structures and is similar in many ways to the Chothia numbering scheme. The AbM scheme is a compromise between the Kabat and Chothia definitions, based on the one used by Oxford Molecular's AbM antibody modeling software.

[0114] In some embodiments, the CDRs can be defined according to any of the Chothia numbering scheme, the Kabat numbering scheme, a combination of Kabat and Chothia, the AbM definition, and / or the contact definition. VHHs contain three CDRs designated CDR1, CDR2, and CDR3. Table 1 below lists exemplary position boundaries of CDR-H1, CDR-H2, CDR-H3 as specified by Kabat, Chothia, AbM, and Contact schemes, respectively. For CDR-H1, the residue numbering is listed using both the Kabat numbering scheme and the Chothia numbering scheme. FRs are located between the CDRs, e.g., FR-H1 is located before CDR-H1, FR-H2 is located between CDR-H1 and CDR-H2, FR-H3 is located between CDR-H2 and CDR-H3, and so on. It is noted that the Kabat numbering scheme shown places the insertion at H35A and H35B, so that the end of the Chothia CDR-H1 loop when numbered using the Kabat numbering rules shown varies between H32 and H34 depending on the length of the loop.

[0115] Table 1. CDR boundaries according to various numbering schemes TIFF2024167342000011.tif311481 - Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD 2 - Al-Lazikani et al., (1997) JMB 273,927-948

[0116] Thus, unless otherwise specified, the "CDR" or "complementarity determining region" of a given antibody or region thereof, such as its variable region, or each designated CDR (e.g., CDR-H1, CDR-H2, CDR-H3) should be understood to encompass a (or specific) complementarity determining region as defined by any of the above schemes. For example, when a particular CDR (e.g., CDR-H3) is stated to contain the amino acid sequence of the corresponding CDR in a given VHH amino acid sequence, it is understood that such CDR has the sequence of the corresponding CDR (e.g., CDR-H3) in the VHH as defined by any of the above schemes. In some embodiments, specific CDR sequences are specified. Exemplary CDR sequences of the provided antibodies are described using various numbering schemes (see, e.g., Table 1), however, it is understood that the provided antibodies may include CDRs as described according to any of the other above numbering schemes or other numbering schemes known to those of skill in the art.

[0117] As used herein, "conjugate", "conjugation" or grammatical variations thereof refer to the joining or linking of two or more compounds to each other, resulting in the formation of another compound, by any joining or linking method known in the art.It can also refer to the compound that is made by joining or linking two or more compounds to each other.For example, a VHH domain that is directly or indirectly linked to one or more chemical moieties or polypeptides is an exemplary conjugate.Such conjugates include fusion proteins, those produced by chemical conjugation, and those produced by any other method.

[0118] Immunoglobulin Fc fusions (Fc fusions), such as VHH-Fc, are molecules that contain one or more VHH domains operably linked to the Fc region of an immunoglobulin. The immunoglobulin Fc region may be indirectly or directly linked to one or more VHH domains. A variety of linkers are known in the art and can be optionally used to link the Fc to a fusion partner to create an Fc fusion. In some such embodiments, the linker comprises 1-20 amino acids, preferably 1-20 amino acids consisting primarily of glycine, and optionally serine. Fc fusions of the same species can be dimerized to form Fc fusion homodimers, or with non-identical species to form Fc fusion heterodimers. In some embodiments, the Fc is a mammalian Fc, such as a human Fc.

[0119] As used herein, the term "heavy chain constant region" refers to the C H 1, hinge, C H 2, and C H 3. Of course, deletions and modifications that do not alter function within a domain are encompassed within the scope of the term "heavy chain constant region" unless otherwise specified. Non-limiting exemplary heavy chain constant regions include gamma, delta, and alpha. Non-limiting exemplary heavy chain constant regions also include epsilon and mu. Each heavy chain constant region corresponds to an antibody isotype. For example, an antibody containing a gamma constant region is an IgG antibody, an antibody containing a delta constant region is an IgD antibody, and an antibody containing an alpha constant region is an IgA antibody. Furthermore, an antibody containing a mu constant region is an IgM antibody, and an antibody containing an epsilon constant region is an IgE antibody. Certain isotypes can be further subdivided into subclasses. For example, IgG antibodies include IgG1 (gamma 1 IgG2(γ 2 IgG3(γ 3 constant region), and IgG4 (γ 4 IgA antibodies include, but are not limited to, IgA1 (α 1 IgA2 (including the constant region) and IgA2 (α 2IgM antibodies include, but are not limited to, IgM1 and IgM2 (including an IgM constant region) antibodies.

[0120] As used herein, "Fc region" refers to a portion of the heavy chain constant region, including CH2 and CH3. In some embodiments, the Fc region includes a hinge, CH2, and CH3. In various embodiments, when the Fc region includes a hinge, the hinge mediates dimerization between two Fc-containing polypeptides. The Fc region may be of any antibody heavy chain constant region isotype discussed herein. In some embodiments, the Fc region is IgG1, IgG2, IgG3, or IgG4.

[0121] A "functional Fc region" possesses the "effector functions" of a native sequence Fc region. Exemplary "effector functions" include Fc receptor binding; C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation. Such effector functions generally require that the Fc region be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using a variety of assays.

[0122] A "native sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc region (non-A and A allotypes); native sequence human IgG2 Fc region; native sequence human IgG3 Fc region; and native sequence human IgG4 Fc region, as well as naturally occurring variants thereof.

[0123] A "variant Fc region" comprises an amino acid sequence that differs from that of a native sequence Fc region by at least one amino acid modification. In some embodiments, a "variant Fc region" comprises an amino acid sequence that differs from that of a native sequence Fc region by at least one amino acid modification, yet retains at least one effector function of the native sequence Fc region. In some embodiments, the variant Fc region has at least one amino acid substitution, e.g., about 1 to about 10 amino acid substitutions in the native sequence Fc region or in the Fc region of the parent polypeptide, and preferably about 1 to about 5 amino acid substitutions, compared to the native sequence Fc region or to the Fc region of the parent polypeptide. In some embodiments, the variant Fc region herein will possess at least about 80% sequence identity to the native sequence Fc region and / or to the Fc region of the parent polypeptide, at least about 90% sequence identity to them, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to them.

[0124] Generally, the numbering of residues in an immunoglobulin heavy chain or portion thereof, such as the Fc region, is that of the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody.

[0125] "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In some embodiments, the FcγR is a native human FcR. In some embodiments, the FcR is one that binds IgG antibodies (gamma receptors) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced ​​forms of those receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. (See, e.g., Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in, for example, Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those that will be identified in the future, are encompassed by the term "FcR" herein. For example, the term "Fc receptor" or "FcR" also includes the neonatal receptor FcRn, which is responsible for the control of maternal IgG transfer to fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and immunoglobulin homeostasis.Methods for measuring binding to FcRn are known (see, e.g., Ghetie and Ward, Immunol. Today 18(12):592-598 (1997); Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton et al., J. Biol. Chem. 279(8):6213-6216 (2004); WO 2004 / 92219 (Hinton et al.)).

[0126] As used herein, an "acceptor human framework" refers to a heavy chain variable domain (V) derived from a human immunoglobulin framework or a human consensus framework, as discussed herein. H ) framework. The acceptor human framework derived from a human immunoglobulin framework or a human consensus framework can contain the same amino acid sequence or can contain amino acid sequence changes. In some embodiments, the number of amino acid changes is less than 10, or less than 9, or less than 8, or less than 7, or less than 6, or less than 5, or less than 4, or less than 3 across all of the human frameworks in a single antigen-binding domain such as a VHH.

[0127] As used herein, "chimeric antigen receptor" or "CAR" refers to an engineered receptor that introduces antigen specificity via an antigen-binding domain onto the cell on which it is engineered (e.g., a T cell, such as a naive T cell, a central memory T cell, an effector memory T cell, or a combination thereof), thus combining the antigen-binding properties of the antigen-binding domain with the T cell activity of the T cell (e.g., lytic ability and self-renewal). CARs typically include an extracellular antigen-binding domain (ectodomain), a transmembrane domain, and an intracellular signaling domain. The intracellular signaling domain generally contains at least one ITAM signaling domain, e.g., from CD3zeta, and optionally at least one costimulatory signaling domain, e.g., from CD28 or 4-1BB. In the CARs provided herein, the VHH domain forms the antigen-binding domain and is located on the extracellular side when expressed in a cell.

[0128] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or VHH-containing polypeptide) and its binding partner (e.g., an antigen). The affinity or apparent affinity of a molecule X for its partner Y is generally measured by the dissociation constant (K D ) or K D-見かけ Affinity can be expressed by the following general methods known in the art, including those described herein (e.g., ELISA K D , KinExA, flow cytometry, and / or surface plasmon resonance devices, etc. Such methods include, but are not limited to, methods involving BIAcore®, Octet®, or flow cytometry.

[0129] As used herein, "K D The term "K" refers to the equilibrium dissociation constant of an antigen-binding molecule / antigen interaction. D As used herein, the term " D and K.D-見かけ Includes:

[0130] In some embodiments, the K of the antigen-binding molecule D is measured by flow cytometry using an antigen-expressing cell line and fitting the mean fluorescence measured at each antibody concentration to a nonlinear one-site binding equation (Prism Software graphpad). In some such embodiments, K D is K D-見かけ It is.

[0131] The term "biological activity" refers to any one or more biological properties of a molecule (whether naturally occurring as found in vivo or provided or enabled by recombinant means). Biological properties include, but are not limited to, binding of a ligand, induction or increase in cell proliferation (e.g., T cell proliferation), and induction or increase in expression of a cytokine.

[0132] An "affinity matured" VHH-containing polypeptide refers to a VHH-containing polypeptide having one or more alterations in one or more CDRs compared to a parent VHH-containing polypeptide that does not possess such alterations, which alterations result in improved affinity of the VHH-containing polypeptide for its antigen.

[0133] As used herein, "humanized VHH" refers to a VHH in which one or more framework regions are substantially replaced with human framework regions. In some instances, certain framework region (FR) residues of a human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized VHH can contain residues that are not found in either the original VHH or human framework sequence, but are included to further improve and optimize the performance of the VHH or VHH-containing polypeptide. In some embodiments, a humanized VHH-containing polypeptide comprises a human Fc region. As will be appreciated, a humanized sequence can be identified by its primary sequence and does not necessarily represent the process by which the antibody was created.

[0134] The term "substantially similar" or "substantially the same" as used herein refers to a sufficiently high degree of similarity between two or more numerical values ​​that those skilled in the art consider the difference between the two or more values ​​to be small or to be devoid of any biological and / or statistical significance within the context of the biological characteristic measured by the values.In some embodiments, two or more substantially similar values ​​differ by only about 5%, 10%, 15%, 20%, 25%, or 50%.

[0135] A polypeptide "variant" refers to a biologically active polypeptide having at least about 80% amino acid sequence identity to a native sequence polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Such variants include, for example, polypeptides in which one or more amino acid residues are added or deleted at the N-terminus or C-terminus of the polypeptide. In some embodiments, a variant has at least about 80% amino acid sequence identity. In some embodiments, a variant has at least about 90% amino acid sequence identity. In some embodiments, a variant has at least about 95% amino acid sequence identity to a native sequence polypeptide.

[0136] As used herein, "percent (%) amino acid sequence identity" and "homology" with respect to a peptide, polypeptide, or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring alignment, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.

[0137] Amino acid substitutions may include, but are not limited to, the replacement of one amino acid in a polypeptide with another amino acid. Exemplary substitutions are shown in Table 2. Amino acid substitutions may be introduced into the antibody of interest, and the product may be screened for the desired activity, such as retaining / improving antigen binding, reducing immunogenicity, or improving ADCC or CDC.

[0138] (Table 2) TIFF2024167342000012.tif90128

[0139] The amino acids may be grouped according to common side chain properties. (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe.

[0140] Non-conservative substitutions entail exchanging a member of one of these classes for another class.

[0141] The term "vector" is used to describe a polynucleotide that can be engineered to contain one or more cloned polynucleotides that can be propagated in a host cell. A vector can include one or more of the following elements: an origin of replication, one or more control sequences (such as promoters and / or enhancers) that control the expression of a polypeptide of interest, and / or one or more selectable marker genes (such as antibiotic resistance genes and genes that can be used in colorimetric assays, such as β-galactosidase). The term "expression vector" refers to a vector that is used to express a polypeptide of interest in a host cell.

[0142] "Host cell" refers to a cell that can be or has been the recipient of a vector or isolated polynucleotide. A host cell may be a prokaryotic or eukaryotic cell. Exemplary eukaryotic cells include mammalian cells, such as primate or non-primate animal cells; fungal cells, such as yeast; plant cells; and insect cells. Non-limiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6® cells (Crucell), and 293 and CHO cells, and their derivatives, such as 293-6E, CHO-DG44, CHO-K1, CHO-S, and CHO-DS cells. A host cell includes the progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutations. A host cell includes a cell transfected in vivo with a polynucleotide provided herein.

[0143] The term "isolated" as used herein refers to a molecule that is separated from at least some of the components that it is typically found or produced with in nature. For example, a polypeptide is said to be "isolated" when it is separated from at least some of the components of the cell in which it was produced. If the polypeptide is secreted by a cell after expression, physically separating the supernatant containing the polypeptide from the cell in which it was produced is considered to "isolate" the polypeptide. Similarly, a polynucleotide is said to be "isolated" when it is not part of a larger polynucleotide (e.g., in the case of a DNA polynucleotide, genomic DNA or mitochondrial DNA, etc.) in which it is typically found in nature, or, for example, in the case of an RNA polynucleotide, when it is separated from at least some of the components of the cell in which it was produced. Thus, a DNA polynucleotide contained in a vector inside a host cell can be said to be "isolated".

[0144] The terms "individual" and "subject" are used interchangeably herein to refer to animals; e.g., mammals. The term patient includes humans and veterinary subjects. In some embodiments, methods are provided for treating mammals, including but not limited to humans, rodents, monkeys, cats, dogs, horses, cows, pigs, sheep, goats, mammalian laboratory animals, mammalian livestock, mammalian sport animals, and mammalian pets. The subject can be male or female and can be of any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects. In some examples, "individual" or "subject" refers to an individual or subject in need of treatment for a disease or disorder. In some embodiments, the subject to be treated can be a patient, which refers to the fact that the subject has been identified as having a disorder associated with the treatment or at sufficient risk of suffering from the disorder. In certain embodiments, the subject is a human, such as a human patient.

[0145] As used herein, a "disease" or "disorder" refers to a condition for which treatment is needed and / or desired.

[0146] The terms "tumor cell," "cancer cell," "cancer," "tumor," and / or "neoplasm," unless otherwise specified, are used interchangeably herein to refer to a cell (or cells) that exhibit uncontrolled growth and / or abnormally increased cell survival and / or inhibited apoptosis that interferes with the normal functioning of the body's organs and systems. Benign and malignant cancers, polyps, hyperplasias, and dormant tumors or micrometastases are included in this definition.

[0147] The terms "cancer" and "tumor" encompass solid cancers and hematological / lymphatic cancers, and also encompass malignant, premalignant, and benign growths, such as dysplasia. Also included in this definition are cells (e.g., virus-infected cells) that have abnormal growth that is not impeded by the immune system (e.g., immune evasion and immune escape mechanisms). Exemplary cancers include, but are not limited to, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colorectal cancer; connective tissue cancer; digestive system cancer; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including gastrointestinal cancer); glioblastoma; liver cancer; hepatocellular carcinoma; intraepithelial neoplasia; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and adenocarcinoma of the lung). squamous cell carcinoma); melanoma; myeloma; neuroblastoma; oral cancer (lips, tongue, mouth, and throat); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; respiratory system cancer; salivary gland cancer; sarcoma; skin cancer; squamous cell carcinoma; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; urinary system cancer; vulvar cancer; lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma, and B-cell lymphomas (including low-grade / follicular non-Hodgkin's lymphoma (NHL)); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky mass disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation associated with nematoses, edema (e.g., associated with brain tumors), and Meigs syndrome.

[0148] The term "non-tumor cell" as used herein refers to normal cells or tissues.Exemplary non-tumor cells include, but are not limited to: T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, macrophages, epithelial cells, fibroblasts, hepatocytes, renal stromal cells, fibroblast-like synoviocytes, osteoblasts, and cells located in breast, skeletal muscle, pancreas, stomach, ovary, small intestine, placenta, uterus, testis, kidney, lung, heart, brain, liver, prostate, colon, lymphoid organs, bone, and bone-derived mesenchymal stem cells.The term "peripherally located cell or tissue" as used herein refers to non-tumor cells that are not located near tumor cells and / or within the tumor microenvironment.

[0149] The term "cells or tissues in tumor microenvironment" as used herein refers to cells, molecules, extracellular matrix, and / or blood vessels that surround and / or feed tumor cells. Exemplary cells or tissues in tumor microenvironment include, but are not limited to: tumor vasculature; tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPCs); cancer-associated fibroblasts; pericytes; other stromal cells; components of extracellular matrix (ECM); dendritic cells; antigen-presenting cells; T cells; regulatory T cells (Treg cells); macrophages; neutrophils; myeloid-derived suppressor cells (MDSCs) and other immune cells located in the vicinity of tumor. Methods for identifying tumor cells and / or cells / tissues located in tumor microenvironment are well known in the art, as described herein below.

[0150] In some embodiments, "increase" or "decrease" refers to a statistically significant increase or decrease, respectively.As will be clear to those skilled in the art, "modulation" can also include: causing a change (can be either increase or decrease) in the affinity, avidity, specificity, and / or selectivity of a target or antigen to one or more of its ligands, binding partners, partners for association into homo- or hetero-multimeric forms, or substrates, compared to the same condition but without the presence of a test substance; causing a change (can be either increase or decrease) in the sensitivity of a target or antigen to one or more conditions (e.g., pH, ionic strength, presence of cofactors, etc.) in the medium or surroundings in which the target or antigen is present; and / or cell proliferation or cytokine production.This can be determined in any suitable manner and / or using any suitable assay known per se or described herein, depending on the target involved.

[0151] As used herein, "immune response" is intended to include a cellular and / or humoral immune response that is sufficient to suppress or prevent the onset of or ameliorate a disease (e.g., cancer or cancer metastasis). An "immune response" can include aspects of both the innate and adaptive immune systems.

[0152] As used herein, the terms "treating", "treatment", and "therapy" of a disease, disorder, or condition are approaches to obtain beneficial or desired clinical results. As used herein, "treatment" covers any administration or application of a therapeutic agent to a disease in a mammal, including a human. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, any one or more of the following: alleviation of one or more symptoms, reduction in the extent of the disease, prevention or delay of disease spread (e.g., metastasis, e.g., to the lungs or to lymph nodes), prevention or delay of disease recurrence, delay or slowing of disease progression, amelioration of the disease state, inhibition of the disease or disease progression, inhibition or slowing of the disease or its progression, cessation of its occurrence, and remission (either partial or complete). By "treatment", reduction of the pathological consequences of a proliferative disease is also encompassed. The methods provided herein contemplate any one or more of these aspects of treatment. Consistent with the above, the term treatment does not require 100 percent elimination of all aspects of the disorder.

[0153] As used herein in the context of cancer, the terms "treatment" of cancer or "inhibit", "inhibiting", or "inhibition" refer to at least one of the following: a statistically significant decrease in the rate of tumor growth, cessation of tumor growth, or a reduction in tumor size, mass, metabolic activity, or volume, or a statistically significant increase in progression-free survival (PFS) or overall survival (OS), as measured by standard criteria, such as, but not limited to, Response Evaluation Criteria for Solid Tumors (RECIST).

[0154] "Ameliorating" refers to a decrease or improvement in one or more symptoms compared to not administering a therapeutic agent. "Ameliorating" also includes a shortening or reduction in the duration of a symptom.

[0155] "Preventing," "prophylaxis," or "prevention" of a disease or disorder refers to the administration of a pharmaceutical composition, either alone or in combination with another compound, to prevent the appearance or development of a disease or disorder or some or all of the symptoms of a disease or disorder, or to reduce the likelihood of developing a disease or disorder.

[0156] The term "inhibit" or "inhibiting" refers to the reduction or cessation of any phenotypic trait, or the reduction or cessation of the incidence, degree, or likelihood of that trait. "Reducing" or "inhibiting" is to decrease, reduce, or stop an activity, function, and / or amount compared to a reference. In some embodiments, "reducing" or "inhibiting" refers to the ability to cause an overall reduction of 10% or more. In some embodiments, "reducing" or "inhibiting" refers to the ability to cause an overall reduction of 50% or more. In some embodiments, "reducing" or "inhibiting" refers to the ability to cause an overall reduction of 75%, 85%, 90%, 95%, or more. In some embodiments, the amount is inhibited or reduced over a period of time compared to a control over the same period of time.

[0157] As used herein, "delaying the onset of disease" means to postpone, prevent, slow down, delay, stabilize, suppress, and / or postpone the onset of disease (e.g., cancer). This delay can be of various lengths of time, depending on the disease history and / or the individual being treated. As will be apparent to one of skill in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, the onset of late-stage cancer, e.g., metastasis, can be delayed.

[0158] As used herein, "preventing" includes providing prophylaxis with respect to the appearance or recurrence of a disease in a subject who may have a predisposition to the disease but has not yet been diagnosed with the disease. Unless otherwise specified, the terms "reducing," "inhibiting," or "preventing" do not represent or require complete prevention all the time, but only over the period of time being measured.

[0159] The term "anticancer agent" is used in the broadest sense herein to refer to the agent used in the treatment of one or more cancers.The exemplary types of such agents include, but are not limited to, chemotherapeutic agents, anticancer biologics (e.g., cytokines, receptor extracellular domain-Fc fusions, and antibodies), radiation therapy, CAR-T therapy, therapeutic oligonucleotides (e.g., antisense oligonucleotides and siRNA), and oncolytic viruses.

[0160] The term "biological sample" refers to any number of substances derived from a living or formerly living organism, including, but not limited to, blood (e.g., whole blood), plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes, and spleen.

[0161] The term "control" or "reference" refers to a composition known to not contain the analyte (a "negative control") or a composition known to contain the analyte (a "positive control"). A positive control can contain a known concentration of the analyte.

[0162] The term "effective amount" or "therapeutically effective amount" refers to an amount and / or concentration of a composition containing an active ingredient (e.g., an sdAb or VHH-containing polypeptide) that, when administered in a patient either alone (i.e., as a monotherapy) or in combination with an additional therapeutic agent, results in a statistically significant reduction in disease progression, e.g., by ameliorating or eliminating the symptoms and / or causes of the disease. An effective amount can be an amount that relieves, reduces, or alleviates at least one symptom or biological response or effect associated with a disease or disorder, prevents the progression of a disease or disorder, or improves the patient's physical function. A therapeutically effective amount of a composition containing an active agent can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the active agent to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or adverse effects of the active agent are outweighed by therapeutically beneficial effects. A therapeutically effective amount can be delivered in one or more administrations. A therapeutically effective amount refers to an amount effective to achieve a desired therapeutic and / or prophylactic result, at the dosages and for the period of time required.

[0163] As used herein, a composition refers to any mixture of two or more products, substances, or compounds, including cells, which may be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous, or any combination thereof.

[0164] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to a preparation that is in a form that allows the biological activity of the active ingredient to be effective and does not contain any additional components that are unacceptably toxic to the subject to which the formulation is administered. It is thus a composition that is suitable for pharmaceutical use in mammalian subjects, often humans. A pharmaceutical composition typically comprises an effective amount of an active agent (e.g., an sdAb or VHH-containing polypeptide) and a carrier, excipient, or diluent. The carrier, excipient, or diluent is typically a pharmaceutically acceptable carrier, excipient, or diluent, respectively. Such formulations may be sterile.

[0165] "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, formulation aid, or carrier conventional in the art for use with therapeutic agents that together constitute a "pharmaceutical composition" for administration to a subject. Pharmaceutically acceptable carriers are non-toxic to recipients at the dosages and concentrations used and are compatible with other ingredients of the formulation. Pharmaceutically acceptable carriers are appropriate for the formulation used.

[0166] Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

[0167] The term "concurrently" is used herein to refer to the administration of two or more therapeutic agents where at least a portion of the administration overlaps in time, or where the administration of one therapeutic agent is within a short period of time relative to the administration of the other therapeutic agent, or where the therapeutic effects of both agents overlap for at least some period of time.

[0168] The term "sequentially" is used herein to refer to the administration of two or more therapeutic agents that do not overlap in time or where the therapeutic effects of the agents do not overlap.

[0169] As used herein, "in conjunction with" refers to the administration of one treatment modality in addition to another treatment modality. As such, "in conjunction with" refers to the administration of one treatment modality to an individual before, during, or after the administration of another treatment modality.

[0170] The term "package insert" is used to refer to instructions typically included in commercial packaging of a therapeutic product that contain information about the indications, usage, dosage, administration, concomitant therapy, contraindications, and / or warnings pertaining to the use of such therapeutic product.

[0171] An "article of manufacture" is any article of manufacture (e.g., package or container) or kit that contains at least one reagent, e.g., an agent for the treatment of a disease or disorder (e.g., cancer), or a probe for specifically detecting a biomarker described herein. In some embodiments, the article of manufacture or kit is promoted, distributed, or sold as a unit for performing a method described herein.

[0172] The terms "label" and "detectable label" refer to a moiety that is added to an antibody or antigen, for example, to make the reaction (e.g., binding) between members of a specific binding pair detectable. A labeled member of a specific binding pair is said to be "detectably labeled." Thus, the term "labeled binding protein" refers to a protein with an incorporated label that provides identification of the binding protein. In some embodiments, the label is a detectable marker that can generate a signal that is detectable by visual or instrumental means, for example, the incorporation of a radiolabeled amino acid, or the addition of a biotinyl moiety to the polypeptide that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or an enzymatic activity that can be detected by optical or colorimetric methods). Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 H, 14 C. 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, or 153Sm); chromogens, fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzyme labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl groups; predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags); and magnetic substances, such as gadolinium chelates. Representative examples of labels commonly used in immunoassays include moieties that produce light, such as acridinium compounds, and moieties that produce fluorescence, such as fluorescein. In this regard, the moiety itself need not be detectably labeled, but may become detectable upon reaction with yet another moiety.

[0173] II. VHH domains that bind to B7H3 Provided herein is a B7H3-binding polypeptide that is a VHH-containing polypeptide that contains at least one VHH domain that specifically binds to B7H3. In some embodiments, the VHH domain binds to human B7H3. In some of any of the provided embodiments, the VHH domain binds to B7H3 having a sequence shown in SEQ ID NO:190, or its mature form lacking a signal sequence. In some embodiments, the VHH domain binds or recognizes 4IgB7H3. In some embodiments, the VHH domain binds or recognizes 2IgB7H3. In some embodiments, the VHH domain binds or recognizes 4IgB7H3 and 2IgB7H3. In some embodiments, the VHH-containing polypeptide incorporates multiple copies of the VHH domain provided herein. In such embodiments, the VHH-containing polypeptide may incorporate multiple copies of the same VHH domain. In some embodiments, a VHH-containing polypeptide may incorporate multiple copies of a VHH domain that are different but recognize the same epitope on B7H3. VHH-containing polypeptides may be formatted in a variety of formats, including any of those described in Section III below.

[0174] A VHH domain is an antibody fragment that is a single monomeric variable antibody domain that can selectively bind to a specific antigen. VHH domains (also called single-domain antibodies) have a molecular weight of only 12-15 kDa, much smaller than a typical antibody (150-160 kDa) that is composed of two heavy and two light protein chains, and even smaller than a Fab fragment (about 50 kDa, one light chain and half a heavy chain) and a single-chain variable fragment (about 25 kDa, two variable domains, one from a light chain and one from a heavy chain).

[0175] A single domain antibody is an antibody whose complementarity determining region is part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally lacking light chains, single domain antibodies derived from conventional four-chain antibodies, engineered antibodies, and single domain scaffolds other than those derived from antibodies. Single domain antibodies can be derived from any species, including, but not limited to, mouse, human, camel, llama, alpaca, vicuna, guanaco, shark, goat, rabbit, and / or cow. In some embodiments, the single domain antibody used herein is a naturally occurring single domain antibody known as a heavy chain antibody lacking light chains. For reasons of clarity, this variable domain derived from a heavy chain antibody naturally lacking light chains is referred to herein as VHH to distinguish it from conventional VH of four-chain immunoglobulins. Such VHH molecules can be derived from antibodies raised in Camelidae species, for example, in camel, llama, dromedary, alpaca, vicuna, and guanaco. Other species besides Camelidae may produce heavy chain antibodies that are naturally devoid of light chains; such VHHs are within the scope of the present disclosure.

[0176] Methods for screening VHH domains, including VHH binding polypeptides, possessing the desired specificity for B7H3 include, but are not limited to, enzyme-linked immunosorbent assays (ELISAs), enzyme assays, flow cytometry, and other immunologically mediated techniques known within the art.

[0177] Among the VHH domains provided herein are B7H3 VHH (llama-derived) and humanized sequences, such as any of the following:

[0178] In some embodiments, the VHH domain that binds to B7H3 may be humanized. Humanized antibodies (e.g., VHH-containing polypeptides) are useful as therapeutic molecules because they reduce or eliminate the immune response to the antibody therapeutic and the human immune response to the non-human antibody that may result in a reduced efficacy of the therapeutic. Generally, a humanized antibody comprises one or more variable domains in which the CDRs (or a portion thereof) are derived from a non-human antibody and the FRs (or a portion thereof) are derived from a human antibody sequence. The humanized antibody optionally also comprises at least a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody are replaced with the corresponding residues from the non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve the specificity or affinity of the antibody.

[0179] Humanized antibodies and methods for making them are reviewed, for example, in Almagro and Fransson, (2008) Front. Biosci. 13: 1619-1633, and are described, for example, in Riechmann et al., (1988) Nature 332:323-329; Queen et al., (1989) Proc. Natl Acad. Sci. USA 86: 10029-10033; U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., (2005) Methods 36:25-34; Padlan, (1991) Mol. Immunol. 28:489-498 (describing "resurfacing"); Dall'Acqua et al., (2005) Methods 36:43-60 (describing "FR shuffling"); and Osbourn et al., (2005) Methods 36:61-68 and Klimka et al., (2000) Br. J. Cancer, 83:252-260 (describing a "guided selection" approach to FR shuffling).

[0180] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al. (1993) J. Immunol. 151:2296); framework regions derived from consensus sequences of human antibodies of particular subgroups of heavy chain variable regions (see, e.g., Carter et al. (1992) Proc. Natl. Acad. Sci. USA, 89:4285; and Presta et al. (1993) J. Immunol, 151:2623); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, (2008) Front. Biosci. 13:1619-1633); and framework regions derived from screening of FR libraries (see, e.g., Baca et al., (1997) J. Biol. Chem. 272: (See, e.g., J. Biol. Chem. 271:22611-22618, 10678-10684 and Rosok et al., (1996) J. Biol. Chem. 271:22611-22618). Typically, the FR regions of VHH are replaced with human FR regions to make a humanized VHH. In some embodiments, certain FR residues of human FRs are replaced to improve one or more properties of the humanized VHH. The VHH domain with such replaced residues is still referred to as "humanized" herein.

[0181] The VHH domain comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 1 to 114, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 1 to 114. HProvided herein is a VHH domain that binds B7H3, comprising a CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H-region amino acids. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 set forth in any one of SEQ ID NOs: 115-145, a CDR2 set forth in any one of SEQ ID NOs: 146-167, and a CDR3 set forth in any one of SEQ ID NOs: 168-189. Among the B7H3 VHH domains provided are those having an amino acid sequence set forth in any one of SEQ ID NOs: 1-114, or a VHH domain selected from any one of SEQ ID NOs: 1-114. H In some embodiments, the B7H3 VHH domain has an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 1-114.

[0182] The VHH domain is a VHH amino acid sequence selected from any one of SEQ ID NOs: 1-114, 466, 467, 489, or 490, 492-518, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 1-114, 466, 467, 489, or 490, 492-518. HProvided herein is a VHH domain that binds to B7H3, comprising a CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 set forth in any one of SEQ ID NOs: 115-145, a CDR2 set forth in any one of SEQ ID NOs: 146-167, and a CDR3 set forth in any one of SEQ ID NOs: 168-189 or 483-488. Among the B7H3 VHH domains provided are those having an amino acid sequence as set forth in any of SEQ ID NOs: 1-114, 466, 467, 489, or 490, 492-518, or a VHH domain selected from any one of SEQ ID NOs: 1-114, 466, 467, 489, or 490, 492-518. H In some embodiments, the B7H3 VHH domain has an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 1-114, 466, 467, 489, or 490, 492-518.

[0183] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, CDR3 contained in a VHH domain set forth in SEQ ID NO:1, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected VHH region amino acids set forth in SEQ ID NO:1. In some embodiments, the B7H3 VHH domain has an amino acid sequence set forth in SEQ ID NO:1, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected amino acids set forth in SEQ ID NO:1. In some embodiments, the B7H3 VHH domain is a humanized variant of the amino acid sequence set forth in SEQ ID NO:1.

[0184] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 set forth in any one of SEQ ID NOs:115, 116, 117, 118, 119, 120, 121, or 122, a CDR2 set forth in any one of SEQ ID NOs:146, 147, 148, 149, 150, 151, and a CDR3 set forth in SEQ ID NO:168.

[0185] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 115, 146, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 116, 146, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 117, 146, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 118, 146, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 119, 146, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 120, 146, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 115, 147, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 115, 148, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 115, 149, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 115, 150, and 168, respectively.In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 115, 151, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 116, 147, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 118, 147, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 119, 147, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 116, 151, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 121, 147, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 119, 149, and 168, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 122, 151, and 168, respectively.

[0186] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 2-34, 467, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 2-34, 467. HIt includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0187] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 2-34, 467, 489-490, and 492-497, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 2-34, 467, 489-490, and 492-497. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0188] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 2-34, 467, or a VHH domain selected from any one of SEQ ID NOs: 2-34, 467. H In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 2-34, 467.

[0189] In some cases, the B7H3 VHH domain provided comprises an amino acid sequence set forth in any one of SEQ ID NOs: 2-34, 467, 489-490, and 492-497, or a VHH domain selected from any one of SEQ ID NOs: 2-34, 467, 489-490, and 492-497. HIn some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 2-34, 467, 489, and 490.

[0190] In some embodiments, the B7H3 VHH domain provided herein contains CDR1, CDR2, CDR3 contained in a VHH domain set forth in SEQ ID NO:35, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected VHH region amino acids set forth in SEQ ID NO:35. In some embodiments, the B7H3 VHH domain has an amino acid sequence set forth in SEQ ID NO:35, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected amino acids set forth in SEQ ID NO:35. In some embodiments, the B7H3 VHH domain is a humanized variant of the amino acid sequence set forth in SEQ ID NO:35.

[0191] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 set forth in SEQ ID NO:123, a CDR2 set forth in SEQ ID NO:152 or 153, and a CDR3 set forth in SEQ ID NO:170 or 171.

[0192] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 123, 152, and 170, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 123, 153, and 170, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 123, 153, and 171, respectively.

[0193] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 36-43, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 36-43. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0194] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 36-43 and 498-503, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 36-43 and 498-503. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0195] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 36-43, or a VHH domain selected from any one of SEQ ID NOs: 36-43. HA humanized variant having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs:36-43.

[0196] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 36-43 and 498-503, or a VHH domain selected from any one of SEQ ID NOs: 36-43 and 498-503. H In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 36-43 and 498-503.

[0197] In some embodiments, the B7H3 VHH domain provided herein contains CDR1, CDR2, CDR3 contained in a VHH domain set forth in SEQ ID NO:44, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected VHH region amino acids set forth in SEQ ID NO:44. In some embodiments, the B7H3 VHH domain has an amino acid sequence set forth in SEQ ID NO:44, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected amino acids set forth in SEQ ID NO:44. In some embodiments, the B7H3 VHH domain is a humanized variant of the amino acid sequence set forth in SEQ ID NO:44.

[0198] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 set forth in any one of SEQ ID NOs:124, 125, 126, 127, 128, 129, 130, 131, 132, 133, a CDR2 set forth in SEQ ID NO:154, and a CDR3 set forth in any one of SEQ ID NOs:172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, or 183.

[0199] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 172, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 174, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 175, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 125, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 126, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 127, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 128, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 129, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 130, 154, 173, respectively.In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 131, 154, 173, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 176, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 177, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 178, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 179, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 180, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 181, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 182, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 124, 154, 183, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 126, 154, 176, respectively.In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 126, 154, 179, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 126, 154, 182, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 132, 154, 176, respectively. In some embodiments, the B7H3 VHH domain provided herein contains a CDR1, CDR2, and CDR3 as set forth in any one of SEQ ID NOs: 133, 154, 173, respectively.

[0200] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 45-91, 466, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 45-91, 466. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0201] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 45-91, 466, and 504-514, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 45-91, 466, and 504-514. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0202] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 45-91, 466, or a VHH domain selected from any one of SEQ ID NOs: 45-91, 466. H In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 45-91, 466.

[0203] In some cases, the B7H3 VHH domain provided comprises an amino acid sequence set forth in any one of SEQ ID NOs: 45-91, 466, and 504-514, or a VHH domain selected from any one of SEQ ID NOs: 45-91, 466, and 504-514. H A humanized variant having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 45-91, 466, and 504-514.

[0204] In some embodiments, the B7H3 VHH domain provided herein contains CDR1, CDR2, CDR3 contained in a VHH domain set forth in SEQ ID NO: 105, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected VHH region amino acids set forth in SEQ ID NO: 105. In some embodiments, the B7H3 VHH domain has an amino acid sequence set forth in SEQ ID NO: 105, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected amino acids set forth in SEQ ID NO: 105. In some embodiments, the B7H3 VHH domain is a humanized variant of the amino acid sequence set forth in SEQ ID NO: 105.

[0205] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 as set forth in SEQ ID NO:145, a CDR2 as set forth in SEQ ID NO:167, and a CDR3 as set forth in SEQ ID NO:195.

[0206] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 as set forth in SEQ ID NO:145, a CDR2 as set forth in SEQ ID NO:167, and a CDR3 as set forth in SEQ ID NO:488.

[0207] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 106-109, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 106-109. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0208] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 106-109, or a VHH domain selected from any one of SEQ ID NOs: 106-109. H A humanized variant having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 106-109.

[0209] In some embodiments, the B7H3 VHH domain provided herein contains CDR1, CDR2, CDR3 contained in a VHH domain set forth in SEQ ID NO:110, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected VHH region amino acids set forth in SEQ ID NO:110. In some embodiments, the B7H3 VHH domain has an amino acid sequence set forth in SEQ ID NO:110, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to selected amino acids set forth in SEQ ID NO:110. In some embodiments, the B7H3 VHH domain is a humanized variant of the amino acid sequence set forth in SEQ ID NO:110.

[0210] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 as set forth in SEQ ID NO:131, a CDR2 as set forth in SEQ ID NO:169, and a CDR3 as set forth in SEQ ID NO:189.

[0211] In some embodiments, the B7H3 VHH domain provided herein contains a CDR1 as set forth in SEQ ID NO:131, a CDR2 as set forth in SEQ ID NO:161, and a CDR3 as set forth in SEQ ID NO:189.

[0212] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 111-114, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 111-114. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0213] In some aspects, the VHH domain that binds to B7H3 comprises a VHH amino acid sequence selected from any one of SEQ ID NOs: 111-114 and 515-528, or a VHH amino acid sequence selected from any one of SEQ ID NOs: 111-114 and 515-518. H It includes CDR1, CDR2, and CDR3 contained in an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids.

[0214] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 111-114, or a VHH domain selected from any one of SEQ ID NOs: 111-114. H A humanized variant having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs:111-114.

[0215] In some cases, the B7H3 VHH domain provided has an amino acid sequence as set forth in any one of SEQ ID NOs: 111-114 and 515-518, or a VHH domain selected from any one of SEQ ID NOs: 111-114 and 515-518. H A humanized variant having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the H region amino acids. In some embodiments, the B7H3 humanized VHH domain has a sequence of amino acids set forth in any one of SEQ ID NOs: 111-114 and 515-518.

[0216] III. Fusion Proteins and Conjugates Containing B7H3-Binding Polypeptides Fusion proteins and conjugates containing B7H3 binding polypeptides are provided herein, which contain at least one VHH domain that specifically binds to B7H3, directly or indirectly linked to one or more additional domains or moieties. In some embodiments, the fusion proteins or conjugates of the present disclosure are composed of a single polypeptide. In other embodiments, the fusion proteins or conjugates of the present disclosure are composed of more than one polypeptide. In some embodiments, the B7H3 binding polypeptides of the present disclosure incorporate at least one VHH domain that specifically binds to B7H3. In some aspects, the B7H3 binding polypeptides are multivalent. In some embodiments, the B7H3 binding polypeptides include two or more copies of a VHH domain that specifically binds to B7H3, such as three or more, four or more, five or more, or six or more copies of a VHH domain that specifically binds to B7H3. In certain aspects, the B7H3 binding polypeptides are multispecific. For example, in some cases, the one or more additional domains may be one or more additional binding domains that bind to one or more additional antigens or proteins.

[0217] In some embodiments, the B7H3 binding polypeptide of the present disclosure comprises two or more polypeptide sequences operably linked via an amino acid linker. In some embodiments, these linkers are composed mainly of the amino acids glycine and serine, herein referred to as GS linkers. The GS linkers of the fusion proteins of the present disclosure can be of various lengths, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids in length. In some embodiments, the GS linker is GGSGGS, i.e. TIFF2024167342000013.tif16166. In some embodiments, the linker comprises an amino acid sequence selected from the group consisting of, by way of non-limiting example, In some embodiments, the linker is (GGGGS)n, where n is 1 to 5 (SEQ ID NO:313); (GGGGGS)n, where n is 1 to 4 (SEQ ID NO:314); TIFF2024167342000015.tif16147. In some embodiments, the B7H3 binding polypeptide comprises a combination of a GS linker and a glycine linker.

[0218] A. Fc fusion Provided herein is a B7H3 binding polypeptide that is a fusion protein that contains at least one VHH domain that binds to B7H3 provided herein and an Fc domain.In some embodiments, provided herein is a B7H3 binding polypeptide that comprises one, two, three or four VHH domains that bind to B7H3 and an Fc domain.

[0219] In some embodiments, the incorporation of an immunoglobulin Fc region into a fusion protein may consist of two polypeptides that in some aspects form a dimer together. In some embodiments, the Fc domain mediates the dimerization of the B7H3 binding polypeptide when expressed, for example, from a cell, under physiological conditions, such that a dimer is formed that doubles the number of B7H3 binding sites. For example, a B7H3 binding polypeptide that includes three VHH domains that bind to B7H3 and an Fc region is trivalent as a monomer, but the Fc region may mediate dimerization such that the B7H3 binding polypeptide exists as a hexavalent dimer under such conditions. In some embodiments, a B7H3 VHH domain is fused to an IgG Fc region, and in these embodiments, the fusion protein is bivalent with two B7H3 VHH domains per molecule. In some embodiments, two B7H3 binding domains (2x) are fused to an IgG Fc region, in these embodiments the fusion protein is tetravalent with four B7H3 VHH domains per molecule. In some embodiments, three B7H3 VHH domains (3x) are fused to an IgG Fc region, in these embodiments the fusion protein is hexavalent with six B7H3 VHH domains per molecule.

[0220] In some embodiments, a multivalent B7H3 binding polypeptide is bivalent. In some embodiments, a bivalent B7H3 binding polypeptide of the disclosure comprises two copies of a B7H3 binding polypeptide having the following structure: (B7H3 VHH)-linker-Fc. In some embodiments, a multivalent B7H3 binding polypeptide is tetravalent. In some embodiments, a tetravalent B7H3 binding polypeptide of the disclosure comprises two copies of a B7H3-polypeptide having the following structure: (B7H3 VHH)-linker-(B7H3 VHH)-linker-Fc. In some embodiments, a multivalent B7H3 binding polypeptide is hexavalent. In some embodiments, a hexavalent B7H3 binding polypeptide of the disclosure comprises two copies of a B7H3 binding polypeptide having the following structure: (B7H3 VHH)-linker-(B7H3 VHH)-linker-(B7H3 VHH)-linker-Fc.

[0221] In some cases, the CH3 domain of the Fc region can be used as a homodimerization domain, so that the resulting fusion protein is formed from two identical polypeptides.In other cases, the CH3 dimer interface region of the Fc region can be mutated to allow heterodimerization.For example, a heterodimerization domain can be incorporated into the fusion protein, so that the construct is an asymmetric fusion protein.

[0222] In any of the embodiments provided, the B7H3 VHH domain can be any of those described above. In some embodiments, the B7H3 VHH domain is a humanized VHH domain that binds to B7H3.

[0223] In various embodiments, the Fc domain contained in the B7H3 binding polypeptide is a human Fc domain or is derived from a human Fc domain. In some embodiments, the fusion protein contains an immunoglobulin Fc region. In some embodiments, the immunoglobulin Fc region is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 subclass.

[0224] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof is of the IgG isotype. For example, the immunoglobulin Fc region of the fusion protein is of the human IgG1 isotype, having the following amino acid sequence: TIFF2024167342000016.tif22146

[0225] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof comprises a human IgG1 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:198.

[0226] In some embodiments where the fusion protein of the present disclosure comprises an Fc polypeptide, the Fc polypeptide is mutated or modified. In some cases, the mutation comprises one or more amino acid substitutions to reduce the effector function of the Fc polypeptide. Various examples of mutations to Fc polypeptide that change, e.g., reduce, effector function are known, including any of the following. In some embodiments, references to amino acid substitutions in the Fc region are by EU numbering according to Kabat (also referred to as Kabat numbering), unless described with respect to a particular SEQ ID NO. EU numbering is according to the well-known and most recently updated IMGT Scientific Chart (IMGT®, the international ImMunoGeneTics information system®, http: / / www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html (created: May 17, 2001, last updated: January 10, 2013)) and the EU index as reported in Kabat, EA et al. Sequences of Proteins of Immunological interest. 5th ed. US Department of Health and Human Services, NIH publication No. 91-3242 (1991).

[0227] In some embodiments, Fc regions exhibiting reduced effector functions may be desirable candidates for applications where B7H3 binding or CD3 binding is desirable, but certain effector functions (e.g., CDC and ADCC) are unnecessary or harmful. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / depleted CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the multispecific polypeptide construct and / or its truncated components lack FcγR binding (and thus likely lack ADCC activity) but retain FcRn binding ability. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see, Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be used (see, e.g., ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc. Mountain View, Calif.); and CytoTox 96™ Non-Radioactive Cytotoxicity Assay (Promega, Madison, Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells.Alternatively, or in addition, the ADCC activity of the molecule of interest may be evaluated in vivo, for example, in an animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). C1q binding assay may also be performed to confirm that the multispecific polypeptide construct or its truncated components cannot bind to C1q and therefore lack CDC activity. For example, see the C1q and C3c binding ELISA in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay may be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006)).

[0228] In some embodiments, the human IgG Fc region is modified to alter antibody-dependent cellular cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC), e.g., Natsume et al., 2008 Cancer Res, 68(10): 3863-72; Idusogie et al., 2001 J Immunol, 166(4): 2571-5; Moore et al., 2010 mAbs, 2(2): 181-189; Lazar et al., 2006 PNAS, 103(11): 4005-4010; Shields et al., 2001 JBC, 276(9): 6591-6604; Stavenhagen et al., 2007 Cancer Res, 67(18): 8882-8890; Stavenhagen et al., 2008 Advan. Enzyme Regul., 48: 152-164; Alegre et al, 1992 J Immunol, 148: 3461-3468; and amino acid modifications reviewed in Kaneko and Niwa, 2011 Biodrugs, 25(1):1-11.

[0229] Examples of mutations that enhance ADCC include modifications at Ser239 and Ile332, such as Ser239Asp and Ile332Glu (S239D, I332E). Examples of mutations that enhance CDC include modifications at Lys326 and Glu333. In some embodiments, the Fc region is modified at one or both of these positions, e.g., having Lys326Ala and / or Glu333Ala (K326A and E333A) using the Kabat numbering system.

[0230] In some embodiments, the Fc region of the fusion protein is altered at one or more of the following positions to reduce Fc receptor binding: Leu234 (L234), Leu235 (L235), Asp265 (D265), Asp270 (D270), Ser298 (S298), Asn297 (N297), Asn325 (N325), Ala327 (A327), or Pro329 (P329). For example, Leu234Ala (L234A), Leu235Ala (L235A), Leu235Glu (L235E), Asp265Asn (D265N), Asp265Ala (D265A), Asp270Asn (D270N), Ser298Asn (S298N), Asn297Ala (N297A), Pro329Ala (P329A) or Pro239Gly (P329G), Asn325Glu (N325E), or Ala327Ser (A327S). In a preferred embodiment, the modifications in the Fc region reduce binding to the Fc receptor gamma receptor while having minimal impact on binding to the neonatal Fc receptor (FcRn).

[0231] In some embodiments, the human IgG1 Fc region is modified at amino acid Asn297 (Kabat numbering) to prevent glycosylation of the fusion protein, e.g., has Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the Fc region of the fusion protein is modified at amino acid Leu235 (Kabat numbering) to alter Fc receptor interactions, e.g., has Leu235Glu (L235E) or Leu235Ala (L235A). In some embodiments, the Fc region of the fusion protein is modified at amino acid Leu234 (Kabat numbering) to alter Fc receptor interactions, e.g., has Leu234Ala (L234A). In some embodiments, the Fc region of the fusion protein is modified at amino acid Leu234 (Kabat numbering) to alter Fc receptor interactions, e.g., has Leu235Glu (L235E). In some embodiments, the Fc region of the fusion protein is altered at both amino acids 234 and 235, e.g., Leu234Ala and Leu235Ala (L234A / L235A) or Leu234Val and Leu235Ala (L234V / L235A). In some embodiments, the Fc region of the fusion protein is altered at amino acids 234, 235, and 297, e.g., Leu234Ala, Leu235Ala, Asn297Ala (L234A / L235A / N297A). In some embodiments, the Fc region of the fusion protein is altered at amino acids 234, 235, and 329, e.g., Leu234Ala, Leu235Ala, Pro239Ala (L234A / L235A / P329A). In some embodiments, the Fc region of the fusion protein is modified at amino acid Asp265 (Kabat numbering) to alter Fc-receptor interactions, e.g., Asp265Ala (D265A). In some embodiments, the Fc region of the fusion protein is modified at amino acid Pro329 (Kabat numbering) to alter Fc-receptor interactions, e.g., Pro329Ala (P329A) or Pro329Gly (P329G).In some embodiments, the Fc region of the fusion protein is altered at both amino acids 265 and 329, e.g., Asp265Ala and Pro329Ala (D265A / P329A) or Asp265Ala and Pro329Gly (D265A / P329G). In some embodiments, the Fc region of the fusion protein is altered at amino acids 234, 235, and 265, e.g., Leu234Ala, Leu235Ala, Asp265Ala (L234A / L235A / D265A). In some embodiments, the Fc region of the fusion protein is altered at amino acids 234, 235, and 329, e.g., Leu234Ala, Leu235Ala, Pro329Gly (L234A / L235A / P329G). In some embodiments, the Fc region of the fusion protein is modified at amino acids 234, 235, 265, and 329, e.g., Leu234Ala, Leu235Ala, Asp265Ala, Pro329Gly (L234A / L235A / D265A / P329G). In some embodiments, the Fc region of the fusion protein is modified at Gly235 to reduce Fc receptor binding. For example, Gly235 is deleted from the fusion protein. In some embodiments, the human IgG1 Fc region is modified at amino acid Gly236 to enhance interaction with CD32A, e.g., Gly236Ala (G236A). In some embodiments, the human IgG1 Fc region lacks Lys447 (Kabat et al 1991 EU Index of Sequences of Proteins of Immunological Interest).

[0232] In some embodiments, the Fc region of the fusion protein lacks one or more amino acids at the following positions to reduce Fc receptor binding: Glu233 (E233), Leu234 (L234), or Leu235 (L235). For example, the Fc region contained in the B7H3-binding polypeptide is derived from a human Fc domain and contains three amino acid deletions at the bottom of the hinge corresponding to IgG1 E233, L234, and L235. In some aspects, such Fc polypeptides do not engage FcγR and are therefore referred to as "effector silent" or "effector null". For example, the Fc deletion of these three amino acids reduces complement protein C1q binding. In some embodiments, polypeptides having an Fc region with the Fc deletion of these three amino acids retain binding to FcRn and therefore have a long half-life and transcytosis associated with FcRn-mediated recycling. Such a modified Fc region is referred to as "Fc xELL" or "Fc deleted" and has the following amino acid sequence: TIFF2024167342000017.tif22145

[0233] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof comprises a human IgG1 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:199.

[0234] In some embodiments, the human IgG Fc region is modified to enhance FcRn binding. Examples of Fc mutations that enhance binding to FcRn are Met252Tyr, Ser254Thr, Thr256Glu (M252Y, S254T, T256E, respectively) (Kabat numbering, Dall'Acqua et al 2006, J. Biol Chem Vol. 281(33) 23514-23524), Met428Leu and Asn434Ser (M428L, N434S) (Zalevsky et al 2010 Nature Biotech, Vol. 28(2) 157-159), or Met252Ile, Thr256Asp, Met428Leu (M252I, T256D, M428L, respectively) (Kabat et al 1991 EU Index of Sequences of Proteins of Immunological Interest).

[0235] In some embodiments, the Fc domain contained in the B7H3 binding polypeptide is derived from a human Fc domain and contains the mutations M252Y and M428V, herein referred to as "Fc-YV". In some embodiments, the mutated or modified Fc polypeptide contains the following mutations using the Kabat numbering system: M252Y and M428L. In some embodiments, such mutations enhance binding to FcRn at the acidic pH of the endosome (around 6.5) while losing detectable binding at neutral pH (about 7.2), which allows for enhanced FcRn-mediated recycling and extended half-life.

[0236] In some embodiments, the Fc domain included in the B7H3 binding polypeptide is derived from a human Fc domain and includes a mutation that induces heterodimerization. In some embodiments, such mutations include those referred to as "knob" and "hole" mutations. For example, an amino acid modification in the CH3 domain at Thr366, when replaced with a bulkier amino acid, such as Try (T366W), can preferentially pair with a second CH3 domain that has less bulky amino acids, such as Ser, Ala, and Val, at positions Thr366, Leu368, and Tyr407 (T366S / L368A / Y407V). In some embodiments, the "knob" Fc domain includes the mutation T366W. In some embodiments, the "hole" Fc domain includes the mutations T366S, L368A, and Y407V. Heterodimerization via CH3 modification can be further stabilized by the introduction of disulfide bonds, for example, by changing Ser354 to Cys (S354C) and Y349 to Cys (Y349C) on opposing CH3 domains (reviewed in Carter, 2001 Journal of Immunological Methods, 248: 7-15). In some embodiments, the Fc domain used for heterodimerization contains an additional mutation, for example, the mutation S354C on the first member of the heterodimeric Fc pair, which forms an asymmetric disulfide with the corresponding mutation Y349C on the second member of the heterodimeric Fc pair. In some embodiments, one member of the heterodimeric Fc pair contains the modification H435R or H435K to prevent Protein A binding while maintaining FcRn binding. In some embodiments, one member of the heterodimeric Fc pair comprises the modification H435R or H435K, while the second member of the heterodimeric Fc pair is not modified at H435. In various embodiments, the hole Fc domain comprises the modification H435R or H435K (in some instances where the modification is H435R, referred to as "hole-R"), while the knob Fc domain does not.In some instances, the hole-R mutation improves purification of the heterodimer over a possible homodimeric hole Fc domain.

[0237] In some embodiments, human IgG Fc region is modified to prevent dimerization.In these embodiments, the fusion protein of the present disclosure is monomeric.For example, modification of residue Thr366 to charge residue, such as Thr366Lys, Thr366Arg, Thr366Asp, or Thr366Glu (T366K, T366R, T366D, or T366E, respectively) prevents CH3-CH3 dimerization.

[0238] In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of the human IgG2 isotype, having the following amino acid sequence: TIFF2024167342000018.tif22145

[0239] In some embodiments, the fusion or immunologically active fragment thereof comprises a human IgG2 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:200.

[0240] In some embodiments, the human IgG2 Fc region is modified at amino acid Asn297 (e.g., to prevent glycosylation of the antibody, e.g., Asn297Ala (N297A) or Asn297Asp (N297D)). In some embodiments, the human IgG2 Fc region lacks Lys447 (Kabat et al 1991 EU Index of Sequences of Proteins of Immunological Interest).

[0241] In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of the human IgG3 isotype, having the following amino acid sequence: TIFF2024167342000019.tif22145

[0242] In some embodiments, the antibody or immunologically active fragment thereof comprises a human IgG3 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:201.

[0243] In some embodiments, the human IgG3 Fc region is modified at amino acid Asn297 (Kabat numbering) to prevent glycosylation of the antibody, e.g., Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the human IgG3 Fc region is modified at amino acid 435 to extend half-life, e.g., Arg435His (R435H). In some embodiments, the human IgG3 Fc region lacks Lys447 (Kabat et al 1991 EU Index of Sequences of Proteins of Immunological Interest).

[0244] In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of the human IgG4 isotype, having the following amino acid sequence: TIFF2024167342000020.tif22145

[0245] In some embodiments, the antibody or immunologically active fragment thereof comprises a human IgG4 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:202.

[0246] In some embodiments, the immunoglobulin Fc region or immunologically active fragment of the fusion protein is of the human IgG4 isotype, having the following amino acid sequence: TIFF2024167342000021.tif22145

[0247] In some embodiments, the antibody or immunologically active fragment thereof comprises a human IgG4 polypeptide sequence that is at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:203.

[0248] In some embodiments, the human IgG4 Fc region is modified at amino acid 235 to alter Fc-receptor interactions, e.g., Leu235Glu (L235E). In some embodiments, the human IgG4 Fc region is modified at amino acid Asn297 (Kabat numbering) to prevent antibody glycosylation, e.g., Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the human IgG4 Fc region lacks Lys447 (Kabat et al 1991 EU Index of Sequences of Proteins of Immunological Interest).

[0249] In some embodiments, the fusion protein contains a polypeptide derived from an immunoglobulin hinge region. The hinge region can be selected from any of the human IgG subclasses. For example, the fusion protein can be In another embodiment, the fusion protein contains a modified IgG1 hinge having the sequence of TIFF2024167342000022.tif4128, in which Cys220, which forms a disulfide with the C-terminal cysteine ​​of the light chain, is mutated to a serine, e.g., Cys220Ser (C220S). In another embodiment, the fusion protein contains a truncated hinge having the sequence DKTHTCPPC (SEQ ID NO:205).

[0250] In some embodiments, the fusion protein has a modified hinge from IgG4 that has been modified to prevent or reduce strand exchange, e.g., with Ser228Pro (S228P), having the sequence ESKYGPPCPPC (SEQ ID NO:206). In some embodiments, the fusion protein contains a linker polypeptide. In other embodiments, the fusion protein contains a linker and a hinge polypeptide.

[0251] In some embodiments, the Fc region lacks or has reduced fucose attached to the N-linked glycan chain at N297. There are numerous ways to prevent fucosylation, including, but not limited to, production in FUT8-deficient cell lines; addition of inhibitors, such as castanospermine, to mammalian cell culture media; and metabolic engineering of the production cell line.

[0252] In some embodiments, the Fc region is engineered to eliminate recognition by pre-existing antibodies found in humans. In some embodiments, the VHH-containing polypeptides of the disclosure are modified by a mutation at position Leu11, e.g., Leu11Glu (L11E) or Leu11Lys (L11K). In other embodiments, the single domain antibodies of the disclosure are modified by changes in the carboxy-terminal region, e.g., the terminal sequence is modified to the sequence TIFF2024167342000023.tif4128 or a modification thereof. In some embodiments, the single domain antibody of the disclosure is modified by an alteration in the carboxy terminal region, for example, the terminal sequence has the sequence "GG" or a modification thereof. In some embodiments, the VHH-containing polypeptide of the disclosure is modified by a mutation at position 11 and by an alteration in the carboxy terminal region.

[0253] In some embodiments, one or more polypeptides of the fusion protein of the present disclosure are functionally linked via amino acid linker.In some embodiments, these linkers are mainly composed of amino acid glycine and serine, and are referred to as GS linker herein.The GS linker of the fusion protein of the present disclosure can be of various lengths, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids in length.

[0254] In some embodiments, the GS linker is GGSGGS, i.e., TIFF2024167342000024.tif16157. In some embodiments, the linker comprises an amino acid sequence selected from the group consisting of, by way of non-limiting example, TIFF2024167342000025.tif4152. In some embodiments, the fusion protein can include a combination of a GS linker and a glycine linker.

[0255] B. Conjugates Provided herein is a conjugate, comprising at least one VHH domain that specifically binds to B7H3 provided herein and one or more additional moieties.Additional moieties can be therapeutic agents, such as cytotoxic agents, or detection agents.In some embodiments, said moieties can be targeting moieties, small molecule drugs (non-polypeptide drugs with molar masses of less than 500 Daltons), toxins, cytostatic agents, cytotoxic agents, immunosuppressants, radioactive agents suitable for diagnostic purposes, radioactive metal ions for therapeutic purposes, prodrug activating enzymes, agents that increase biological half-life, or agents that are diagnostic or detectable.

[0256] In some embodiments, the conjugate is an antibody drug conjugate (ADC, also called an immunoconjugate) comprising one or more B7H3 VHH domains provided herein conjugated to a therapeutic agent that is either cytotoxic, cytostatic, or other action that provides some therapeutic effect. In some embodiments, the cytotoxic agent is a chemotherapeutic agent, a drug, a growth inhibitor, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or a fragment thereof), or a radioisotope (i.e., a radioconjugate). In some embodiments, the antibody drug conjugate provided in the present disclosure allows for targeted delivery of the drug moiety to the tumor. In some cases, this can result in the death of the targeted tumor cells.

[0257] In some embodiments, provided herein is a B7H3 binding conjugate comprising at least one B7H3 VHH domain provided herein conjugated to a therapeutic agent. In some embodiments, the therapeutic agent includes, for example, daunomycin, doxorubicin, methotrexate, and vindesine (Rowland et al., Cancer Immunol. Immunother. 21:183-187, 1986). In some embodiments, the therapeutic agent has intracellular activity. In some embodiments, the B7H3 binding conjugate is internalized and the therapeutic agent is a cytotoxin that blocks protein synthesis in cells, resulting in cell death therein. In some embodiments, the therapeutic agent is a cytotoxin that includes a polypeptide with ribosome inactivation activity, including, for example, gelonin, bouganin, saporin, ricin, ricin A chain, bryodin, diphtheria toxin, restrictocin, pseudomonas exotoxin A, and variants thereof. In some embodiments, when the therapeutic agent is a cytotoxin comprising a polypeptide having ribosome inactivating activity, the B7H3 binding conjugate must be internalized upon binding to the target cell in order for the protein to be cytotoxic to the cell.

[0258] In some embodiments, provided herein is a B7H3 binding conjugate comprising at least one B7H3 VHH domain provided herein conjugated to a toxin. In some embodiments, toxins include, for example, bacterial toxins such as diphtheria toxin, plant toxins such as ricin, geldanamycin (Mandler et al., J. Nat. Cancer Inst. 92(19):1573-1581(2000); Mandler et al., Bioorganic & Med. Chem. Letters 10:1025- 1028(2000); Mandler et al., Bioconjugate Chem. 13:786-791(2002)), maytansinoids (EP 1391213; Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623(1996)), and calicheamicin (Lode et al., Cancer Res. 58:2928(1998); Hinman et al., Cancer Res. 53:3336-3342 (1993)). Toxins may exert their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition.

[0259] In some embodiments, provided herein is a B7H3 binding conjugate comprising at least one B7H3 VHH domain provided herein conjugated with a label that can directly or indirectly generate detectable signals.These IgSF conjugates can be used in research or diagnostic applications, for example, in the in vivo detection of cancer.The label is preferably capable of directly or indirectly generating detectable signals.For example, the label can be a radiopaque or radioisotope, for example, 3H, 14C, 32P, 35S, 123I, 125I, 131I; a fluorescent (fluorophore) or chemiluminescent (chromophore) compound, for example, fluorescein isothiocyanate, rhodamine, or luciferin; an enzyme, for example, alkaline phosphatase, β-galactosidase, or horseradish peroxidase; a contrast agent; or a metal ion. In some embodiments, the label is a radioactive atom, such as 99Tc or 123I, for scintigraphic studies, or a spin label, such as zirconium 89, iodine 123, iodine 131, indium 111, fluorine 19, carbon 13, nitrogen 15, oxygen 17, gadolinium, manganese, or iron, for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI). Zirconium 89 may be complexed with various metal chelators and conjugated to antibodies, for example for PET imaging (WO 2011 / 056983).

[0260] B7H3 binding conjugates can be prepared using any method known in the art, see, for example, WO 2009 / 067800, WO 2011 / 133886, and U.S. Patent Application Publication No. 2014322129, which are incorporated by reference in their entireties.

[0261] In some embodiments, the binding may be covalent or non-covalent, for example, via biotin-streptavidin non-covalent interactions. In some embodiments, one, two, three, four, or five or more moieties, which may be the same or different, are conjugated, linked, or fused to the B7H3 VHH domain to form a B7H3 binding conjugate. In some embodiments, such moieties can be attached to the VHH domain using various molecular biological or chemical conjugation and linking methods known in the art. In some embodiments, linkers, such as peptide linkers, cleavable linkers, non-cleavable linkers, or linkers that facilitate conjugation reactions, can be used to link or conjugate effector moieties to variant polypeptides or immunomodulatory proteins.

[0262] In some embodiments, the B7H3 VHH domain is conjugated to one or more moieties, e.g., about 1 to about 20 drug moieties per VHH, through a linker (L). In some embodiments, a B7H3 binding conjugate comprises the following components: (VHH domain), (L) q , and (part) m wherein the VHH domain is any of the described VHH domains capable of specific binding to B7H3 as described; L is a linker for linking the protein or polypeptide to the moiety; m is at least 1; q is 0 or greater; and the resulting B7H3 binding conjugate binds to B7H3. In certain embodiments, m is 1-4 and q is 0-8.

[0263] Linker can be composed of one or more linker components. For covalent attachment of antibody and drug moiety, linker typically has two reactive functional groups, i.e., bivalent in the sense of reactivity. Bivalent linker reagents useful for binding two or more functional or biologically active moieties, such as peptides, nucleic acids, drugs, toxins, antibodies, haptens, and reporter groups, are known, and methods are described for their resulting conjugates (Hermanson, GT (1996) Bioconjugate Techniques; Academic Press: New York, p 234-242).

[0264] Exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit"), alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl ("PAB"), N-succinimidyl 4-(2-pyridylthio)pentanoate ("SPP"), N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-I carboxylate ("SMCC"), and N-succinimidyl (4-iodo-acetyl)aminobenzoate ("SIAB").

[0265] In some embodiments, the linker may comprise an amino acid residue. Exemplary amino acid linker components include dipeptides, tripeptides, tetrapeptides, or pentapeptides. Exemplary dipeptides include valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe). Exemplary tripeptides include glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). Amino acid residues that comprise the amino acid linker component include naturally occurring, as well as minor amino acids and non-natural amino acid analogs, such as citrulline. Amino acid linker components can be designed and optimized for selectivity for enzymatic cleavage by specific enzymes, such as tumor-associated proteases, cathepsins B, C, and D, at plasmin proteases.

[0266] Conjugates of VHH domains and cytotoxic agents can be prepared using a wide variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyladipimidate HCl), active esters (e.g., disuccinimidyl substrates), aldehydes (e.g., glutaraldehyde), bis-azide compounds (e.g., bis(p-azidobenzoyl)hexanediamine)), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene).

[0267] Antibody drug conjugates can be prepared by a wide variety of methods, such as organic chemical reactions, conditions, and reagents known to those skilled in the art.In one embodiment, the methods include: (1) reacting the nucleophilic group of the VHH domain with a bivalent linker reagent to form VHH-L via a covalent bond, followed by reaction with the drug moiety D; and (2) reacting the nucleophilic group of the drug moiety with a bivalent linker reagent to form DL via a non-covalent bond, followed by reaction with the nucleophilic group of the VHH domain.

[0268] Nucleophilic groups on antibodies, including VHH domains, include, but are not limited to, (i) N-terminal amine groups, (ii) side chain amine groups, e.g., lysine, (iii) side chain thiol groups, e.g., cysteine, and (iv) hydroxyl or amino groups of sugars, if the antibody is glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic and can react to form covalent bonds with electrophilic groups on linker moieties and linker reagents, including (i) active esters, such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides, e.g., haloacetamides; and (iii) aldehyde, ketone, carboxyl, and maleimide groups. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysine with 2-iminothiolane (Traut's reagent), which results in the conversion of the amine to a thiol. Reactive thiol groups may be introduced into an antibody (or fragment thereof) by introducing one, two, three, four, or more cysteine ​​residues (e.g., by preparing a mutant antibody that contains one or more non-naturally occurring cysteine ​​amino acid residues).

[0269] Conjugates, such as antibody-drug conjugates, may be produced by modification of antibodies (e.g., VHH domains) to introduce electrophilic moieties that can react with nucleophilic substituents on the linker reagent or drug. The sugars of glycosylated antibodies can be oxidized, for example, by periodate oxidation reagents to form aldehyde or ketone groups that can be brought about by amine groups on the linker reagent or drug moiety. The resulting imine Schiff base groups can form stable linkages or can be reduced, for example, by borohydride reagents to form stable amine linkages. In one embodiment, reaction of the carbohydrate moiety of a glycosylated antibody with either galactose oxidase or sodium meta-iodide can result in carbonyl (aldehyde and ketone) groups in the protein that can react with the appropriate groups on the drug (Hermanson, Bioconjugate Techniques). In another embodiment, proteins containing N-terminal serine or threonine residues can be reacted with sodium meta-iodide to result in the production of an aldehyde in place of the first amino acid. Such aldehydes can react with a drug moiety or a linker nucleophile.

[0270] Similarly, nucleophilic groups on the drug moiety include, but are not limited to, (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides, e.g., haloacetamides; (iii) amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and aryl hydrazide groups that can react to form covalent bonds with electrophilic groups on the linker moieties and linker reagents, including aldehyde, ketone, carboxyl, and maleimide groups.

[0271] Alternatively, a fusion protein containing a VHH domain and a cytotoxic agent can be produced, for example, by recombinant techniques or peptide synthesis. The length of DNA can include regions each encoding the two parts of the conjugate, either adjacent to each other or separated by a region encoding a linker peptide that does not disrupt the desired properties of the conjugate.

[0272] C. Multisingularity form Provided herein is a multispecific B7H3 binding polypeptide, comprising at least one VHH domain that binds to B7H3 and one or more additional binding domains.Typically, one or more additional domains bind to a second antigen or protein other than B7H3.In some embodiments, one or more additional domains are antibodies or antigen-binding fragments that are specific for the second antigen or protein.In some embodiments, the additional domain is a VHH domain.

[0273] In some embodiments, the multispecific B7H3 binding polypeptide comprises at least one VHH domain that binds to B7H3 and at least one additional binding domain that binds to a second antigen or protein. In some embodiments, this second antigen is a tumor-associated antigen (TAA) or a tumor microenvironment-associated antigen (TMEAA). In some embodiments, this second antigen is an immunomodulatory antigen, which is involved in enhancing or attenuating signaling pathways in immune cells.

[0274] In some cases, the multispecific B7H3 binding polypeptide can further comprise an Fc domain, such as any of those described above. In some embodiments, the multispecific B7H3 binding polypeptides provided herein comprise at least one VHH domain that binds to B7H3, at least one additional binding domain that binds to a second antigen or protein, and an Fc domain. In some embodiments, the Fc domain mediates dimerization of the multispecific B7H3 binding polypeptide under physiological conditions such that dimers are formed that double the number of binding sites for B7H3 and the additional antigen or protein.

[0275] Non-limiting exemplary multispecific B7H3 binding polypeptides are described below.

[0276] 1. Bispecific T Cell Engagers In some embodiments, the B7H3 binding polypeptide is a bispecific construct that is or comprises at least one B7H3 VHH domain provided herein and at least one additional binding molecule that can bind to a surface molecule expressed on a T cell. In some embodiments, the surface molecule is an activation component of a T cell, such as a component of a T cell receptor complex. In certain aspects, the surface molecule is an activating T cell antigen expressed on a T cell, and can induce T cell activation upon interaction with an antigen binding molecule. For example, in some aspects, the interaction of an antigen binding molecule with an activating T cell antigen can induce T cell activation by triggering the signal transduction cascade of the T cell receptor complex. Suitable assays for measuring T cell activation are known and include any assay for measuring or evaluating proliferation, differentiation, cytokine secretion, cytotoxic activity, and / or expression of one or more activation markers. In some embodiments, simultaneous or near-simultaneous binding of such a B7H3 binding polypeptide to both of its targets, B7H3 expressed on a target cell and a T cell molecule (e.g., an activating T cell antigen) expressed on a T cell, can result in a transient interaction between the target cell and the T cell, thereby resulting in activation of the T cell, e.g., cytotoxic activity, and subsequent lysis of the target cell.

[0277] In some embodiments, the T surface molecule, e.g., the activating T cell antigen, is CD3 or CD2. In particular, the bispecific B7H3 binding polypeptides provided can specifically bind to an activating T cell antigen, e.g., human CD3 or human CD3, expressed on a human T cell. In certain aspects, the additional binding domain specific for an activating T cell antigen (e.g., CD3 or CD2) is an antibody or antigen-binding fragment. In some embodiments, the B7H3 binding polypeptide can be a bispecific antibody T cell engager comprising at least one B7H3 VHH domain that specifically binds to B7H3, and an additional binding molecule that is an antibody or antigen-binding fragment specific for an activation component of a T cell (e.g., a T cell surface molecule, e.g., CD3 or CD2).

[0278] Bispecific antibody T cell engagers can be tandem scFv molecules fused by a flexible linker (see, e.g., Nagorsen and Bauerle, Exp Cell Res 317, 1255-1260 (2011); tandem scFv molecules further comprising an Fc domain comprised of a first and a second subunit fused to each other, e.g., via a flexible linker, and capable of stable association (WO2013026837); diabodies and derivatives thereof, including tandem diabodies (Holliger et al, Prot Eng 9, 299-305 (1996); Kipriyanov et al, J Mol Biol 293, 41-66 (1999)); dual affinity retargeting (DART) molecules, which can include diabody formats with a C-terminal disulfide bridge; or triomabs, which comprise a whole hybrid mouse / rat IgG molecule (Seimetz et al, Cancer Treat Rev 36, 458-467 (2010)). Similar formats of any of the above molecules can be made using any of the B7H3 VHH domains provided herein.

[0279] In some embodiments, the additional binding domain specific for an activating T cell antigen is a Fab fragment, F(ab') 2 The antigen-binding fragment is selected from a fragment, an Fv fragment, an scFv, a disulfide-stabilized Fv fragment (dsFv), an scAb, a dAb, a single-domain heavy chain antibody (VHH), or a single-domain light chain antibody. In some embodiments, the additional binding domain is monovalent for binding to an activating T cell antigen, such as CD2 or CD3.

[0280] In some embodiments, the additional binding domain is capable of binding to CD3 or the CD3 complex. The CD3 complex is a complex of at least five membrane-bound polypeptides in mature T lymphocytes that non-covalently associate with each other and with the T cell receptor. The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (also referred to as subunits). In some embodiments, the additional binding molecule is an antibody or antigen-binding fragment capable of specifically binding to CD3 or the CD3 complex, also referred to as a CD3 binding domain. In some embodiments, the CD3 binding domain capable of binding to CD3 or the CD3 complex includes anti-CD3 Fab fragments, anti-CD3 F(ab') 2 In some embodiments, the anti-CD3 binding domain is monovalent for binding to CD3.

[0281] In some cases, the CD3 binding domain recognizes the CD3ε chain. In some embodiments, the anti-CD3ε binding domain includes an anti-CD3ε Fab fragment, an anti-CD3ε F(ab') 2 The anti-CD3ε binding domains include one or more copies of anti-CD3ε Fv fragments, anti-CD3ε scFv, anti-CD3ε dsFv, anti-CD3ε scAb, anti-CD3ε dAb, anti-CD3ε single domain heavy chain antibody (VHH), and anti-CD3ε single domain light chain antibody. In some embodiments, the anti-CD3ε binding domain is monovalent for binding to CD3ε.

[0282] Exemplary monoclonal antibodies against CD3 or the CD3 complex include, but are not limited to, OKT3, SP34, UCHT1 or 64.1, or antigen-binding fragments thereof (see, e.g., June, et al., J. Immunol. 136:3945-3952 (1986); Yang, et al., J. Immunol. 137:1097-1100 (1986); and Hayward, et al., Immunol. 64:87-92 (1988)). In some aspects, clustering of CD3 on T cells, for example by immobilized or cell-localized or tethered anti-CD3 antibodies, results in T cell activation similar to T cell receptor engagement, but independent of its clonal typical specificity. In one embodiment, the CD3 binding domain binds monovalently and specifically to the CD3 antigen and is selected from the group consisting of OKT3 (ORTHOCLONE-OKT3™ (muromonab-CD3); humanized OKT3 (U.S. Pat. No. 7,635,475 and published international application WO2005040220); SP34 ((Pessano et al. The EMBO Journal. 4: 337-344, 1985); humanized variants of SP34 (WO2015001085); Teplizumab™ (MGA031, Eli Lilly); anti-CD3 binding molecules described in US2011 / 0275787; UCHT1 (Pollard et al. 1987 J Histochem Cytochem. 35(11):1329-38; WO2000041474); NI0401 (WO2007 / 033230); visilizumab (U.S. Pat. No. 5,834,597); BC-3 (Anasetti et al., Transplantation 54: 844 (1992)); H2C (described in PCT Publication No. WO2008 / 119567); V9 (described in Rodrigues et al., Int J Cancer Suppl 7, 45-50 (1992) and U.S. Pat. No. 6,054,297).Other anti-CD3 antibodies can also be used in the constructs provided herein, including any of those described in International Published PCT Application Nos. WO199404679, WO2008119567, WO2015095392, WO2016204966, WO2019133761; Published Patent Application Nos. US20170369563, US20180194842, US20180355038; U.S. Patent Nos. 7,728,114, 7,381,803, and 7,994,289.

[0283] In some embodiments, the CD3 binding domain comprises a variable heavy (VH) chain set forth in SEQ ID NO:209 and / or a variable light chain set forth in SEQ ID NO:210, or a VH and / or VL sequence having at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% identity to these sequences, and specifically binds to CD3. In some embodiments, the CD3 binding domain comprises CDRH1, CDRH2, and CDRH3 of the variable heavy (VH) chain set forth in SEQ ID NO:209, and CDRL1, CDRL2, and CDRL3 of the variable light chain set forth in SEQ ID NO:210. In some cases, the CD3 binding region comprises a humanized version of the VH sequence set forth in SEQ ID NO:209 and a humanized version of the VL sequence set forth in SEQ ID NO:210. In some embodiments, the CD3 binding region may comprise a VH domain sequence from humanized OKT3 as set forth in any one of SEQ ID NOs:211;212;213 and / or a VL domain sequence as set forth in any one of SEQ ID NOs:214, 215, 216, or a VH and / or VL sequence having at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% identity thereto, and specifically binds to CD3. In some embodiments, the CD3 binding domain is a Fab, scFv, Fv, or dsFv comprising therein any combination of the above VH and VL sequences, in particular any combination of the VH sequence as set forth in any one of SEQ ID NOs:211, 212, or 213 and the VL sequence as set forth in any one of SEQ ID NOs:214, 215, or 216.

[0284] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence TYAMN (SEQ ID NO:219); At least the amino acid sequence VH CDR2 sequence containing TIFF2024167342000026.tif3128; At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000027.tif4128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000028.tif4128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 sequence including at least the amino acid sequence ALWYSNLWV (SEQ ID NO:224) In some embodiments, the CD3 binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence TYAMN (SEQ ID NO:219); At least the amino acid sequence VH CDR2 sequence containing TIFF2024167342000029.tif3128; At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000030.tif3128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000031.tif3128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 sequence including at least the amino acid sequence ALWYSNLWV (SEQ ID NO:224) is included therein.

[0285] In some embodiments, the CD3 binding domain comprises a variable heavy (VH) chain set forth in SEQ ID NO:217 and / or a variable light chain set forth in SEQ ID NO:218, or a VH and / or VL sequence having at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% identity to these sequences, and specifically binds to CD3. In some embodiments, the CD3 binding domain comprises CDRH1, CDRH2, and CDRH3 of the variable heavy (VH) chain set forth in SEQ ID NO:217, and CDRL1, CDRL2, and CDRL3 variable light chains set forth in SEQ ID NO:218. In some embodiments, the CD3 binding domain comprises CDRH1, CDRH2, and CDRH3 set forth in SEQ ID NO:219, 220, and 221, respectively, and CDRL1, CDRL2, and CDRL3 variable light chains set forth in SEQ ID NO:222, 223, and 224, respectively. In some cases, the CD3 binding region comprises a humanized version of the VH sequence set forth in SEQ ID NO:217 and a humanized version of the VL sequence set forth in SEQ ID NO:218. In some embodiments, the CD3 binding region can comprise a humanized VH domain sequence set forth in any one of SEQ ID NOs:225-255, 460, 462, or 480, and / or a VL domain sequence set forth in any one of SEQ ID NOs:256-274, 417, 459, or 461, or a VH and / or VL sequence having at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% identity thereto, and specifically binds to CD3. In some embodiments, the anti-CD3ε binding domain comprises a variable heavy chain (Hv) comprising the amino acid sequence of SEQ ID NO:237 and a variable light chain (Lv) comprising the amino acid sequence of SEQ ID NO:265.In some embodiments, the CD3 binding domain is a Fab, scFv, Fv, or dsFv comprising therein any combination of the VH and VL sequences described above, in particular any combination of a VH sequence set forth in any of SEQ ID NOs:225-255, 460, 462, or 480 and a VL sequence set forth in any of SEQ ID NOs:256-274, 417, 459, or 461. In some embodiments, the anti-CD3 binding domain is a Fab, scFv, Fv, or dsFv comprising therein a variable heavy chain (Hv) comprising the amino acid sequence of SEQ ID NO:237 and a variable light chain (Lv) comprising the amino acid sequence of SEQ ID NO:265.

[0286] In some embodiments, the CD3 binding domain comprises a variable heavy (VH) chain set forth in any one of SEQ ID NOs:537, 538, 541, or 542. In some embodiments, the CD3 binding domain comprises a variable light (VL) chain set forth in any one of SEQ ID NOs:539, 540, 543, or 544.

[0287] The provided bispecific constructs can be made in any of several formats that contain at least one B7H3 VHH domain and at least one additional domain specific for an activating T cell antigen, such as a CD3 binding domain.

[0288] In one embodiment, the bispecific construct is a bispecific single domain antibody-linked Fab (S-Fab) comprising at least one B7H3 VHH domain as described, directly or indirectly linked to a Fab antigen-binding fragment specific for a T cell activation antigen, e.g., CD3, e.g., an anti-CD3 Fab. The Fab for a T cell activation antigen, e.g., an anti-CD3 Fab, can comprise any of the VH and VL sequences as described. In some embodiments, the B7H3 VHH domain is linked to the C-terminus of the VH or VL chain of the anti-CD3 Fab. In some embodiments, the S-Fab can be further modified, e.g., by conjugation with polyethylene glycol (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer, protein (such as albumin), polyglutamic acid, or PASification (Pan et al. (2018) International Jounral of Nanomedicine, 2018:3189-3201).

[0289] In another embodiment, the bispecific construct is a scFv-single domain antibody, in which the construct comprises at least one B7H3 VHH as described, directly or indirectly linked to a scFv comprising the VH and VL of an antigen binding domain specific for a T cell activation antigen, e.g., CD3. The scFv against a T cell activation antigen, e.g., an anti-CD3 scFv, can comprise any of the VH and VL sequences as described. In some embodiments, the VHH domain and the scFv are linked by a linker, such as a peptide linker. In some embodiments, the peptide linker can be a peptide linker as described herein. In some embodiments, the VHH domain and the scFv are each linked to an Fc region, e.g., the N-terminus of the Fc region, optionally through a hinge region or a linker (e.g., a peptide linker). The Fc region can be any of those described herein, e.g., a human Fc region or a variant thereof, e.g., a human IgG1 Fc region or a variant thereof. In certain instances, the Fc region is formed by a variant Fc domain, e.g., a variant human IgG1 domain, that has been mutated or modified to promote heterodimerization, capable of dimerizing different polypeptides to obtain heterodimers.

[0290] In further embodiments, the CD3 binding domain is a single domain antibody, for example, a VHH domain that specifically binds to CD3. Single domain antibodies that contain a VHH domain and bind to CD3 are known, see, for example, published US patent application US20160280795. In some embodiments, the CD3 binding domain is an anti-CD3 VHH as set forth in SEQ ID NO:275, or a sequence that exhibits at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% identity to SEQ ID NO:275 and specifically binds to CD3. In such aspects, the bispecific constructs provided herein may comprise at least one B7H3 VHH domain and at least one CD3 VHH domain.

[0291] In the formatting of the construct, in some cases, each VHH domain is linked to an Fc region, e.g., the N-terminus of the Fc region, optionally through a hinge region or a linker (e.g., a peptide linker). The Fc region can be any of those described herein, e.g., a human Fc region or a variant thereof, e.g., a human IgG1 Fc region or a variant thereof. In certain examples, the Fc region is formed by a variant Fc domain, e.g., a variant human IgG1 domain, that has been mutated or modified to promote heterodimerization, which can dimerize different polypeptides to obtain a heterodimer.

[0292] In the above embodiments, exemplary modifications of the Fc region that promote heterodimerization are known and include any of those described below, e.g., in Table 3. In some embodiments, one Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NOs: 293, 297, 305, 307, 445, or 451, and the other Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NOs: 294, 298, 301, 303, 309, 311, 446, 449, or 453. In some embodiments, one Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NOs: 295, 299, 306, 308, 447, or 452, and the other Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NOs: 296, 300, 302, 304, 310, 312, 448, 450, or 454.

[0293] 2. Constrained CD3 Multispecific Constructs In some embodiments, the B7H3 binding polypeptide is a multispecific polypeptide construct that is a constrained T cell engaging fusion protein. In certain aspects, the constrained multispecific constructs provided herein bind to an activating T cell antigen, such as CD3, and B7H3. The constrained multispecific polypeptide constructs provided herein include at least a first component that includes an immunoglobulin Fc region, a second component that includes one or more copies of at least one binding domain that binds to CD3 (referred to herein as an anti-CD3 binding domain or a CD3 binding domain, which are used interchangeably herein), and a linker, e.g., a polypeptide linker, that links the first component and the second component. In the provided multispecific polypeptide constructs, one or both of the first and second components include at least one B7H3 VHH domain that, when engaged by binding to an antigen, allows the constrained CD3 binding region to substantially bind to CD3. Figures 3A-3E illustrate exemplary formats of constrained multispecific constructs.

[0294] In some embodiments, the constrained multispecific polypeptide constructs provided herein exist in two states in terms of their ability to bind CD3 and subsequently activate T cells: (1) an "inactive" state occurs in the absence of binding of any or all of the antigen binding domains to B7H3, in which case CD3 binding is restricted and T cell interaction is suppressed or reduced; and (2) upon antigen binding by any or all of the antigen binding domains, an "active" state occurs in which the CD3 binding region can bind CD3 and allow T cell interaction.

[0295] In some embodiments, the Fc region is linked to the CD3 binding domain via one or more linkers. In some embodiments, the Fc region is linked to the CD3 binding region via one or more non-cleavable linkers. In some embodiments, the Fc region is linked to the CD3 binding region via a cleavable linker or one or more other labile linkers. In some embodiments, the cleavable linker is a linker that can be specifically cleaved in the presence of a protease. In some aspects, enhanced CD3 binding occurs after cleavage of the cleavable linker. In some such aspects, the "active" state can be further amplified through multiple mechanisms, including cleavage of the linker that connects the CD3 binding region and the Fc region. In some embodiments, the cleavable linker is a linker that contains a substrate recognition site for a protease. In some embodiments where the Fc region and the CD3 binding region are linked by a cleavable linker, enhanced CD3 binding can occur after cleavage within the linker.

[0296] Furthermore, in aspects where the Fc region and the CD3 binding region are operably linked by a cleavable linker, cleavage of the linker between the Fc region and the CD3 binding region may separate the constrained multispecific polypeptide construct into a first component and a second component. Depending on the configuration of the constrained multispecific polypeptide construct, the first component and the second component may have different functionalities. In some embodiments, the Fc region is a region that exhibits one or more effector functions, such as ADCC, CDC, or ADCP functions. In such instances, the constrained multispecific polypeptide construct of the present disclosure can be used to generate a self-amplifying system. For example, in some aspects, incorporation of a protease-cleavable linker between the Fc and CD3 binding domain components allows for amplification of T cell activation potential by allowing complete exposure of the CD3 binding domain. Depending on the particular linker included, the amplification step may be mediated by tumor-associated proteases or granzymes released after antigen-dependent T cell activation. When a tumor protease cleavable linker is included, amplification is mediated by tumor or tumor microenvironment.On the other hand, when a granzyme B cleavable linker is included, amplification can be self-mediated by T cells after antigen-dependent activation.Furthermore, when an effector-capable Fc is included in the construct, amplification can be mediated by granzymes released from NK cells that occur through ADCC mechanisms.

[0297] The constrained multispecific polypeptide constructs provided include a configuration in which a first component comprising an Fc region is N-terminal to a second component comprising a CD3 binding region. In such embodiments, the first and second components are linked via a linker that is C-terminal to the end of the Fc region. In some embodiments, at least one B7H3 VHH domain is located at the amino-terminal (N-terminal) region of the multispecific polypeptide construct. In some embodiments, at least one B7H3 VHH domain is located at the carboxy-terminal (C-terminal) region of the multispecific polypeptide construct. In some embodiments, the constrained multispecific polypeptide construct comprises at least two B7H3 VHH domains located at both the N- and C-terminal regions of the multispecific polypeptide construct.

[0298] In some embodiments, the constrained multispecific polypeptide construct is a dimer, where dimerization is formed by covalent or non-covalent interactions between the two polypeptide chains. In some embodiments, the two polypeptide chains are covalently linked to each other, for example, by interchain disulfide bonds. In some embodiments, the Fc region mediates dimerization via interchain disulfide bonds. In certain embodiments, the constrained multispecific polypeptide construct comprises a heterodimeric Fc region, where in some cases the polypeptide chains of the multispecific polypeptide construct are different (heterodimers). In certain examples of heterodimeric multispecific polypeptide constructs, the CD3 binding region is a two-chain polypeptide comprising a VH and a VL chain, for example, an Fv antibody fragment comprising a VH and a VL. In some embodiments, the Fv antibody fragment comprises a disulfide-stabilized anti-CD3 binding Fv fragment (dsFv).

[0299] In certain embodiments, the Fv is H -V LThe heterodimer is a disulfide-stabilized Fv fragment (dsFv) stabilized by an interchain disulfide bond. In some embodiments, the interchain disulfide bond is engineered by mutation of positions in the framework positions of the VH and / or VL chain. In some embodiments, the VH chain comprises the mutation G44C and the VL chain comprises the mutation G100C, each according to the Kabat numbering. In some embodiments, the disulfide-stabilized anti-CD3 Fv comprises an anti-CD3 VH with a mutation at position 105 to Cys and an anti-CD3 VL with a mutation at position 43 to Cys, according to the Kabat numbering.

[0300] In some embodiments, the constrained multispecific polypeptide construct is formed from or comprises two polypeptides, comprising a first polypeptide comprising a first Fc polypeptide of a heterodimeric Fc region, a linker (e.g., a cleavable or non-cleavable linker), a VH domain of an anti-CD3 antibody or antigen-binding fragment (e.g., Fv); and a second polypeptide comprising a second Fc polypeptide of a heterodimeric Fc region, a linker (e.g., a cleavable or non-cleavable linker), a VL domain of an anti-CD3 antibody or antigen-binding fragment (e.g., Fv). In some embodiments, the first polypeptide comprises one or two VHH domains that bind to B7H3. In some embodiments, the second polypeptide comprises one or two VHH domains that bind to B7H3. In some embodiments, the constrained multispecific polypeptide construct comprises at least two B7H3 VHH domains. In some cases, at least one B7H3 VHH domain is located at the N-terminus of an Fc polypeptide and at least one B7H3 VHH domain is located at the C-terminus of a chain of a CD3 binding region.

[0301] In some embodiments, the first or second polypeptide or both the first and second polypeptides comprise a costimulatory receptor binding region (CRBR) that binds to a costimulatory receptor. In some embodiments, the CRBR of the first and / or second polypeptide may be located at the N-terminus of the Fc polypeptide and / or at the C-terminus of a chain of the CD3 binding region.

[0302] In some embodiments, the constrained multispecific polypeptide construct further comprises at least two VHH domains that bind B7H3 and at least one costimulatory receptor binding region (CRBR) that binds a costimulatory receptor. In some embodiments, the constrained multispecific polypeptide construct comprises: (1) a first polypeptide comprising, in order from N-terminus to C-terminus: a first B7H3 VHH domain, a first Fc polypeptide of a heterodimeric Fc region, a linker (e.g., a cleavable linker), a chain (e.g., VH or VL) of an anti-CD3 antibody or antigen-binding fragment (e.g., Fv or dsFv), and a second B7H3 VHH domain; and (2) a second polypeptide comprising, in order from N-terminus to C-terminus: a second Fc polypeptide of a heterodimeric Fc region, the same linker (e.g., the same cleavable linker), the other chain (another VH or VL) of an anti-CD3 antibody or antigen-binding fragment, and a costimulatory receptor binding region (CRBR) that binds a costimulatory receptor.

[0303] In some embodiments, the first or second polypeptide or both the first and second polypeptides further comprise an inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor. In some embodiments, the IRBR of the first and / or second polypeptide may be located at the N-terminus of the Fc polypeptide and / or the C-terminus of the chain of the CD3 binding region.

[0304] In some embodiments, the constrained multispecific polypeptide construct comprises at least two VHH domains that bind to B7H3 and at least one inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor. In some embodiments, the constrained multispecific polypeptide construct comprises: (1) a first polypeptide comprising, in order from N-terminus to C-terminus: a first B7H3 VHH domain, a first Fc polypeptide of a heterodimeric Fc region, a linker (e.g., a cleavable or non-cleavable linker), a chain (e.g., VH or VL) of an anti-CD3 antibody or antigen-binding fragment (e.g., Fv or dsFv), and a second B7H3 VHH domain; and (2) a second polypeptide comprising, in order from N-terminus to C-terminus: a second Fc polypeptide of a heterodimeric Fc region, the same linker (e.g., the same cleavable linker), the other chain (another VH or VL) of an anti-CD3 antibody or antigen-binding fragment, and an inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor.

[0305] In some embodiments, at least one of the first or second polypeptides further comprises a costimulatory receptor binding region (CRBR) that binds to a costimulatory receptor, and at least one of the first or second polypeptides further comprises an inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor. In some embodiments, the CRBR of the first and / or second polypeptide may be located at the N-terminus of the Fc polypeptide and / or the C-terminus of the chain of the CD3 binding region. In some embodiments, the IRBR of the first and / or second polypeptide may be located at the N-terminus of the Fc polypeptide and / or the C-terminus of the chain of the CD3 binding region.

[0306] In some embodiments, the constrained multispecific polypeptide construct comprises at least two VHH domains that bind to B7H3, a costimulatory receptor binding region (CRBR) that binds to a costimulatory receptor, and an inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor. In some embodiments, the constrained multispecific polypeptide construct comprises: (1) a first polypeptide comprising, in order from N-terminus to C-terminus: a first B7H3 VHH domain, a first Fc polypeptide of a heterodimeric Fc region, a linker (e.g., a cleavable or non-cleavable linker), a chain (e.g., VH or VL) of an anti-CD3 antibody or antigen-binding fragment (e.g., Fv or dsFv), and a second B7H3 VHH domain; and (2) a second polypeptide comprising, in order from N-terminus to C-terminus: one of an IRBR or a CRBR, a second Fc polypeptide of a heterodimeric Fc region, the same linker (e.g., the same cleavable or non-cleavable linker), the other chain (another VH or VL) of an anti-CD3 antibody or antigen-binding fragment, and the other of an IRBR or CRBR.

[0307] Each of the components of the multispecific polypeptide constructs of the present disclosure is described in more detail below.

[0308] B7H3 VHH antigen-binding domain The constrained multispecific polypeptide constructs of the present disclosure comprise at least one B7H3 VHH domain from any of those provided herein. In some embodiments, the B7H3 VHH domain comprises a sequence of amino acids set forth in any of SEQ ID NOs: 1-114, 466, 467.

[0309] The constrained multispecific polypeptide constructs of the present disclosure comprise at least one B7H3 VHH domain from any of those provided herein. In some embodiments, the B7H3 VHH domain comprises a sequence of amino acids set forth in any of SEQ ID NOs: 1-114, 466, 467, 489, 490, or 492-518.

[0310] In certain embodiments, the constrained multispecific polypeptide construct comprises at least two B7H3 domains. In some cases, at least one B7H3 VHH domain is positioned amino-terminal to the Fc polypeptide of the heterodimeric Fc, and at least one B7H3 VHH domain is positioned carboxy-terminal to the VH or VL chain of the CD3 binding region.

[0311] In the aspect of a constrained multispecific polypeptide construct comprising at least two B7H3 VHH domains or comprising two B7H3 VHH domains, each of the B7H3 VHH domains can bind to the same or overlapping epitope on B7H3.

[0312] In the aspect of a constrained multispecific polypeptide construct comprising at least two B7H3 VHH domains or comprising two B7H3 VHH domains, each of the B7H3 VHH domains can bind to a different or non-overlapping epitope on B7H3.

[0313] In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO:67 and SEQ ID NO:43. In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO:67 and SEQ ID NO:503. In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO:67 and SEQ ID NO:67. In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO:67 and SEQ ID NO:1. In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO:67 and SEQ ID NO:8. In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO: 467 and SEQ ID NO: 466. In some embodiments, the first sdAb VHH domain and the second sdAb VHH domain comprise the amino acid sequences set forth in SEQ ID NO: 467 and SEQ ID NO: 85.

[0314] In some embodiments, the antigen binding domain, e.g., the B7H3 VHH domain, is linked to the Fc region and / or the CD3 binding region, directly or indirectly, via a linker. In some embodiments, the link is via a linker. In some embodiments, the linker is a linking peptide (LP), which can include any flexible or rigid linker as described. In some embodiments, the linker is GGSGGS, i.e., In some embodiments, the linker is selected from the group consisting of: TIFF2024167342000032.tif16158. In some embodiments, the linker is selected from the group consisting of: TIFF2024167342000033.tif4151. In some embodiments, the linker comprises a combination of a GS linker and a glycine linker.

[0315] b.Fc region The constrained multispecific polypeptide construct comprises an immunoglobulin Fc region. In general, the constrained multispecific polypeptide construct is a dimer formed by polypeptides each comprising an Fc. The Fc polypeptide can be any of those described above.

[0316] In certain embodiments, the Fc region is formed by an Fc domain that is mutated or modified to promote heterodimerization, which allows different polypeptides to dimerize to obtain heterodimers. Thus, in some embodiments, the dimer is a heterodimer in which the two polypeptide chains of the multispecific polypeptide construct are different.

[0317] Various methods for promoting heterodimerization of complementary Fc polypeptides are known, e.g., Ridgway et al, Protein Eng. 9:617-621 (1996);Merchant et al, Nat. Biotechnol. 16(7): 677-81 (1998);Moore et al. (2011) MAbs, 3:546-57;Von Kreudenstein et al. MAbs, (2013) 5:646-54;Gunasekaran et al. (2010) J. Biol. Chem., 285:19637-46;Leaver-Fay et al. (2016) Structure, 24:641-51;Ha et al. (2016) Frontiers in Immunology, 7:1;Davis et al. (2010) Protein Eng Des Sel, 23:195-202; Published International PCT Application Nos. WO 1998 / 050431, WO 2009 / 089004, WO2011143545, WO 2014 / 067011, WO See WO2012 / 058768, WO2018027025; Published U.S. Patent Application Nos. US20140363426, US20150307628, US20180016354, US20150239991; and U.S. Patent Nos. US5731168, US7183076, US9701759, US9605084, and US9650446. Methods for promoting Fc chain heterodimerization include mutagenesis of the Fc region, for example, by including a set of "knobs-into-holes" mutations, or by including mutations that result in electrostatic steering of Fc in favor of attractive interactions between different polypeptide chains.For example, in some embodiments, the heterodimeric Fc polypeptide contains mutations that alter the charge polarity between the Fc dimer interface, such that co-expression of electrostatically matched Fc chains favors favorable attractive interactions, thereby promoting desirable Fc heterodimer formation, whereas unfavorable repulsive charge interactions suppress undesirable Fc homodimer formation ((Guneskaran et al. (2010) JBC, 285: 19637-19646). When co-expressed in cells, the chains do not substantially self-associate due to charge repulsion, although inter-chain association is permitted. Other strategies for generating heterodimeric Fc include mixing human IgG and IgA CH3 domain segments to generate complementary CH3 heterodimers, referred to as SEED Fc.

[0318] Methods and variants for heterodimerization also include those described in published international PCT application WO2014 / 145806, including "knob and hole" mutations (also called "skew" variants), mutations related to "electrostatic steering" or "charge pairing", and pI variants. Heterodimer variants also include any described in U.S. published application US2012 / 0149876 or US2018 / 011883.

[0319] In some embodiments, both polypeptides of the Fc heterodimer contain paired or complementary amino acid modifications to promote heterodimerization. Exemplary paired amino acid modifications of Fc fusion polypeptides are listed in Table 3.

[0320] Table 3: Amino acids that form heterodimeric Fc pairs TIFF2024167342000034.tif43133

[0321] In some embodiments, the modification comprises introducing a protuberance (knob) into a first Fc polypeptide and a cavity (hole) into a second Fc polypeptide such that the protuberance is positionable within the cavity to facilitate complex formation of the first and second Fc-containing polypeptides. The amino acids targeted for substitution and / or modification to create protuberances and cavities in a polypeptide are typically interface amino acids that interact or contact one or more amino acids in the interface of a second polypeptide.

[0322] In some embodiments, the first Fc polypeptide modified to include a protrusion (hole) amino acid includes a replacement of a native or original amino acid with an amino acid having at least one side chain that protrudes from the interface of the first Fc polypeptide and can therefore be located in a compensatory cavity (hole) in the adjacent interface of the second polypeptide. In most cases, the replacement amino acid has a larger side chain volume than the original amino acid residue. Those skilled in the art will understand how to determine and / or evaluate the properties of amino acid residues to identify amino acid residues that are ideal replacement amino acids for creating protrusions. In some embodiments, the replacement residues for the formation of protrusions are naturally occurring amino acid residues, including, for example, arginine (R), phenylalanine (F), tyrosine (Y), or tryptophan (W). In some examples, the original residues identified for replacement are amino acid residues with small side chains, such as, for example, alanine, asparagine, aspartic acid, glycine, serine, threonine, or valine.

[0323] In some embodiments, the second Fc polypeptide modified to include a cavity (hole) comprises a replacement of a native or original amino acid with an amino acid having at least one side chain that can be recessed from the interface of the second polypeptide and thus accommodate a corresponding protrusion from the interface of the first polypeptide. In most cases, the replacement amino acid has a smaller side chain volume than the original amino acid residue. Those skilled in the art will understand how to determine and / or evaluate the properties of amino acid residues to identify amino acid residues that are ideal replacement residues for forming a cavity. Generally, replacement residues for forming a cavity are naturally occurring amino acids, including, for example, alanine (A), serine (S), threonine (T), and valine (V). In some examples, the original amino acid identified for replacement is an amino acid with a large side chain, such as, for example, tyrosine, arginine, phenylalanine, or tryptophan.

[0324] The CH3 interface of human IgG1, for example, contains 16 residues on each domain that are located in four antiparallel β-strands that are buried 1090 Å from each surface (see, e.g., Deisenhofer et al. (1981) Biochemistry, 20:2361-2370; Miller et al., (1990) J Mol. Biol., 216, 965-973; Ridgway et al., (1996) Prot. Engin., 9: 617-621; U.S. Patent No. 5,731,168). Modification of CH3 domain to create protrusion or cavity is described in, for example, U.S. Patent No. 5,731,168; International Patent Application No. WO98 / 50431 and WO 2005 / 063816; and Ridgway et al., (1996) Prot. Engin., 9: 617-621.In some examples, modification of CH3 domain to create protrusion and cavity typically targets residues located in two central antiparallel β-strands.The purpose is to minimize the risk that the protrusion created can be accommodated by protruding into the surrounding solvent rather than being accommodated by the compensatory cavity in the partner CH3 domain.

[0325] For example, in some embodiments, a heterodimeric Fc comprises a polypeptide having an amino acid modification in the CH3 domain at Thr366, which, when substituted with a bulkier amino acid, e.g., Try (T366W), can preferentially pair with a second CH3 domain having less bulky amino acids at positions Thr366, Leu368, and Tyr407, e.g., Ser, Ala, and Val (T366S / L368A / Y407V). Heterodimerization by CH3 modifications can be further stabilized by the introduction of disulfide bonds, e.g., by changing Ser354 to Cys (S354C) and Tyr349 to Cys (Y349C) on the opposing CH3 domain (Reviewed in Carter, 2001 Journal of Immunological Methods, 248: 7-15).

[0326] In certain embodiments, the multispecific polypeptide construct comprises a first Fc and a second Fc capable of mediating Fc heterodimerization, comprising a first Fc polypeptide comprising the mutations T366W and S354C and a second Fc polypeptide comprising the mutations T366S, L368A, Y407V, and Y349C. In some embodiments, the first Fc polypeptide is selected from an Fc polypeptide comprising a sequence set forth in SEQ ID NO: 445 or 451, and the second Fc polypeptide is selected from an Fc polypeptide comprising a sequence set forth in SEQ ID NO: 446, 449, or 453. In some embodiments, the first Fc polypeptide is or comprises a sequence of amino acids set forth in any of SEQ ID NO: 293, 297, 305, or 307, and the second Fc polypeptide is or comprises a sequence of amino acids set forth in any of SEQ ID NO: 294, 298, 301, 303, 309, or 311.

[0327] In some embodiments, the Fc polypeptide exhibits characteristics that result in Fc-mediated effector functions. In a particular example, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:445, and the second Fc polypeptide is or comprises SEQ ID NO:446 or 449. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:293, and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:294 or 301. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:297, and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:298 or 303. The first and second Fc polypeptides may be formatted into either polypeptide chain of the construct.

[0328] In some embodiments, one or both of the first and second Fc polypeptides can further comprise one or more amino acid mutations to further reduce one or more Fc effector functions (e.g., reduced Fc receptor binding). Exemplary mutations for reducing Fc effector functions include any described. In some embodiments, the modification can be a deletion of one or more positions Glu233 (E233), Leu234 (L234), or Leu235 (L235), e.g., a deletion of amino acids Glu233 (E233), Leu234 (L234), and Leu235 (L235). In some embodiments, the first Fc polypeptide is selected from an Fc polypeptide comprising a sequence set forth in SEQ ID NO:447 or 452, and the second Fc polypeptide is selected from an Fc polypeptide comprising a sequence set forth in SEQ ID NO:448, 450, or 454. In some embodiments, the first Fc polypeptide is or comprises a sequence of amino acids set forth in any of SEQ ID NOs:295, 299, 306, or 308, and the second Fc polypeptide is or comprises a sequence of amino acids set forth in any of SEQ ID NOs:296, 300, 302, 304, 310, or 312.

[0329] In a particular example, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:447 and the second Fc polypeptide is or comprises SEQ ID NO:448 or 450. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:295 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:296 or 302. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:299 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:300 or 304. The first and second Fc polypeptides may be formatted into either polypeptide chain of the construct.

[0330] In some embodiments, the first Fc polypeptide or the second Fc polypeptide further comprises the mutation M252Y and / or M428V. In a particular example, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:451 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:453. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:305 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:309. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:307 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:311. In other examples, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:452 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:454. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:306 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:310. In some embodiments, the first Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:308 and the second Fc polypeptide is or comprises the sequence set forth in SEQ ID NO:312. The first and second Fc polypeptides may be formatted into either polypeptide chain of the construct.

[0331] Further examples of variants that can help promote heterodimerization include the following: S364K / E357Q and L368D / K370S; L368D / K370S and S364K; L368E / K370S and S364K; T411T / E360E / Q362E and D401K; L368D / K370S and S364K / E357L, K370S and S364K / E357Q, and T 366S / L368A / Y407V and T366W, or 366S / L368A / Y407V / Y349C and T366W / S354C), where each pair represents a mutation in the first and second Fc polypeptide. In certain embodiments, the provided construct comprises a first and second Fc polypeptide comprising the pair of mutations L368D / K370S and S364K and E357Q.

[0332] An additional mechanism that can be used to create heterodimers is sometimes referred to as "electrostatic steering" as described in Gunasekaran et al., J. Biol. Chem. 285(25):19637 (2010). This is sometimes referred to herein as "charge pairing". In this embodiment, electrostatics are used to skew the formation towards heterodimerization. As one skilled in the art will appreciate, these may also have effects on pI and therefore purification, and therefore in some cases may also be considered pI variants. However, because they were created to force heterodimerization and were not used as a purification tool, they are classified as "stereovariants". In one embodiment, the first Fc polypeptide may contain the mutations D221E / P228E / L368E and the second Fc polypeptide may contain the mutations D221R / P228R / K409R. In another embodiment, the first Fc polypeptide may comprise the mutations C220E / P228E / 368E and the second Fc polypeptide may comprise the mutations C220R / E224R / P228R / K409R.

[0333] In some embodiments, heterodimerization can be promoted by pI variants. In some aspects, pI variants can include those that increase the pI of the protein (basic changes). In other aspects, pI variants can include those that decrease the pI of the protein (acidic changes). In some cases, all combinations of these variants can be made, including combinations where one Fc polypeptide can be wild type or a variant that does not show a significantly different pI from wild type, and the other Fc polypeptide can be either more basic or more acidic. Alternatively, each Fc polypeptide can be altered, one more basic and one more acidic. In some embodiments, at least one Fc polypeptide is a negative pI variant Fc, including mutations Q295E / N384D / Q418E / N421D.

[0334] In some embodiments, a combination of stereochemical heterodimerization variants (eg, knobs and holes) and pI or charge pair variants can be used.

[0335] In certain embodiments, the provided construct comprises (a) a first Fc polypeptide comprising the asymmetric variant S364K / E357Q; and b) a second Fc polypeptide comprising the asymmetric variant L368D / K370S and the pI variant N208D / Q295E / N384D / Q418E / N421D. In some embodiments, one or both of the first and second polypeptides can further comprise a mutation that reduces Fc effector activity, for example, the exemplary mutations E233P / L234V / L235A / G236del / S267K. Examples of such first and second Fc polypeptides that can mediate Fc heterodimerization include the sequences set forth in SEQ ID NOs:457 and 458. The first and second Fc polypeptides can be formatted into either polypeptide chain of the construct.

[0336] The resulting constrained multispecific polypeptide construct can be purified by any suitable method, such as affinity chromatography on a protein A or protein G column. When two nucleic acid molecules encoding different polypeptides are transformed into a cell, homo- and heterodimer formation occurs. The conditions for expression can be adjusted so that heterodimer formation is more favorable than homodimer formation.

[0337] Techniques are known for recovering heterodimers from homodimers based on the different affinities of the heterodimers for affinity reagents. In some aspects, such techniques include designing a heterodimer such that one of the Fc polypeptide chains does not bind to the affinity reagent Protein A. In some cases, one of the polypeptide chains may contain one or more amino acid substitutions that suppress or reduce the affinity for Protein A reagent in one of the polypeptides of the Fc heterodimer, see, e.g., WO2017134440, WO2010151792, Jendeberg et al. (Jendeberg et al., (1997) J. Immunol. Methods, 201(1): 25-34. In some of these embodiments, the Fc region may be modified at the Protein A binding site on one member of the heterodimer to prevent Protein A binding, thereby allowing for more efficient purification of the heterodimeric fusion protein. An exemplary modification within this binding site is Ile253, e.g., Ile253Arg (I253R). In some embodiments, the modification may be H435R or H435R / Y436F. In some embodiments, the Fc polypeptide of the Fc heterodimer may include modifications such that it is capable of binding Protein A but not Protein G (pA+ / pG-). An exemplary pA+ / pG- amino acid modification includes an Fc that includes a serine at position 428, a serine at position 434, and optionally a histidine at position 436 relative to human IgG1, or includes these residues at the corresponding positions in human IgG 2, 3, or 4. In some aspects, one IgG Such amino acid modifications at positions 428, 434, and optionally 436 in the Fc polypeptide reduce or abolish Protein G binding and enhance purification of the protein.

[0338] In some embodiments, any of such modifications that confer different affinities to affinity reagents can be combined with any of one or more other amino acid modifications described above. For example, the I253R modification can be combined with either the T366S / L368A / Y407V modification or the T366W modification. The T366S / L368A / Y407V modified Fc can form homodimers, as in the case of the T336W modified Fc, due to the absence of steric closure of the dimerization interface. Thus, in some embodiments, the I253R modification is combined with the T366S / L368A / Y407V modified Fc, which makes it impossible to purify any homodimeric Fc that may have formed. A similar modification can be utilized by combining T366S / L368A / Y407V and H453R.

[0339] In some embodiments, the Fc region of the heterodimeric molecule may additionally comprise one or more other Fc mutations, such as any of those described above. In some embodiments, the heterodimeric molecule comprises an Fc region with a mutation that reduces effector function. In some embodiments, the Fc region is altered to provide reduced Fc-mediated effector function, for example, via reduced Fc receptor binding, for example, via binding to FcγR binding but generally not FcRn binding.

[0340] In some embodiments, the Fc region is mutated at one or more of the following positions to reduce Fc receptor binding: Glu233 (E233), Leu234 (L234), or Leu235 (L235). The one or more mutations may include E233P, L234V, and / or L235A.

[0341] In certain embodiments, mutations in the Fc region to reduce Fc effector function, e.g., via reduced Fc receptor binding to FcγR, include G236R / L328R, E233P / L234V / L235A / G236del / S239K, E233P / L234V / L235A / G236del / S267K, E233P / L234V / L235A / G236del / S239K / A327G, E233P / L234V / L235A / G236del / S239K / A327G, / G236del / S267K / A327G, E233P / L234V / L235A / G236del, D265A / P329A, D265A / P329G, D265A / N297A, L234V / L235A / D265A, L234V / L235A / N297A, L234V / L235A / P329A, or L234V / L235A / P329G. In some embodiments, one Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NO:445 (e.g., SEQ ID NO:293 or 297), 451 (e.g., SEQ ID NO:305 or 307), and the other Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NO:446 (e.g., SEQ ID NO:294 or 298), 449 (e.g., SEQ ID NO:301 or 303), or 453 (e.g., SEQ ID NO:309 or 311). In some embodiments, one Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NO:447 (e.g., SEQ ID NO:295 or 299), 452 (e.g., SEQ ID NO:306 or 308), and the other Fc polypeptide of the heterodimeric Fc comprises a sequence of amino acids set forth in any of SEQ ID NO:448 (e.g., SEQ ID NO:296 or 300), 450 (e.g., SEQ ID NO:302 or 304), 454 (e.g., SEQ ID NO:310 or 312).

[0342] In some embodiments, the Fc region of the provided multispecific polypeptide construct exhibits one or more effector functions. In some cases, the Fc region can provide Fc-mediated effector functions, such as ADCC (e.g., release of granzyme B by NK cells), ADCP, and / or CDC. In general, the Fc region is responsible for effector functions such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in addition to antigen binding, which is the main function of immunoglobulin. In addition, the FcRn sequence present in the Fc region plays a role in regulating IgG levels in serum by increasing in vivo half-life through conjugation to in vivo FcRn receptor. In some embodiments where the multispecific polypeptide construct comprises a cleavable linker, cleavage of the linker may generate two components, each of which has biological activity: a CD3 binding region capable of binding and engaging with CD3 on T cells, which in some aspects may also comprise a CRBR for inducing a costimulatory signal on T cells and / or an IRBR for inducing an inhibitory signal on T cells; and an Fc region linked to a B7H3 VHH domain that may exhibit target-specific effector function. In certain embodiments provided herein, the multispecific polypeptide construct comprises a non-cleavable linker, which in some aspects may not exhibit independent Fc-mediated effector function.

[0343] In some embodiments, the Fc region comprises an Fc polypeptide that is mutated or modified to alter one or more effector functions. Thus, in some cases, one or more of the effector functions, such as ADCC, ADCP, and / or CDC, can be altered, e.g., reduced or enhanced, in the Fc for use with the provided constrained multispecific polypeptide constructs. Exemplary mutations that reduce effector function include any of those described above.

[0344] In some embodiments, an IgG1 Fc polypeptide or variant thereof, such as any described below, can be made with the G1 m1 or G1 m3 allotype. In some embodiments, the Fc region can include amino acids of the human G1 m1 allotype, such as residues at positions 356 and 358 including Asp (D) and Leu (L), as set forth in SEQ ID NO:198. In some cases, the Fc polypeptide can include amino acid substitutions E356D and M358L to reconstitute residues of the allotype G1 m1. In other embodiments, the Fc region can include amino acids of the human G1 m3 allotype, such as residues Glu (E) and Met (M), as set forth in SEQ ID NO:457 and 458, according to EU numbering. In some cases, the Fc polypeptide can include amino acid substitutions D356E and L358M to reconstitute residues of the allotype G1 m3.

[0345] C. CD3 binding domain The constrained multispecific polypeptide construct comprises one or more copies of an anti-CD3 binding domain. The anti-CD3 binding domain of the present disclosure activates T cells through engagement of CD3 or a member of the CD3 complex on the T cell. In a preferred embodiment, the anti-CD3 binding domain of the present disclosure specifically binds to the ε chain of CD3, also known as CD3ε. The anti-CD3ε binding domain of the present disclosure activates T cells through engagement of CD3ε on the T cell. The anti-CD3 binding domain of the present disclosure agonizes, stimulates, activates, and / or otherwise enhances CD3-mediated T cell activation. The biological activity of CD3 includes, for example, T cell activation and other signaling through the interaction between CD3 and the antigen-binding subunit of the T cell receptor (TCR). For example, the anti-CD3 binding domain of the present disclosure activates T cells fully or partially through engagement of CD3ε on the T cell by partially or fully modulating, for example, agonizing, stimulating, activating, or otherwise enhancing, CD3-mediated T cell activation.

[0346] The CD3 binding domain can be any of those described above. In certain embodiments, the CD3 binding domain is an Fv antibody fragment that binds to CD3ε (herein referred to as an anti-CD3ε Fv fragment). In some embodiments, the anti-CD3ε Fv antibody fragment is a disulfide-stabilized anti-CD3 binding Fv fragment (dsFv). In some embodiments, the anti-CD3 binding domain is monovalent for binding to CD3.

[0347] In some embodiments, the CD3 binding region is an Fv antibody fragment, such as any described, comprising a variable heavy chain (Hv, also referred to as VH) and a variable light chain (Lv, also referred to as VL). In aspects of such embodiments, the immunoglobulin Fc region is a heterodimeric Fc region, such as any described, comprising two different Fc polypeptides that allow heterodimeric association between both polypeptides of the Fc heterodimer. In such embodiments, the variable heavy chain (VH) and variable light chain (VL) of the CD3 binding region are linked to opposing chains of the heterodimeric Fc.

[0348] In some embodiments, the CD3 binding region is an Fv or dsFv of SP34 (Pessano et al. The EMBO Journal. 4: 337-344, 1985) or a humanized variant of SP34 (WO2015001085).

[0349] In some embodiments, the anti-CD3ε binding domain is an Fv or dsFv fragment that comprises a combination of a heavy chain variable amino acid sequence and a light chain variable amino acid sequence. A VH CDR1 sequence comprising at least the amino acid sequence TYAMN (SEQ ID NO:219); At least the amino acid sequence VH CDR2 sequence containing TIFF2024167342000035.tif3128; At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000036.tif3128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000037.tif3128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 sequence including at least the amino acid sequence ALWYSNLWV (SEQ ID NO:224) The Fv or dsFv fragment comprises:

[0350] In some embodiments, the anti-CD3ε binding domain comprises: a VH CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence TYAMN (SEQ ID NO:219); Amino acid sequence a VH CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000038.tif4128; Amino acid sequence a VH CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000039.tif4128; Amino acid sequence a VL CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000040.tif4128; A VL CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GTNKRAP (SEQ ID NO:223); and A VL CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence ALWYSNLWV (SEQ ID NO:224). Includes.

[0351] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); A VH CDR2 sequence comprising at least the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); a VH CDR3 sequence comprising at least the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 221); a VL CDR1 sequence comprising at least the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 222); A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 sequence including at least the amino acid sequence ALWYSNLWV (SEQ ID NO:224) Includes.

[0352] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); A VH CDR2 sequence comprising at least the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000041.tif3128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000042.tif4128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 sequence including at least the amino acid sequence ALWYSNLWV (SEQ ID NO:224) Includes.

[0353] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); a VH CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); Amino acid sequence a VH CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000043.tif4128; Amino acid sequence a VL CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000044.tif4128; A VL CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GTNKRAP (SEQ ID NO:223); and A VL CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence ALWYSNLWV (SEQ ID NO:224). Includes.

[0354] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); A VH CDR2 sequence comprising at least the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000045.tif3128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000046.tif4128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:479); and A VL CDR3 sequence comprising at least the amino acid sequence ALWYSNHWV (SEQ ID NO:474) Includes.

[0355] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); A VH CDR2 sequence comprising at least the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000047.tif4128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000048.tif4128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and A VL CDR3 sequence comprising at least the amino acid sequence ALWYSNHWV (SEQ ID NO:474) Includes.

[0356] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); a VH CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); Amino acid sequence a VH CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000049.tif4128; Amino acid sequence a VL CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000050.tif3128; A VL CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GTNKRAP (SEQ ID NO:223); and A VL CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence ALWYSNHWV (SEQ ID NO:474). In some embodiments, the anti-CD3 epsilon binding domain comprises: A VH CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GFTFNTYAMN (SEQ ID NO:471); a VH CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence RIRSKYNNYATY (SEQ ID NO:472); Amino acid sequence a VH CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000051.tif3128; Amino acid sequence a VL CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000052.tif4128; A VL CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GTNKRAP (SEQ ID NO:479); and A VL CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence ALWYSNHWV (SEQ ID NO:474). Includes.

[0357] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence comprising at least the amino acid sequence GFTFSTYAMN (SEQ ID NO:476); A VH CDR2 sequence comprising at least the amino acid sequence RIRSKYNNYATY (SEQ ID NO:477); At least the amino acid sequence VH CDR3 sequence containing TIFF2024167342000053.tif3128; At least the amino acid sequence VL CDR1 sequence containing TIFF2024167342000054.tif3128; A VL CDR2 sequence comprising at least the amino acid sequence GTNKRAP (SEQ ID NO:223); and A VL CDR3 sequence comprising at least the amino acid sequence ALWYSNHWV (SEQ ID NO:474) Includes.

[0358] In some embodiments, the anti-CD3ε binding domain comprises: A VH CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GFTFSTYAMN (SEQ ID NO:476); a VH CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence RIRSKYNNYATY (SEQ ID NO:477); Amino acid sequence a VH CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000055.tif3128; Amino acid sequence a VL CDR1 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to TIFF2024167342000056.tif3128; a VL CDR2 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence GTNKRAP (SEQ ID NO:223); A VL CDR3 sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence ALWYSNHWV (SEQ ID NO:474). Includes.

[0359] In some embodiments, the anti-CD3 epsilon binding domain comprises a CDR3 comprising at least the amino acids VLWYSNRWV (SEQ ID NO:475). In some embodiments, the anti-CD3 epsilon binding domain comprises a CDR3 having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acids VLWYSNRWV (SEQ ID NO:475).

[0360] In some embodiments, the anti-CD3ε binding domain is a Fab fragment, F(ab') 2 The anti-CD3 binding domain comprises one or more copies of an antibody or antigen-binding fragment selected from the group consisting of a fragment, an Fv fragment, an scFv, a scAb, a dAb, a single-domain heavy chain antibody, and a single-domain light chain antibody. In some embodiments, the anti-CD3 binding domain comprises an Fv antibody fragment (herein referred to as an anti-CD3ε Fv fragment) that binds to CD3ε. In some embodiments, the anti-CD3ε Fv antibody fragment is a disulfide-stabilized anti-CD3 binding Fv fragment (dsFv). In some embodiments, the anti-CD3 binding domain is monovalent for binding to CD3.

[0361] In some embodiments, the CD3 binding region is not a single chain antibody, e.g., in some aspects, the CD3 binding region is not a single chain variable fragment (scFv).

[0362] In some embodiments, the CD3 binding region is an Fv antibody fragment comprising a variable heavy chain (Hv, also referred to as VH) and a variable light chain (Lv, also referred to as VL), such as any of those described. In aspects of such embodiments, the immunoglobulin Fc region is a heterodimeric Fc region comprising two different Fc polypeptides that allow heterodimeric association between both polypeptides of the Fc heterodimer, such as any of those described in section III.C.2.b. In such embodiments, the variable heavy chain (VH) and variable light chain (VL) of the CD3 binding region are linked to opposing chains of the heterodimeric Fc.

[0363] In some embodiments, the anti-CD3ε binding domain comprises a combination of a heavy chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NOs: 225-274, 417, and 459-462 and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NOs: 225-255, 460, and 462 and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NOs: 256-274, 417, 459, and 461.

[0364] In some embodiments, the anti-CD3ε binding domain comprises a combination of a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NOs: 217, 218, 225-274, 417, 459-462, and 480. In some embodiments, the anti-CD3ε binding domain comprises a combination of a heavy chain variable region amino acid sequence selected from the group of SEQ ID NOs: 217, 225-255, 460, 462, and 480 and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NOs: 218, 256-274, 417, 459, and 461.

[0365] In some embodiments, the anti-CD3ε binding domain is an Fv fragment comprising a combination of a heavy chain variable amino acid sequence and a light chain variable amino acid sequence. In some embodiments, the anti-CD3ε binding domain comprises a combination of a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 225-274, 417, and 459-462. In some embodiments, the anti-CD3ε binding domain is an Fv fragment comprising a combination of a heavy chain variable amino acid sequence and a light chain variable amino acid sequence comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 225-274, 417, and 459-462.

[0366] In some embodiments, the anti-CD3ε binding domain is an Fv fragment comprising a combination of a heavy chain variable amino acid sequence and a light chain variable amino acid sequence. In some embodiments, the anti-CD3ε binding domain comprises a combination of a heavy chain variable region amino acid sequence and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 217, 218, 225-274, 417, 459-462, and 480. In some embodiments, the anti-CD3ε binding domain is an Fv fragment comprising a combination of a heavy chain variable amino acid sequence and a light chain variable amino acid sequence comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 217, 218, 225-274, 417, 459-462, and 480.

[0367] In some embodiments, the anti-CD3 epsilon binding domain is an Fv, e.g., a dsFv fragment, comprising a heavy chain variable amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 225-255, 460, and 462, and a light chain variable amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 256-274, 417, 459, and 461. In some embodiments, the anti-CD3 epsilon binding domain comprises a combination of a heavy chain variable region amino acid sequence selected from the group of SEQ ID NOs: 225-255, 460, and 462 and a light chain variable region amino acid sequence comprising an amino acid sequence selected from the group of SEQ ID NOs: 256-274, 417, 459, and 461. In some embodiments, the anti-CD3 epsilon binding domain is an Fv, e.g., a dsFv fragment, comprising a heavy chain variable amino acid sequence selected from the group of SEQ ID NOs: 225-255, 460, and 462 and a light chain variable amino acid sequence selected from the group consisting of SEQ ID NOs: 256-274, 417, 459, and 461. In some embodiments, the anti-CD3 binding domain is an Fv, e.g., a dsFv, comprising therein a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 237 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 265. In some embodiments, the anti-CD3 binding domain is an Fv, e.g., a dsFv, comprising a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:237 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:417.

[0368] In some embodiments, the anti-CD3ε binding domain is an Fv fragment comprising a combination of a heavy chain variable amino acid sequence selected from the group of SEQ ID NOs: 217, 225-255, 460, 462, and 480 and a light chain variable amino acid sequence selected from the group consisting of SEQ ID NOs: 218, 256-274, 417, 459, and 461. In some embodiments, the anti-CD3 epsilon binding domain is an Fv fragment comprising a combination of a heavy chain variable amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 217, 225-255, 460, 462, and 480, and a light chain variable amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 218, 256-274, 417, 459, and 461.

[0369] In some embodiments, the anti-CD3ε Fv antibody fragment comprises a combination of a heavy chain variable amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 217, 225-236, 238-240, 460, and 241 and a light chain variable amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 218, 256, 258-264, 266, 268, 270, and 461. In some embodiments, the anti-CD3ε Fv antibody fragment comprises a combination of a heavy chain variable amino acid sequence selected from the group of SEQ ID NOs: 217, 225-236, 238-240, 460, and 241 and a light chain variable amino acid sequence selected from the group consisting of SEQ ID NOs: 218, 256, 258-264, 266, 268, 270, 459, and 461.

[0370] In some embodiments, the anti-CD3ε binding domain comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:217. In some embodiments, the anti-CD3ε binding domain comprises a variable light chain (VL) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:218. In some embodiments, the anti-CD3ε binding domain comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:217, and a variable light chain (VL) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:218. In some embodiments, the anti-CD3ε binding domain comprises a variable heavy chain (VH) comprising an amino acid sequence of SEQ ID NO:217. In some embodiments, the anti-CD3ε binding domain comprises a variable light chain (VL) comprising an amino acid sequence of SEQ ID NO:218. In some embodiments, the anti-CD3 epsilon binding domain comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:217, and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:218.

[0371] In some embodiments, the anti-CD3 epsilon binding domain comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO: 460. In some embodiments, the anti-CD3 epsilon binding domain comprises a variable light chain (VL) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO: 461. In some embodiments, the anti-CD3ε binding domain comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:460, and a variable light chain (VL) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:461. In some embodiments, the anti-CD3ε binding domain comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:460. In some embodiments, the anti-CD3ε binding domain comprises a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:461. In some embodiments, the anti-CD3 epsilon binding domain comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:460, and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:461.

[0372] In certain embodiments, the Fv is H -V LThe heterodimer is a disulfide-stabilized Fv fragment (dsFv) in which the heterodimer is stabilized by an interchain disulfide bond. In some embodiments, the interchain disulfide bond is engineered by mutation of positions in the framework positions of the VH and / or VL chain. In some embodiments, the disulfide-stabilized anti-CD3 Fv comprises an anti-CD3 VH with a mutation to Cys at position 44 and an anti-CD3 VL with a mutation to Cys at position 100 according to the Kabat numbering. For example, in some embodiments, the VH chain comprises a mutation G44C and the VL chain comprises a mutation G100C, each according to the Kabat numbering. In some embodiments, the disulfide-stabilized anti-CD3 Fv comprises an anti-CD3 VH with a mutation to Cys at position 105 and an anti-CD3 VL with a mutation to Cys at position 43 according to the Kabat numbering.

[0373] In some embodiments, the anti-CD3ε Fv antibody fragment comprises a combination of a variable heavy chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 237, and 242-255, and 462, and a variable light chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 257, 265, 267, 269, 271-274, 417, and 459. In some of any such embodiments, the anti-CD3 Fv is a dsFv having a VH chain containing the mutation G44C and a VL chain containing the mutation G100C, each according to the Kabat numbering. In some embodiments, the anti-CD3ε Fv antibody fragment comprises a combination of a variable heavy chain amino acid sequence selected from the group of SEQ ID NOs: 237, and 242-255, and 462, and a variable light chain amino acid sequence selected from the group consisting of SEQ ID NOs: 257, 265, 267, 269, 271-274, 417, and 459.

[0374] In some embodiments, the anti-CD3ε Fv antibody fragment comprises a combination of a variable heavy chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 237 and 242-255, 462, and 480, and a variable light chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 257, 265, 267, 269, 271-274, 417, and 459. In some of any such embodiments, the anti-CD3 Fv is a dsFv having a VH chain containing the mutation G44C and a VL chain containing the mutation G100C, each according to the Kabat numbering. In some embodiments, the anti-CD3ε Fv antibody fragment comprises a combination of a variable heavy chain amino acid sequence selected from the group of SEQ ID NOs: 237 and 242-255, 462, and 480 and a variable light chain amino acid sequence selected from the group consisting of SEQ ID NOs: 257, 265, 267, 269, 271-274, 417, and 459.

[0375] In some embodiments, the anti-CD3 epsilon binding domain comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 9...

Claims

1. A B7H3-binding polypeptide construct comprising at least one heavy chain-only variable domain (B7H3 VHH domain) that specifically binds to B7H3 and one or more additional binding domains that bind to a target other than B7H3.

2. said at least one B7H3 VHH domain comprising: Complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, and 145; A complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, and 167; and Complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, and 483-488.

2. The B7H3 binding polypeptide construct of claim 1, comprising:

3. Complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, and 145; A complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, and 167; and Complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, and 483-488. At least one heavy chain-only variable domain (B7H3 VHH domain) comprising 23. A B7H3 binding polypeptide construct comprising:

4. The B7H3 binding polypeptide construct of any one of claims 1 to 3, wherein said B7H3 is human B7H3.

5. The B7H3 binding polypeptide construct of any one of claims 1 to 4, wherein said at least one B7H3 VHH domain is humanized.

6. The B7H3-binding polypeptide construct of any one of claims 1, 2, 4, and 5, wherein the one or more additional binding domains bind to an activating receptor on an immune cell.

7. The B7H3 binding polypeptide construct of claim 6, wherein the immune cell is a T cell.

8. 8. The B7H3 binding polypeptide construct of claim 6 or claim 7, wherein the activating receptor is CD3 (CD3ε).

9. 9. The B7H3 binding polypeptide construct of claim 8, which is bispecific for B7H3 and CD3.

10. The B7H3 binding polypeptide construct of claim 9, wherein the immune cell is a natural killer (NK) cell.

11. The B7H3 binding polypeptide construct of claim 6 or claim 10, wherein the activating receptor is CD16 (CD16a).

12. 12. The B7H3-binding polypeptide construct of claim 11, which is bispecific for B7H3 and CD16a.

13. The B7H3-binding polypeptide construct of any one of claims 1, 2, 4, and 5, wherein said one or more additional binding domains bind to a cytokine receptor.

14. The B7H3-binding polypeptide construct of any one of claims 1, 2, and 4-13, wherein said one or more additional binding domains comprise an antibody or an antigen-binding fragment thereof.

15. The B7H3-binding polypeptide construct of any one of claims 1, 2, and 4-14, wherein said one or more additional binding domains are monovalent.

16. The B7H3-binding polypeptide construct of claim 14 or claim 15, wherein the antibody or antigen-binding fragment thereof is an Fv, a disulfide-stabilized Fv (dsFv), a scFv, a Fab, a single domain antibody (sdAb), a VNAR, or a VHH.

17. 14. The B7H3 binding polypeptide construct of claim 13, wherein said one or more additional binding domains is a cytokine or a truncated fragment or variant thereof capable of binding to a cytokine receptor.

18. 18. The B7H3 binding polypeptide construct of claim 17, wherein said cytokine is an interferon or a truncated fragment or variant of an interferon.

19. 20. The B7H3 binding polypeptide construct of claim 18, wherein said interferon is a type I interferon, a type II interferon, a truncated fragment or variant of a type I interferon, or a variant of a truncated fragment of a type II interferon.

20. The interferon A type I interferon that is IFN-α or IFN-β, or a truncated fragment or variant thereof; or A type II interferon that is IFN-γ or a truncated fragment or variant thereof 20. The B7H3 binding polypeptide construct of claim 19, selected from:

21. 21. The B7H3 binding polypeptide construct of any one of claims 1 to 20, comprising an immunoglobulin Fc region.

22. an immunoglobulin Fc region linking said at least one B7H3 VHH domain and said one or more additional binding domains; 22. The B7H3 binding polypeptide construct of any one of claims 1, 2, and 4-21, comprising:

23. 23. The B7H3 binding polypeptide construct of any one of claims 1 to 22, which is a dimer.

24. The B7H3 binding polypeptide construct of any one of claims 21 to 23, wherein said Fc region is a homodimeric Fc region.

25. 25. The B7H3 binding polypeptide construct of any one of claims 21 to 24, wherein said Fc region comprises a sequence of amino acids set forth in any of SEQ ID NOs: 198, 200, 201, 202, or 203, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 198, 200, 201, 202, or 203.

26. The B7H3 binding polypeptide construct of any one of claims 21 to 24, wherein said Fc region is human IgG1.

27. 27. The B7H3-binding polypeptide construct of claim 26, wherein the Fc region comprises a sequence of amino acids set forth in SEQ ID NO:198, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:

198.

28. The B7H3 binding polypeptide construct of any one of claims 21 to 23, wherein said Fc region is a heterodimeric Fc region.

29. 29. The B7H3 binding polypeptide construct of any one of claims 21 to 28, wherein said Fc region exhibits effector function.

30. The Fc region is Polypeptides comprising one or more amino acid modifications that reduce effector function and / or reduce binding to an effector molecule selected from an Fcγ receptor or C1q 30. The B7H3 binding polypeptide construct of any one of claims 21 to 29, comprising:

31. 31. The B7H3 binding polypeptide construct of claim 30, wherein said one or more amino acid modifications are a deletion of one or more of Glu233, Leu234, or Leu235.

32. 32. The B7H3-binding polypeptide construct of claim 30 or claim 31, wherein the Fc region comprises a sequence of amino acids set forth in SEQ ID NO:199 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:

199.

33. 33. The B7H3 binding polypeptide construct of any one of claims 1-32, wherein said at least one B7H3 VHH domain comprises a VHH domain sequence as set forth in any of SEQ ID NOs: 1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, and binds to B7H3.

34. 34. The B7H3 binding polypeptide construct of any one of claims 1 to 33, wherein said at least one B7H3 VHH domain comprises (i) the sequence shown in SEQ ID NO:1, (ii) a humanized variant of SEQ ID NO:1, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and binds to B7H3.

35. said at least one B7H3 VHH domain comprising: CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, and 121; CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, and 151; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 168 and 169 35. The B7H3 binding polypeptide construct of any one of claims 1 to 34, comprising:

36. the at least one B7H3 VHH domain is selected from the group consisting of SEQ ID NOs: 115, 146, and 168, respectively; SEQ ID NOs: 115, 147, and 168, respectively; SEQ ID NOs: 115, 148, and 168, respectively; SEQ ID NOs: 115, 149, and 168, respectively; SEQ ID NOs: 115, 150, and 168, respectively; SEQ ID NOs: 116, 146, and 168, respectively; SEQ ID NOs: 117, 146, and 168, respectively; SEQ ID NOs: 118, 146, and 168, respectively; SEQ ID NOs: 115, 146, and 169, respectively; SEQ ID NOs: 119, 146, and 168, respectively; SEQ ID NOs: 120, 146, and 168, respectively; SEQ ID NOs: 115, 151, and 168, respectively; 36. The B7H3 binding polypeptide construct of any one of claims 1 to 35, comprising CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 116, 147 and 168, respectively; SEQ ID NOs: 118, 147 and 168, respectively; SEQ ID NOs: 119, 147 and 168, respectively; SEQ ID NOs: 116, 151 and 168, respectively; SEQ ID NOs: 115, 146 and 168, respectively; SEQ ID NOs: 121, 147 and 168, respectively; SEQ ID NOs: 115, 146 and 168, respectively; SEQ ID NOs: 119, 149 and 168, respectively; or SEQ ID NOs: 122, 151 and 168, respectively.

37. 37. The B7H3 binding polypeptide construct of any one of claims 1-36, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, and binds to B7H3.

38. The B7H3-binding polypeptide construct of claims 1-37, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497.

39. 34. The B7H3-binding polypeptide construct of any one of claims 1 to 33, wherein said at least one B7H3 VHH domain comprises (i) the sequence depicted in SEQ ID NO:35, (ii) a humanized variant of SEQ ID NO:35, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:35, and binds to B7H3.

40. said at least one B7H3 VHH domain comprising: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 123; CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 152 and 153; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 170 and 171 40. The B7H3-binding polypeptide of any one of claims 1 to 33 and 39, comprising:

41. The B7H3 binding polypeptide construct of any one of claims 1 to 33, 39 and 40, wherein said at least one B7H3 VHH domain comprises CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 123, 152 and 170, respectively; SEQ ID NOs: 123, 152 and 171, respectively; SEQ ID NOs: 123, 153 and 170, respectively; or SEQ ID NOs: 123, 153 and 171, respectively.

42. 42. The B7H3 binding polypeptide construct of any one of claims 1-33 and 39-41, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 40, 41, or 498-503, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 40, 41, or 498-503, and binds to B7H3.

43. The B7H3-binding polypeptide construct of claims 1 to 33 and 39 to 42, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 40, 41, or 498 to 503.

44. 34. The B7H3-binding polypeptide construct of any one of claims 1 to 33, wherein said at least one B7H3 VHH domain comprises (i) the sequence depicted in SEQ ID NO: 44, (ii) a humanized variant of SEQ ID NO: 44, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 44, and binds to B7H3.

45. said at least one B7H3 VHH domain comprising: CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 154; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, and 183 45. The B7H3 binding polypeptide construct of any one of claims 1 to 33 and 44, comprising:

46. the at least one B7H3 VHH domain is selected from the group consisting of SEQ ID NOs: 124, 154, and 172, respectively; SEQ ID NOs: 124, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 174, respectively; SEQ ID NOs: 124, 154, and 175, respectively; SEQ ID NOs: 125, 154, and 173, respectively; SEQ ID NOs: 126, 154, and 173, respectively; SEQ ID NOs: 127, 154, and 173, respectively; SEQ ID NOs: 128, 154, and 173, respectively; SEQ ID NOs: 129, 154, and 173, respectively; SEQ ID NOs: 130, 154, and 173, respectively; SEQ ID NOs: 131, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 176, respectively; SEQ ID NOs: 124, 154, and 177, respectively; SEQ ID NOs: 124, 154, and 178, respectively; SEQ ID NOs: 124, 154, and 179, respectively; SEQ ID NOs: 124, 154, and 180, respectively; SEQ ID NOs: 124, 154, and 181, respectively; SEQ ID NOs: 124, 154, and 182, respectively; SEQ ID NOs: 124, 154, and 183, respectively; SEQ ID NOs: 126, 154, and 176, respectively; SEQ ID NOs: 124, 154, and 179, respectively; SEQ ID NOs: 124, 154, and 182, respectively; SEQ ID NOs: 132, 154, and 176, respectively; or SEQ ID A B7H3 binding polypeptide construct according to any one of claims 1 to 33, 44 and 45, comprising CDR1, CDR2 and CDR3 as set forth in NOs: 133, 154 and 173.

47. 47. The B7H3 binding polypeptide construct of any one of claims 1-33 and 44-46, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 56-91, 466, and 504-514, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 56-91, 466, and 504-514, and binds to B7H3.

48. The B7H3-binding polypeptide construct of claims 1-33 and 44-47, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 56-91, 466, and 504-514.

49. 34. The B7H3 binding polypeptide construct of any one of claims 1 to 33, wherein said at least one B7H3 VHH domain comprises (i) the sequence depicted in SEQ ID NO: 105, (ii) a humanized variant of SEQ ID NO: 105, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 105, and binds to B7H3.

50. said at least one B7H3 VHH domain comprising: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 145; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 167; and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 488 50. The B7H3 binding polypeptide construct of any one of claims 1 to 33 and 49, comprising:

51. 51. The B7H3 binding polypeptide construct of any one of claims 1-33, 49 and 50, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 106-109, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 106-109, and binds to B7H3.

52. The B7H3-binding polypeptide construct of claims 1-33 and 49-51, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 106-109.

53. 34. The B7H3 binding polypeptide construct of any one of claims 1 to 33, wherein said at least one B7H3 VHH domain comprises (i) the sequence depicted in SEQ ID NO: 110, (ii) a humanized variant of SEQ ID NO: 110, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 110, and binds to B7H3.

54. said at least one B7H3 VHH domain comprising: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 139; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 161; and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 189 54. The B7H3-binding polypeptide of any one of claims 1 to 33 and 53, comprising:

55. 55. The B7H3 binding polypeptide construct of any one of claims 1-33, 53 and 54, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 515-518, or a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 515-518, and binds to B7H3.

56. The B7H3-binding polypeptide construct of claims 1-33 and 53-55, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 515-518.

57. The at least one B7H3 VHH domain is selected from the group consisting of (i) a sequence as set forth in SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104, (ii) a humanized variant of SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104, or (iii) a sequence as set forth in SEQ ID 34. The B7H3 binding polypeptide construct of any one of claims 1 to 33, comprising a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to NO:92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104, and binds to B7H3.

58. the at least one B7H3 VHH domain is selected from the group consisting of SEQ ID NOs: 134, 155, and 184, respectively; SEQ ID NOs: 135, 156, and 168, respectively; SEQ ID NOs: 136, 157, and 185, respectively; SEQ ID NOs: 137, 158, and 186, respectively; SEQ ID NOs: 138, 159, and 187, respectively; SEQ ID NOs: 138, 160, and 188, respectively; SEQ ID NOs: 139, 161, and 189, respectively; SEQ ID NOs: 140, 162, and 483, respectively; SEQ ID NOs: 141, 163, and 484, respectively; SEQ ID NOs: 139, 161, and 189, respectively; SEQ ID NOs: 142, 164, and 485, respectively; SEQ ID NOs: 143, 165, and 486, respectively; 20. The B7H3 binding polypeptide construct of any one of claims 1 to 33 and 57, comprising CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 144, 166 and 487.

59. The B7H3 binding polypeptide construct of any one of claims 1 to 33, 57 and 58, wherein said at least one B7H3 VHH domain is set forth in SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 or 104.

60. (a) a first component comprising a heterodimeric Fc region comprising a first Fc polypeptide and a second Fc polypeptide, and (b) a second component comprising an anti-CD3 antibody or antigen-binding fragment comprising a variable heavy chain region (VH) and a variable light chain region (VL). A multispecific polypeptide construct comprising: the VH and VL constituting the anti-CD3 antibody or antigen-binding fragment are linked to opposing polypeptides of a heterodimeric Fc; the first and second components are coupled by a linker, and the heterodimeric Fc region is positioned at the N-terminus of the anti-CD3 antibody; and one or both of the first and second components comprises at least one antigen binding domain (B7H3 VHH domain) that comprises a single domain antibody that specifically binds to B7H3; The multispecific polypeptide construct.

61. at least (i) a first polypeptide comprising a first Fc polypeptide of a heterodimeric Fc region, a linker, and a VH or VL domain of an anti-CD3 antibody or antigen-binding fragment; and (ii) a second polypeptide comprising a second Fc polypeptide of a heterodimeric Fc region, a linker, optionally the same linker as present in the first polypeptide, and the other of the VH or VL domain of the anti-CD3 antibody or antigen-binding fragment. Including, one or both of the first and second polypeptides comprises at least one B7H3 VHH domain; 61. The multispecific polypeptide construct of claim 60.

62. 62. The multispecific polypeptide construct of claim 60 or claim 61, wherein one or both of the first and second Fc polypeptides of the heterodimeric Fc region comprise at least one modification that induces heterodimerization compared to a polypeptide of a homodimeric Fc region, and optionally compared to an Fc polypeptide as set forth in SEQ ID NO: 198 or an immunologically active fragment thereof.

63. 63. The multispecific polypeptide construct of claim 62, wherein each of the first and second Fc polypeptides of the heterodimeric Fc region independently comprises at least one amino acid modification.

64. 64. The multispecific polypeptide construct of claim 63, wherein each of the first and second Fc polypeptides of the heterodimeric Fc region comprises a knob-into-hole modification or a charge mutation that increases electrostatic complementarity of the polypeptides.

65. 65. The multispecific polypeptide construct of claim 64, wherein the amino acid modification is a knob-into-hole modification.

66. 66. The multispecific polypeptide construct of any one of claims 60 to 65, wherein said first Fc polypeptide of said heterodimeric Fc region comprises an alteration selected from among Thr366Ser, Leu368Ala, Tyr407Val, and a combination thereof, and said second Fc polypeptide of said heterodimeric Fc region comprises the alteration Thr366Trp.

67. 67. The multispecific polypeptide of claim 66, wherein said first and said second Fc polypeptides further comprise a modification of a non-cysteine ​​residue to a cysteine ​​residue, wherein the modification of said first polypeptide is at one of positions Ser354 and Tyr349 and the modification of said second Fc polypeptide is at the other of positions Ser354 and Tyr349.

68. 65. The multispecific polypeptide construct of any one of claims 62 to 64, wherein said amino acid modification is a charge mutation that increases electrostatic complementarity of said polypeptide.

69. 69. The multispecific polypeptide construct of any one of claims 60 to 64 and 68, wherein said first and / or said second Fc polypeptide, or each of said first and said second Fc polypeptides, comprises a modification at a complementary position, which modification is a substitution with an amino acid having an opposite charge to the complementary amino acid of the other polypeptide.

70. 70. The multispecific polypeptide construct of any one of claims 60 to 69, wherein one of the first or second Fc polypeptides of said heterodimeric Fc region further comprises an alteration at residue Ile253.

71. 71. The multispecific polypeptide construct of claim 70, wherein said modification is Ile253Arg.

72. 72. The multispecific polypeptide construct of any one of claims 60 to 71, wherein one of the first or second Fc polypeptides of said heterodimeric Fc region further comprises a modification at residue His435.

73. The multispecific polypeptide construct of claim 72, wherein the modification is His435Arg.

74. 74. The multispecific polypeptide construct of any one of claims 60 to 73, wherein the Fc region comprises a polypeptide lacking Lys447.

75. 75. The multispecific polypeptide construct of any one of claims 60 to 74, wherein said Fc region comprises a polypeptide comprising at least one modification that enhances FcRn binding.

76. 76. The multispecific polypeptide construct of claim 75, wherein the modification is at one or more positions selected from the group consisting of Met252, Ser254, Thr256, Met428, Asn434, and combinations thereof.

77. 77. The multispecific polypeptide construct of claim 76, wherein the modification is selected from the group consisting of Met252Y, Ser254T, Thr256E, Met428L, Met428V, Asn434S, and combinations thereof.

78. 77. The multispecific polypeptide construct of claim 75 or claim 76, wherein the modifications are at positions Met252 and Met428.

79. The multispecific polypeptide construct of claim 78, wherein said modifications are Met252Y and Met428L.

80. The multispecific polypeptide construct of claim 78, wherein said modifications are Met252Y and Met428V.

81. 81. The multispecific polypeptide construct of any one of claims 60 to 80, wherein said first Fc polypeptide of said heterodimeric Fc region comprises a sequence of amino acids as set forth in any of SEQ ID NOs: 293, 297, 305, or 307, and said second Fc polypeptide of said heterodimeric Fc region comprises a sequence of amino acids as set forth in any of SEQ ID NOs: 294, 298, 301, 303, 309, or 311.

82. The Fc region is Polypeptides comprising at least one amino acid modification that reduces effector function and / or reduces binding to an effector molecule selected from an Fcγ receptor or C1q 82. The multispecific polypeptide construct of any one of claims 21 to 81, comprising:

83. 83. The multispecific polypeptide construct of claim 82, wherein said at least one amino acid modification is a deletion of one or more of Glu233, Leu234, or Leu235.

84. 84. The multispecific polypeptide construct of any one of claims 60 to 83, wherein said first Fc polypeptide of said heterodimeric Fc region comprises a sequence of amino acids as set forth in any of SEQ ID NOs: 295, 299, 306, or 308, and said second Fc polypeptide of said heterodimeric Fc region comprises a sequence of amino acids as set forth in any of SEQ ID NOs: 296, 300, 302, 304, 310, or 312.

85. 85. The multispecific polypeptide construct of any one of claims 60 to 84, wherein said anti-CD3 antibody or antigen-binding fragment is monovalent.

86. 86. The multispecific polypeptide construct of any of claims 60 to 85, wherein said anti-CD3 antibody or antigen-binding fragment is not a single chain antibody and optionally is not a single chain variable fragment (scFv).

87. 87. The multispecific polypeptide construct of any one of claims 60 to 86, wherein said anti-CD3 antibody or antigen-binding fragment is an Fv antibody fragment.

88. 88. The multispecific polypeptide construct of claim 87, wherein said Fv antibody fragment comprises a disulfide-stabilized anti-CD3 binding Fv fragment (dsFv).

89. the anti-CD3 antibody or antigen-binding fragment thereof VH CDR1 comprising the amino acid sequence TYAMN (SEQ ID NO:219); Amino acid sequence VH CDR2 comprising: Amino acid sequence a VH CDR3 comprising Amino acid sequence VL CDR1 comprising: VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO:223); and VL CDR3 containing the amino acid sequence ALWYSNLWV (SEQ ID NO: 224) 89. The multispecific polypeptide construct of claims 60 to 88, comprising:

90. the anti-CD3 antibody or antigen-binding fragment thereof a VH having an amino acid sequence of any of SEQ ID NOs: 225-255, 480, 460, or 462, or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 225-255, 460, or 462, and that binds to CD3; and A VL having an amino acid sequence of any one of SEQ ID NOs: 256-274, 417, 459, or 461, or a sequence that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 256-274, 417, 459, or 461, and that binds to CD3.

90. The multispecific polypeptide construct of any one of claims 60 to 89, comprising:

91. 91. The multispecific polypeptide construct of any one of claims 60 to 90, wherein said anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 237 and the amino acid sequence of SEQ ID NO:

265.

92. 91. The multispecific polypeptide construct of any one of claims 60 to 90, wherein said anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 237 and the amino acid sequence of SEQ ID NO:

417.

93. 91. The multispecific polypeptide construct of any one of claims 60 to 90, wherein said anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 460 and the amino acid sequence of SEQ ID NO:

461.

94. 91. The multispecific polypeptide construct of any one of claims 60 to 90, wherein said anti-CD3 antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 480 and the amino acid sequence of SEQ ID NO:

459.

95. 95. The multispecific polypeptide construct of any one of claims 60 to 94, wherein said at least one B7H3 single domain antibody is positioned amino-terminal to the Fc region of said multispecific polypeptide construct and / or carboxy-terminal to the CD3 binding region of said multispecific polypeptide construct.

96. 96. The multispecific polypeptide construct of any one of claims 60 to 95, comprising a first B7H3 VHH domain that specifically binds to B7H3 and a second B7H3 VHH domain that specifically binds to B7H3.

97. 97. The multispecific polypeptide construct of claim 96, wherein the first or the second B7H3 VHH domain is positioned amino-terminal to the Fc region of the multispecific construct and the other of the first or the second B7H3 VHH domain is positioned carboxy-terminal to the CD3 binding region of the multispecific construct.

98. the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, the first Fc polypeptide of the heterodimeric Fc region, the linker, a VH or VL domain of the anti-CD3 antibody or antigen-binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises, in order from N-terminus to C-terminus, the second Fc polypeptide of the heterodimeric Fc region, the linker, optionally the same linker as present in the first component, and the other of the VH or VL domains of the anti-CD3 antibody or antigen-binding fragment.

98. A multispecific polypeptide construct according to claim 96 or claim 97.

99. 99. The multispecific polypeptide construct of any one of claims 96 to 98, wherein said first and said second B7H3 VHH domains are the same.

100. 99. The multispecific polypeptide construct of any one of claims 96 to 98, wherein said first and said second B7H3 VHH domains are different.

101. The multispecific polypeptide construct of claim 100, wherein said first and said second B7H3 VHH domains bind to distinct or non-overlapping epitopes of B7H3 and / or do not compete for binding to B7H3.

102. 102. The multispecific polypeptide construct of any of claims 60-101, wherein said at least one B7H3 VHH domain or each of said first and second B7H3 VHH domains independently comprises a VHH domain sequence as set forth in any of SEQ ID NOs: 1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, and binds to B7H3.

103. 103. The multispecific polypeptide construct of any of claims 60-102, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, comprises (i) the sequence as set forth in SEQ ID NO:1, (ii) a humanized variant of SEQ ID NO:1, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and binds to B7H3.

104. each of said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, and 121; CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, and 151; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 168 and 169 104. The multispecific polypeptide construct of any one of claims 60 to 103, comprising:

105. wherein said at least one B7H3 VHH domain, or each of said first and said second B7H3 VHH domains, independently, is selected from the group consisting of SEQ ID NOs: 115, 146, and 168, respectively; SEQ ID NOs: 115, 147, and 168, respectively; SEQ ID NOs: 115, 148, and 168, respectively; SEQ ID NOs: 115, 149, and 168, respectively; SEQ ID NOs: 115, 150, and 168, respectively; SEQ ID NOs: 116, 146, and 168, respectively; SEQ ID NOs: 117, 146, and 168, respectively; SEQ ID NOs: 118, 146, and 168, respectively; SEQ ID NOs: 115, 146, and 169, respectively; SEQ ID NOs: 119, 146, and 168, respectively; 106. The multispecific polypeptide construct of any one of claims 60 to 104, comprising the CDR1, CDR2 and CDR3 as depicted in SEQ ID NOs: 120, 146 and 168, respectively; SEQ ID NOs: 115, 151 and 168, respectively; SEQ ID NOs: 116, 147 and 168, respectively; SEQ ID NOs: 118, 147 and 168, respectively; SEQ ID NOs: 119, 147 and 168, respectively; SEQ ID NOs: 116, 151 and 168, respectively; SEQ ID NOs: 115, 146 and 168, respectively; SEQ ID NOs: 121, 147 and 168, respectively; SEQ ID NOs: 115, 146 and 168, respectively; SEQ ID NOs: 119, 149 and 168, respectively; or SEQ ID NOs: 122, 151 and 168, respectively.

106. 106. The multispecific polypeptide construct of any of claims 60-105, wherein said at least one B7H3 VHH domain or each of said first and second B7H3 VHH domains independently comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, and binds to B7H3.

107. 107. The multispecific polypeptide construct of any one of claims 60-106, wherein said at least one B7H3 VHH domain, or each of said first and said second B7H3 VHH domains, independently, comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497.

108. 103. The multispecific polypeptide construct of any of claims 60-102, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, comprises (i) the sequence depicted in SEQ ID NO:35, (ii) a humanized variant of SEQ ID NO:35, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:35, and binds to B7H3.

109. each of said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently CDR1 comprising the amino acid sequence shown in SEQ ID NO: 123; CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 152 and 153; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 170 and 171 109. The multispecific polypeptide construct of any one of claims 60 to 102 and 108, comprising:

110. 110. The multispecific polypeptide construct of any one of claims 60 to 102, 108 and 109, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, comprises CDR1, CDR2 and CDR3 as depicted in SEQ ID NOs: 123, 152 and 170, respectively; SEQ ID NOs: 123, 152 and 171, respectively; SEQ ID NOs: 123, 153 and 170, respectively; or SEQ ID NOs: 123, 153 and 171, respectively.

111. 110. The multispecific polypeptide construct of any one of claims 60-102 and 108-110, wherein said at least one B7H3 VHH domain or each of said first and second B7H3 VHH domains independently comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 40, 41, or 498-503, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 40, 41, or 498-503, and binds to B7H3.

112. The multispecific polypeptide construct of claims 60-102 and 108-111, wherein said at least one B7H3 VHH domain, or each of said first and said second B7H3 VHH domains, independently, comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 40, 41, or 498-503.

113. 103. The multispecific polypeptide construct of any of claims 60-102, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, comprises (i) the sequence depicted in SEQ ID NO:44, (ii) a humanized variant of SEQ ID NO:44, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:44, and binds to B7H3.

114. each of said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 154; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, and 183 114. The multispecific polypeptide construct of any one of claims 60 to 102 and 113, comprising:

115. wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, is selected from SEQ ID NOs: 124, 154, and 172, respectively; SEQ ID NOs: 124, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 174, respectively; SEQ ID NOs: 124, 154, and 175, respectively; SEQ ID NOs: 125, 154, and 173, respectively; SEQ ID NOs: 126, 154, and 173, respectively; SEQ ID NOs: 127, 154, and 173, respectively; SEQ ID NOs: 128, 154, and 173, respectively; SEQ ID NOs: 129, 154, and 173, respectively; SEQ ID NOs: 130, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 176, respectively; SEQ ID NOs: 124, 154, and 177, respectively; SEQ ID NOs: 124, 154, and 178, respectively; SEQ ID NOs: 124, 154, and 179, respectively; SEQ ID NOs: 124, 154, and 180, respectively; SEQ ID NOs: 124, 154, and 181, respectively; SEQ ID NOs: 124, 154, and 182, respectively; SEQ ID NOs: 124, 154, and 183, respectively; SEQ ID NOs: 126, 154, and 176, respectively; SEQ ID NOs: 124, 154, and 179, respectively; SEQ ID NOs: 124, 154, and 182, respectively; The multispecific polypeptide construct of any one of claims 60 to 102, 113 and 114, comprising CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 132, 154 and 176; or SEQ ID NOs: 133, 154 and 173, respectively.

116. 116. The multispecific polypeptide construct of any one of claims 60-102 and 113-115, wherein said at least one B7H3 VHH domain or each of said first and second B7H3 VHH domains independently comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 56-91, 466, and 504-514, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 56-91, 466, and 504-514, and binds to B7H3.

117. 117. The multispecific polypeptide construct of claims 60-102 and 113-116, wherein said at least one B7H3 VHH domain, or each of said first and said second B7H3 VHH domains, independently, comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 56-91, 466, and 504-514.

118. 103. The multispecific polypeptide construct of any one of claims 60-102, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, comprises (i) the sequence depicted in SEQ ID NO: 105, (ii) a humanized variant of SEQ ID NO: 105, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 105, and binds to B7H3.

119. each of said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently CDR1 comprising the amino acid sequence shown in SEQ ID NO: 145; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 167; and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 488 119. The multispecific polypeptide construct of any one of claims 60 to 102 and 118, comprising:

120. 120. The multispecific polypeptide construct of any one of claims 60-102, 118 and 119, wherein said at least one B7H3 VHH domain or each of said first and second B7H3 VHH domains independently comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 106-109, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 106-109, and binds to B7H3.

121. 121. The multispecific polypeptide construct of any one of claims 60-102 and 118-120, wherein said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently, comprise a sequence of amino acids as set forth in any one of SEQ ID NOs: 106-109.

122. 103. The multispecific polypeptide construct of any one of claims 60-102, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, comprises (i) the sequence as set forth in SEQ ID NO:110, (ii) a humanized variant of SEQ ID NO:110, or (iii) a sequence of amino acids exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:110, and binds to B7H3.

123. each of said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently CDR1 comprising the amino acid sequence shown in SEQ ID NO: 139; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 161; and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 189 123. The multispecific polypeptide construct of any one of claims 60 to 102 and 122, comprising:

124. 124. The multispecific polypeptide construct of any one of claims 60-102, 122 and 123, wherein said at least one B7H3 VHH domain or each of said first and second B7H3 VHH domains independently comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 515-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 515-518, and binds to B7H3.

125. 125. The multispecific polypeptide construct of any one of claims 60-102 and 122-124, wherein said at least one B7H3 VHH domain, or said first and said second B7H3 VHH domains, independently, comprise a sequence of amino acids as set forth in any one of SEQ ID NOs: 515-518.

126. wherein the at least one B7H3 VHH domain, or each of the first and second B7H3 VHH domains, independently, has (i) a sequence as set forth in SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104; (ii) a humanized variant of SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104; or (iii) a humanized variant of SEQ ID NO:

103. The multispecific polypeptide construct of any one of claims 60 to 102, comprising a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to NO:92, 93, 94, 95, 96, 97, ...

127. wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, independently, is selected from the group consisting of SEQ ID NOs: 134, 155, and 184, respectively; SEQ ID NOs: 135, 156, and 168, respectively; SEQ ID NOs: 136, 157, and 185, respectively; SEQ ID NOs: 137, 158, and 186, respectively; SEQ ID NOs: 138, 159, and 187, respectively; SEQ ID NOs: 138, 160, and 188, respectively; SEQ ID NOs: 139, 161, and 189, respectively; SEQ ID NOs: 140, 162, and 483, respectively; SEQ ID NOs: 141, 163, and 484, respectively; SEQ ID NOs: 139, 161, and 189, respectively; The multispecific polypeptide construct of any one of claims 60 to 102 and 126, comprising CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 142, 164 and 485; SEQ ID NOs: 143, 165 and 486; and SEQ ID NOs: 144, 166 and 487, respectively.

128. 128. The multispecific polypeptide construct of any one of claims 60 to 102, 126 and 127, wherein said at least one B7H3 VHH domain, or each of said first and second B7H3 VHH domains, is independently set forth in SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 or 104.

129. 129. The multispecific polypeptide construct of any one of claims 60 to 128, wherein one or both of said first and second components comprises at least one costimulatory receptor binding region (CRBR) that binds to a costimulatory receptor.

130. 130. The multispecific polypeptide construct of claim 129, wherein said at least one costimulatory receptor binding region (CRBR) is positioned amino-terminal to the Fc region of said multispecific polypeptide construct and / or carboxy-terminal to the CD3 binding region of said multispecific polypeptide construct.

131. 131. The multispecific polypeptide construct of claim 129 or claim 130, which comprises only one costimulatory receptor binding region (CRBR).

132. the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, a first Fc polypeptide of a heterodimeric Fc region, a linker, a VH or VL domain of an anti-CD3 antibody or antigen-binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises a CRBR and comprises, in order from N-terminus to C-terminus, a second Fc polypeptide of a heterodimeric Fc region, a linker, optionally the same linker as present in the first component, the other of the VH or VL domains of an anti-CD3 antibody or antigen-binding fragment, wherein the CRBR is positioned amino-terminal to the Fc region of the second component or carboxy-terminal to the anti-CD3 antibody or antigen-binding fragment of the second component.

132. A multispecific polypeptide construct according to any one of claims 129 to 131.

133. The at least one costimulatory receptor binding region (CRBR) is The extracellular domain of the natural cognate binding partner of said costimulatory receptor or a binding fragment thereof, or a variant thereof that exhibits binding activity to said costimulatory receptor.

133. The multispecific polypeptide construct of any one of claims 129 to 132, which is or comprises:

134. 133. The multispecific polypeptide construct of any of claims 129-132, wherein said at least one costimulatory receptor binding region (CRBR) is an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

135. The multispecific polypeptide construct of claim 134, wherein the antibody or antigen-binding fragment thereof is an Fv, scFv, Fab, single domain antibody (sdAb), VNAR, or VHH.

136. 136. The multispecific polypeptide construct of claim 134 or claim 135, wherein the antibody or antigen-binding fragment is an sdAb.

137. 137. The multispecific polypeptide construct of claim 136, wherein said sdAb is a human sdAb or a humanized sdAb.

138. 138. The multispecific polypeptide construct of any of claims 129-137, wherein said at least one costimulatory receptor binding region (CRBR) binds to a costimulatory receptor selected from among 41BB (CD137), OX40 (CD134), CD27, glucocorticoid-inducible TNFR-related protein (GITR), CD28, ICOS, CD40, B-cell activating factor receptor (BAFF-R), B-cell maturation antigen (BCMA), Transmembrane activator and CAML interactor (TACI), and NKG2D.

139. 139. The multispecific polypeptide construct of any one of claims 129-138, wherein said at least one costimulatory receptor binding region (CRBR) binds to a costimulatory receptor selected from among 41BB (CD137), OX40 (CD134), and glucocorticoid-inducible TNFR-related protein (GITR).

140. 140. The multispecific polypeptide construct of any one of claims 129 to 139, wherein said at least one costimulatory receptor binding region (CRBR) comprises a sequence of amino acids as set forth in SEQ ID NO:400, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence as set forth in SEQ ID NO:400, and binds to 4-1BB.

141. 141. The multispecific polypeptide construct of any one of claims 60 to 140, wherein one or both of said first and second components comprises at least one inhibitory receptor binding region (IRBR) that binds to an inhibitory receptor.

142. 142. The multispecific polypeptide construct of claim 141 , wherein said at least one inhibitory receptor binding region (IRBR) is positioned amino-terminal to said Fc region of said multispecific polypeptide construct and / or carboxy-terminal to said CD3 binding region of said multispecific polypeptide construct.

143. 143. The multispecific polypeptide construct of claim 141 or claim 142, comprising only one inhibitory receptor binding region (IRBR).

144. the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, the first Fc polypeptide of the heterodimeric Fc region, the linker, a VH or VL domain of the anti-CD3 antibody or antigen-binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises an IRBR and comprises, in order from N-terminus to C-terminus, the second Fc polypeptide of the heterodimeric Fc region, the linker, optionally the same linker as is present in the first component, the other of the VH or VL domains of the anti-CD3 antibody or antigen-binding fragment; the IRBR is positioned amino-terminal to the Fc region of the second component or carboxy-terminal to the anti-CD3 antibody or antigen-binding fragment of the second component; 144. A multispecific polypeptide construct according to any one of claims 141 to 143.

145. The at least one IRBR is The extracellular domain of the natural cognate binding partner of said inhibitory receptor or a binding fragment thereof, or a variant thereof that exhibits binding activity to said inhibitory receptor.

145. The multispecific polypeptide construct of any one of claims 141 to 144, which is or comprises:

146. 145. The multispecific polypeptide construct of any of claims 141 to 144, wherein said at least one IRBR is an antibody or an antigen-binding fragment thereof selected from the group consisting of a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

147. The multispecific polypeptide construct of claim 146, wherein the antibody or antigen-binding fragment thereof is an Fv, scFv, Fab, single domain antibody (sdAb), VNAR, or VHH.

148. 148. The multispecific polypeptide construct of claim 146 or claim 147, wherein the antibody or antigen-binding fragment is an sdAb.

149. 149. The multispecific polypeptide construct of any one of claims 146 to 148, wherein said sdAb is a human sdAb or a humanized sdAb.

150. The multispecific polypeptide construct of any of claims 141-149, wherein said at least one IRBR binds to an inhibitory receptor selected from among PD-1, CTLA-4, TIGIT, VISTA, and TIM3.

151. 150. The multispecific polypeptide construct of any of claims 141-149, wherein said at least one IRBR binds to PD-1.

152. the first component comprises, in order from N-terminus to C-terminus, a first B7H3 VHH domain that binds B7H3, the first Fc polypeptide of the heterodimeric Fc region, the linker, a VH or VL domain of the anti-CD3 antibody or antigen-binding fragment, and a second B7H3 VHH domain that binds B7H3; and the second component comprises, in order from N-terminus to C-terminus, one of the IRBR or the CRBR, a second Fc polypeptide of the heterodimeric Fc region, the linker, optionally the same linker as is present in the first component, the other of the VH or VL domains of the anti-CD3 antibody or antigen-binding fragment, and the other of the CRBR or the IRBR; 152. The multispecific polypeptide construct of any one of claims 141 to 151.

153. 153. The multispecific polypeptide construct of any one of claims 60-152, wherein said linker is a peptide or polypeptide linker, optionally said linker being 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length.

154. The multispecific polypeptide construct of any one of claims 60 to 153, wherein said linker is a non-cleavable linker.

155. The non-cleavable linker is and combinations thereof.

156. The linker has the sequence 156. The multispecific polypeptide construct of any one of claims 60 to 155, which is or comprises:

157. The multispecific polypeptide construct of any one of claims 60 to 153, wherein said linker is a cleavable linker.

158. The multispecific polypeptide construct of claim 157, wherein said cleavable linker is a polypeptide that functions as a substrate for a protease.

159. The multispecific polypeptide construct of claim 158, wherein said protease is produced by an immune effector cell, by the tumor, or by a cell present in the tumor microenvironment.

160. 160. The multispecific polypeptide construct of claim 158 or claim 159, wherein said protease is produced by an immune effector cell, said immune effector cell being an activated T cell, a natural killer (NK) cell, or a NK T cell.

161. 161. The multispecific polypeptide construct of any one of claims 158 to 160, wherein said protease is selected from among matriptase, matrix metalloprotease (MMP), granzyme B, and combinations thereof.

162. The multispecific polypeptide construct of claim 161, wherein the protease is granzyme B.

163. The cleavable linker has the amino acid sequence 163. The multispecific polypeptide construct of any one of claims 158 to 162, comprising:

164. Complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, and 145; A complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, and 167; and Complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, and 483-488. An isolated single domain antibody that binds to B7H3, comprising:

165. 165. The isolated single domain antibody of claim 164, comprising an amino acid sequence as set forth in any of SEQ ID NOs: 1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 1, 8-35, 40, 41, 44, 56-110, 466, 467, 489, 490, or 492-518, and which binds to B7H3.

166. 166. The isolated single domain antibody of claim 164 or claim 165, wherein the single domain antibody comprises (i) the sequence depicted in SEQ ID NO:1, (ii) a humanized variant of SEQ ID NO:1, or (iii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and binds to B7H3.

167. The sdAb CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 115, 116, 117, 118, 119, 120, and 121; CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149, 150, and 151; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 168 and 169 167. The isolated single domain antibody of any one of claims 164 to 166, comprising:

168. The sdAb is selected from the group consisting of SEQ ID NOs: 115, 146, and 168, respectively; SEQ ID NOs: 115, 147, and 168, respectively; SEQ ID NOs: 115, 148, and 168, respectively; SEQ ID NOs: 115, 149, and 168, respectively; SEQ ID NOs: 115, 150, and 168, respectively; SEQ ID NOs: 116, 146, and 168, respectively; SEQ ID NOs: 117, 146, and 168, respectively; SEQ ID NOs: 118, 146, and 168, respectively; SEQ ID NOs: 115, 146, and 169, respectively; SEQ ID NOs: 119, 146, and 168, respectively; SEQ ID NOs: 120, 146, and 168, respectively; SEQ ID NOs: 115, 151, and 168, respectively; SEQ ID NOs: 116, 147, and 168, respectively; SEQ ID NOs: 118, 147, and 168, respectively; SEQ ID NOs: 119, 147, and 168, respectively; SEQ ID NOs: 116, 151, and 168, respectively; SEQ ID NOs: 115, 146, and 168, respectively; SEQ ID NOs: 121, 147, and 168, respectively; SEQ ID NOs: 115, 146, and 168, respectively; SEQ ID NOs: 119, 149, and 168, respectively; or CDR1, CDR2, and CDR3 as shown in SEQ ID NOs: 122, 151, and 168, respectively.

168. The isolated single domain antibody of any one of claims 164-167, comprising:

169. 169. The isolated single domain antibody of any one of claims 164-168, wherein said sdAb comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497, and binds to B7H3.

170. 170. The isolated single domain antibody of any one of claims 164-169, wherein said sdAb comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 8-34, 467, 489-490, and 492-497.

171. 166. The isolated single domain antibody of claim 164 or claim 165, wherein the sdAb comprises (i) the sequence depicted in SEQ ID NO:35, (ii) a humanized variant of SEQ ID NO:35, or (iii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:35, and binds to B7H3.

172. The sdAb CDR1 comprising the amino acid sequence shown in SEQ ID NO: 123; CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 152 and 153; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 170 and 171 172. The isolated single domain antibody of any one of claims 164, 165, and 171, comprising:

173. The isolated single domain antibody of any one of claims 164, 165, 171 and 172, wherein said sdAb comprises CDR1, CDR2 and CDR3 as shown in SEQ ID NOs: 123, 152 and 170, respectively; SEQ ID NOs: 123, 152 and 171, respectively; SEQ ID NOs: 123, 153 and 170, respectively; or SEQ ID NOs: 123, 153 and 171, respectively.

174. 174. The isolated single domain antibody of any one of claims 164, 165, and 171-173, wherein said sdAb comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 40, 41, or 498-503, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 40, 41, or 498-503, and binds to B7H3.

175. The isolated single domain antibody of any one of claims 164, 165, and 171-174, wherein said sdAb comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 40, 41, or 498-503.

176. 166. The isolated single domain antibody of claim 164 or claim 165, wherein the sdAb comprises (i) the sequence depicted in SEQ ID NO:44, (ii) a humanized variant of SEQ ID NO:44, or (iii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:44, and binds to B7H3.

177. The sdAb CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 124, 125, 126, 127, 128, 129, 130, 131, 132, or 133; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 154; and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, and 183 177. The isolated single domain antibody of claim 164, claim 165, or claim 176, comprising:

178. The sdAb is selected from the group consisting of SEQ ID NOs: 124, 154, and 172, respectively; SEQ ID NOs: 124, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 174, respectively; SEQ ID NOs: 124, 154, and 175, respectively; SEQ ID NOs: 125, 154, and 173, respectively; SEQ ID NOs: 126, 154, and 173, respectively; SEQ ID NOs: 127, 154, and 173, respectively; SEQ ID NOs: 128, 154, and 173, respectively; SEQ ID NOs: 129, 154, and 173, respectively; SEQ ID NOs: 130, 154, and 173, respectively; SEQ ID NOs: 131, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 176, respectively; SEQ ID NOs: 125, 154, and 173, respectively; SEQ ID NOs: 124, 154, and 177, respectively; SEQ ID NOs: 124, 154, and 178, respectively; SEQ ID NOs: 124, 154, and 179, respectively; SEQ ID NOs: 124, 154, and 180, respectively; SEQ ID NOs: 124, 154, and 181, respectively; SEQ ID NOs: 124, 154, and 182, respectively; SEQ ID NOs: 124, 154, and 183, respectively; SEQ ID NOs: 126, 154, and 176, respectively; SEQ ID NOs: 124, 154, and 179, respectively; SEQ ID NOs: 124, 154, and 182, respectively; SEQ ID NOs: 132, 154, and 176, respectively; or SEQ ID The isolated single domain antibody of any one of claims 164, 165, 176, and 177, comprising CDR1, CDR2, and CDR3 as set forth in NOs: 133, 154, and 173.

179. 179. The isolated single domain antibody of any one of claims 164, 165, and 176-178, wherein said sdAb comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 56-91, 466, and 504-514, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 56-91, 466, and 504-514, and binds to B7H3.

180. The isolated single domain antibody of any one of claims 164, 165, and 176-179, wherein said at least one B7H3 VHH domain comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 56-91, 466, and 504-514.

181. 166. The isolated single domain antibody of claim 164 or claim 165, wherein the sdAb comprises (i) the sequence depicted in SEQ ID NO: 105, (ii) a humanized variant of SEQ ID NO: 105, or (iii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 105, and binds to B7H3.

182. The sdAb CDR1 comprising the amino acid sequence shown in SEQ ID NO: 145; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 167; and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 488 182. The isolated single domain antibody of claim 164, 165, or 181, comprising:

183. 183. The isolated single domain antibody of any one of claims 164, 165, 181 and 182, wherein said sdAb comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 106-109, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 106-109, and binds to B7H3.

184. The isolated single domain antibody of any one of claims 164, 165, and 181-183, wherein said sdAb comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 106-109.

185. 166. The isolated single domain antibody of claim 164 or claim 165, wherein the sdAb comprises (i) the sequence depicted in SEQ ID NO:110, (ii) a humanized variant of SEQ ID NO:110, or (iii) a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO:110, and binds to B7H3.

186. The sdAb CDR1 comprising the amino acid sequence shown in SEQ ID NO: 139; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 161; and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 189 186. The isolated single domain antibody of any one of claims 164, 165, and 185, comprising:

187. 187. The isolated single domain antibody of any one of claims 164, 165, 185 and 186, wherein said sdAb comprises a sequence of amino acids as set forth in any one of SEQ ID NOs: 515-518, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 515-518, and binds to B7H3.

188. The isolated single domain antibody of any one of claims 164, 165, and 185-187, wherein said sdAb comprises a sequence of amino acids set forth in any one of SEQ ID NOs: 515-518.

189. The sdAb is selected from the group consisting of: (i) a sequence as set forth in SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104; (ii) a humanized variant of SEQ ID NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104; or (iii) a sequence as set forth in SEQ ID NO:

166. The isolated single domain antibody of claim 164 or claim 165, comprising a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of NO: 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, or 104, and which binds to B7H3.

190. the at least one B7H3 VHH domain is selected from the group consisting of SEQ ID NOs: 134, 155, and 184, respectively; SEQ ID NOs: 135, 156, and 168, respectively; SEQ ID NOs: 136, 157, and 185, respectively; SEQ ID NOs: 137, 158, and 186, respectively; SEQ ID NOs: 138, 159, and 187, respectively; SEQ ID NOs: 138, 160, and 188, respectively; SEQ ID NOs: 139, 161, and 189, respectively; SEQ ID NOs: 140, 162, and 483, respectively; SEQ ID NOs: 141, 163, and 484, respectively; SEQ ID NOs: 139, 161, and 189, respectively; SEQ ID NOs: 142, 164, and 485, respectively; SEQ ID NOs: 143, 165, and 486, respectively; The isolated single domain antibody of any one of claims 164, 165, and 189, comprising CDR1, CDR2, and CDR3 as set forth in NOs: 144, 166, and 487.

191. A polynucleotide encoding the B7H3-binding polypeptide of any one of claims 1-59.

192. A polynucleotide encoding the multispecific polypeptide construct of any one of claims 60 to 163.

193. A polynucleotide comprising a first nucleic acid sequence encoding a first polypeptide of a multispecific construct according to any one of claims 60 to 163 and a second nucleic acid sequence encoding a second polypeptide of said multispecific construct, the first and second nucleic acid sequences are separated by an internal ribosome entry site (IRES) or a nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping; The polynucleotide.

194. 194. The polynucleotide of claim 193, wherein said first nucleic acid sequence and said second nucleic acid sequence are operably linked to the same promoter.

195. 195. The polynucleotide of claim 194, wherein said nucleic acid encoding a self-cleaving peptide or a peptide that causes ribosome skipping is selected from T2A, P2A, E2A, or F2A.

196. A polynucleotide encoding the single domain antibody of any one of claims 164 to 190.

197. A vector comprising the polynucleotide of any one of claims 191 to 196.

198. The vector of claim 197 which is an expression vector.

199. 199. The vector of claim 197 or claim 198, which is a viral vector or a eukaryotic vector, optionally wherein the eukaryotic vector is a mammalian vector.

200. 197. A cell comprising one or more polynucleotides of any one of claims 191-196, or one or more vectors of any one of claims 197-199.

201. 201. The cell of claim 200, which is recombinant or isolated.

202. The cell of claim 201, which is a mammalian cell.

203. 1. A method for producing a polypeptide comprising the steps of: Introducing one or more polynucleotides according to any one of claims 191 to 196 or one or more vectors according to any one of claims 197 to 199 into a cell; and culturing said cells under conditions to produce the multispecific polypeptide construct. The method comprising:

204. The method of claim 203, further comprising isolating or purifying said polypeptide from said cell.

205. 205. A polypeptide produced by the method of claim 203 or claim 204.

206. An extracellular domain comprising the single domain antibody of any one of claims 164 to 190; A transmembrane domain; and Intracellular signaling domains An engineered immune cell comprising a chimeric antigen receptor comprising:

207. The engineered immune cell of claim 206, wherein said cell is a lymphocyte.

208. The engineered immune cell of claim 206 or claim 207, wherein said cell is a T cell or a natural killer (NK) cell.

209. The engineered immune cell of any of claims 206-208, wherein said intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM) signaling domain.

210. The engineered immune cell of any one of claims 206-209, wherein said intracellular signaling domain is or comprises a CD3 zeta signaling domain, optionally a human CD3 zeta signaling domain.

211. The engineered immune cell of claim 209 or claim 210, wherein said intracellular signaling domain further comprises a signaling domain of a costimulatory molecule.

212. The engineered immune cell of claim 211, wherein said costimulatory molecule is CD28, ICOS, 41BB, or OX40, optionally human CD28, human ICOS, human 41BB, or human OX40.

213. 214. A pharmaceutical composition comprising a B7H3 binding polypeptide according to any one of claims 1 to 59, a multispecific polypeptide construct according to any one of claims 60 to 163, a single domain antibody according to any one of claims 164 to 190, or an engineered immune cell according to any one of claims 206 to 212.

214. 214. The pharmaceutical composition of claim 213, comprising a pharma- ceutically acceptable carrier.

215. 215. The pharmaceutical composition of claim 213 or claim 214, which is sterile.

216. 1. A method of stimulating or inducing an immune response in a subject, comprising: administering to a subject in need thereof a B7H3 binding polypeptide according to any one of claims 1 to 59, a multispecific polypeptide construct according to any one of claims 60 to 163, a single domain antibody according to any one of claims 164 to 190, or an engineered immune cell according to any one of claims 206 to 212, or a pharmaceutical composition according to claims 213 to 215. The method comprising:

217. The method of claim 216, wherein the immune response is increased against a tumor or cancer, optionally against a tumor or cancer that expresses B7H3.

218. The method of claim 216 or claim 217, for treating a disease or condition in the subject.

219. 1. A method of treating a disease or condition in a subject, comprising: administering to a subject in need thereof a therapeutically effective amount of a B7H3 binding polypeptide of any one of claims 1-59, a multispecific polypeptide construct of any one of claims 60-163, a single domain antibody of any one of claims 164-190, or an engineered immune cell of any one of claims 206-212, or a pharmaceutical composition of claims 213-215. The method comprising:

220. The method of claim 218 or claim 219, wherein the disease or condition is a tumor or cancer.

221. The method of any one of claims 216 to 220, wherein the subject is a human.

Citation Information

Patent Citations

  • CD3-binding molecules capable of binding to human and non-human CD3.

    JP2014517844A

  • Anti-b7-h3 antibody and its diagnostic use

    JP2017524725A

  • Antibodies, Compositions, and Uses

    JP2017532952A

  • Anti-b7-h3 antibody

    WO2012147713A1

  • Bivalent antibody having single-domain antigen-binding fragment fused to conventional fab fragment

    WO2016192613A1